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 ABSTRACT 
 
  Vali Azhal Keel Vayu is one of the commonest  disease now a days, number of 
suffers increases day by day. The evidence of the disease VALI AZHAL KEEL VAYU 
was derived from “Sabapathy Manuscript of Book Noi Nadal Noi Mudhal Naadal 
Thirattu Part – II”  2nd Edition, by Dr. M. Shanmugavelu, B.H.I.M,  (Page No. 623).  
The signs and symptoms metnioned in the Literature of Siddha Book closely resembles 
with  “Rheumatoid Arthritis” in modern medicine. 
 
  Out of 40 patients, 20 In patients and 20 Out patients of both sex were selected. 
They were administered with the clinical trial medicine  “AKKINI CHOORANAM”  
4.2 gms BID with sugar during the whole study period. Akkini chooranam was chosen 
for this clinical study with reference from  “Koshayi Anuboga Vaithiya Bramma 
Ragasiyam, Part – II, Pg.No.104. 
 
  The clinical trial drug was subjected to Biochemical and Pharmacological 
anal;ysis. At the end of the Clinical trial study, the majority of the cases which showed 
good results. 
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CHAPTER-I 
INTRODUCTION 
    The Siddha medicine was found by Siddhars.  Siddhars have a unique and 
added to supernatural powers. 
Siddha medicine is found in south India.  It is based on the 96 Udal 
Thathuvam, including  Panjapootham and Naadi. 
The three thathuvas  are Vatham, Pitham, Kabam. 
The Panjapoothams are Mann, Neer, Thee, Vayu and Akayam. 
These five Panjapoothas are the basic principles of the siddha system. 
According to Sathaga Naadi, 
“hivh<hi!H,kjlf<K!l{<fQi<!OkB!
hiquiB!uigib!jlf<kq!eiOz,!
Osvh<hi!smlis<S!l{<{qe<!%X!
osxqlbqi<Okiz<!we<hqjxs<sq!fvl<jhf<!kiGl<!
Ofvh<hi!nh<Huqe<%!Xkqv!ls<js 
fQi<&jt!Sg<gqz!Olijmf<!kiGl<!
givh<hi!OkBg<%X!hblir<!givr<!
gMR<Osil<hz<!fqk<kqjvjl!Ker<g!tR<Os”. 
“nR<sie!uiBuqe<%X!bqVk<k!Ozimz<!
njufmk<kz<!gqmk<kZm!eqVk<kzR<sil<, 
nR<siG!ligibg<!%X!gil!
nkqx<GOvikl<!dOzihOlig!lklR<!siGl<!” 
Relations  between the panjapootham and tridosam 
Vayu + Akayam = Vatham 
Thee = Pitham 
Mann + Neer = Kabam 
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Disturbances of this three dhosa are causes to the disease. 
According to Thiruvalluvar, 
“lqgqEl<!GjxbqEl<!Ofib<!osb<Bl<!F~Ozii< 
   utqLkzi!w{<{qb!&e<X”. 
Vatham is placed first.  
According to Theraiyar, 
“uiklziK!Oleq!ogmiK” 
According to Yugi vaidhya cinthamani, Vatha disease were classified into 80 
types. 
Among 80 types of vatha disease, vali azhal keel vayu is one of the type of 10 
keel vayu. 
The symptoms of vali azhal keel vayu is correlated in modern science is 
Rheumatoid Arthritis. 
In  2005 Rheumatoid Arthritis was estimated to affect  1.3 million adults in the 
U.S. representing  0.6 percent of the population. 
By 2007, an estimated 1.5 million adults had Rheumatoid Arthritis. 
A 2010 study found that about one-fourth to one half of all patients with 
Rheumatoid Arthritis become unable to work within 10 – 20 years of follow –up. 
From 2012 the increased rate of hospitalization was found in both sexes, all 
age groups and throughout disease duration. 
In 2015, estimated national indirect costs of  Rheumatoid Arthritis related 
absenteeism from work were  252 million annually. 
Siddha system has standard and cost effective treatment for  “Vali Azhal Keel 
Vayu”. 
So, I have selected “Vali Azhal Keel Vayu” for the clinical study with Akkini 
chooranam for my dissertation work, on the basis of the Siddha. 
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CHAPTER–II 
AIM AND OBJECTIVE 
AIM 
Vali Azhal Keel Vayu is a disease cause more pain and disabilities that 
involves poor as well as rich people.  
So,  I selected this disease and treated the cases with the help of ng<gqeq!<<<
$v{l< (AKKINI CHOORANAM) 4.2 gms with sugar 2 times morning and night 
after food  internally. 
The Objectives are:- 
 To evaluate the therapeutic efficacy of AKKINI CHOORANAM(internal) in 
the treatment of “VALI AZHAL KEEL VAYU” (Rheumatoid Arthritis). 
 To explore the apt definition, Aetiology, clinical features, pathology, 
diagnosis,  prognosis, complications and treatment for Vali Azhal Keel Vayu 
in Siddha literatures and its correlation with modern science. 
 To survey the incidence of the disease, according to Age, Occupation, Socio 
Economic status, Habits, Family History, Paruva kaalangal, Thinai and Three 
Vital Humours. 
 To divulge how the Mukkutram and Seven Udal kattugal are deranged in this 
disease. 
 To document the changes in the Envagai Thervugal in this disease.  
 To do a detailed Clinical investigations. 
 To use Modern parameters to confirm the diagnosis and prognosis of the 
disease. 
 To analyse the Clinical trial of the drug in Biochemical and Pharmacological 
studies. 
 To do a safety profile of a clinical trial of the drug “AKKINI 
CHOORANAM”. 
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CHAPTER-III 
REVIEW OF LITERATURE 
 a). SIDDHA ASPECTS  
The concepts of Siddha system are based on fundamental principles of five 
basic elements viz;  Panchabootham – Mann, Neer, Thee, Kaatru, Aahayam, 96 
Thathuvangal, Three Vital Humours and Seven Udal Kattugal.  
The three physical constituents of the human system i.e., the humours are 
Vatham, Pitham, Kapham. They are called Uyirthatus or Thiri thathus under normal 
condition, which regulates all the physiological activities of the human body and 
keeps healthy.  
uikOfib<g<gie!-bz<H< < << < << < <  
! “sf<kqvuik!Lml<H!Gtqv<f<!!okPf<Ok!fMg<GR<!sQkiuib<!uil<!
! Lf<kqb!Gf<kq!squf<K!sf<Kgt<!OkiXr<!Gjmf<K!olitqgt<!uQr<Gl<!!
! uf<kqb!okif<k!uikl<!fvl<Hgotz<zi!!lqsqf<K!uzl<!uqmiK!
! nf<K!nu<uiG!uikl<!uQg<gL{<mi!Lmzqx<xq!!LV{<miOl”!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!Okjvbv<!uigml<!himz<!< < << < << < < –!322!!!
 Pain in the upper and lower limbs , pain in the costo chondral junction will be 
seen in vatha disease . 
 According to Theraiyar, 
“ohix<xi!ljvbie<!Hjeolb<!bv{<gig<Gl<!
ohix<xi!ljvbie<!Hgz<uoke<!ohix<xil<!
utuqeqOz!big<Gvl<jh!le<oee<e!le<e!
!!!!!!!!!!!!!utuqeqOz!big<Gl<!utq”!
.!Okjvbi<!blg!ou{<hi/< << << < !
Vatham is being hailed as the king ,who rules the body and enables the 
dwelling  
of the soul (Uyir) in the body. Hence Theraiyar said, Vatham as the prime force. 
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! “uikl<!uf<Kx<x!OhiK!ubqxK!!ohiVlq!ogit<Tl<!!
! kikuqp<f<kqMh<H!jggiz<!sf<Kgt<!gMh<H!Okie<Xl<!!
! sQokiV!lzLl<!fQVf<!sqXk<Kme<!gMk<K!uqP!
!! likuljv!!Olz<!uf<k!uikk<kqe<!G{lqkiOl”!
. B,gq! Lequv<! ohVF~z<! juk<kqb!< < << < << < < !!!!!!!!!!!!!!!!
giuqbl<!<<< 2111!
  When vatham is increased,  abdominal discomfort, pain in the hip joint and in 
the joints of upper and lower limbs, decreased and painful voiding of stools and urine 
will be seen . 
! “osiz<zOu!!uiklK!lQxqx<xieiz<!
! Osiv<ujmf<K!uiBuqeiz<!Okgolr<Gl<!!
! olz<zOu!!jggiz<g!jskqB{<mil<!!
! olb<Lmr<Gl<!kqlqvoui{<{ik<!kqlqV!{<miGl<!!
! uz<zOu!Bmz<!ohiVLl<!ubqXjtg<Gl<!!
! uqVl<hq!be<es<!osz<ziK!uqf<K!f]<ml<!
! ogit<tOu!fih<Htqg<Gl<!gpqs<sZ{<mil<!!
! %xqeiv<!ljz!Leq!%xqeiOv”!
. ngk<kqbv<!sqgqs<si!-vk<kqe!kQhl<< < < < Q << < < < Q << < < < Q <!
! uikl<! lqGl<OhiK!uiB!lqGl</! se<eq! Oki]l<! Ohie<x! hz!!uqbikqgt<!
uf<K! OsVl<! /dmz<! olzqU?! dmz<! Osiv<U?! jg! giz<! nskq?! dmzqz<!
kqlqV{<mikz<?!ubqx<Xh<!ohiVlz<! ?!gpqs<sz<!uqf<K!f]<ml<! ?!fijuh<!Htqg<gs<!
osb<kz<!Ohie<x!GxqG{r<gt<!d{<miGl</!
According to Theriyar, 
“kg<guiB!Ogihqk<kiz<!sf<KUjtf<K!kjzOfiui!!!
lqg<g&iq!ogim<miuq!uqm<mr<ogiqB!lzr<gm<Ml<!!
yg<gfvl<H!kie<Lmr<G!LzIf<K!uib<fQ!'xquVl<”!!!!
! ! ! ! .!OkjvbI!uigml<<<<!)himz<!w{</53?!hg<gl<!w{</24< < < < << < < < << < < < < *!
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According to Agasthiyar,  
           “gi{h<hi!uiklQxqz<!giz<jggt<!ohiVk<K!OfiUl<!!!
H,{h<hi!Gmz<!Hvm<Ml!<lzszl<!ohiVlqg<gm<Ml<”!!!!
.!ngk<kqbI!juk<kqb!giuqbl<!2611!!!!!< < << < << < < !!
!!)himz<!<<< w{</21/<<< !h/!w{</3<<< !*  
 According to Thiruvalluvar in Thirukural explains,     
  “lqgqEl<!GjxbqEl<!Ofib<!osb<Bl<!F~OziI!
!! utqLkzi!w{<{qb!&e<X”!!
Based on this theory, the problems of various systems are classified as Vatha, 
Pitha, and Kapha diseases. 
According to Thirumoolar,  
“wxqb!fz<uikl<!wxqg<Gl<!G{r<OgT!!!!
Gxqobeg<!jggiz<!Gjts<S!uqzis<!sf<K!
Hxqobe!ofif<Kmz<!hs<jsh<H{<!NGOl”!
.!kqV&zI!gVg<gqjm!juk<kqbl<< < << < << < <.711!!
!)himz<!<<< w{</47?!hg<gl<!w{</22< < < << < < << < < < *!!
KEEL VAYU   
sqk<k!lVk<Kuk<kqz<!w{<hK!ujg!utq!Ofib<gt<!hx<xqg<!%xh<hm<Mt<tK/!
utq! npzg<gQz<! uiB! we<hK?! gQz<uiB! we<x! kjzh<hqe<! gQp<! %xh<hm<m! hk<K!
ujggTt<!ye<X/!gQz<uiB!we<hK!&m<M!lx<Xl<!nkjes<!Sx<xqt<t!hGkqgtqz<!
Wxh<Ml<!Ofibg<jtg<!Gxqh<hkiGl</!!
Vali Azhal  Keel  Vayu comes under the heading of Vatha diseases, 
 According to Yugi vaidhya cinthamani, 
“we<eOu!uikf<ki!oe{<hkiGl<!!
-gk<kqOz!leqki<gTg<!ogb<BliX!
!
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hqe<eOu!ohie<ekjeOb!OsivR<osb<K!
ohvqObiv<gt<!hqvil{jvk<!Kimeqk<Kl<!
ue<e!Okus<!osik<kqz<!OsivR<osb<K!
likihqki!GVju!lxf<k!Ohv<g<Gl<!
ge<eOu!Oukk<jk!fqf<jk!osb<kiz<!
gibk<kqx<!gzf<kqMOl!uikf<kiOe”!
. B,gq!juk<kqb!sqf<kil{q?!< << << < himz<!354/<<< !
Frittering away Gold, Blaspheming elders, Holymen and Vedas, Obsession of 
temple property; Obliviousness of parents, Teachers and God all leads to vatha 
disease.  
OuX!ohbIgt<<<< (SYNONYMS):   
 The synonyms in AGASTHIYAR GUNAVAGADAM text is,    
!! sf<Kuzq?! &m<Muzq?! Olg$jz?!Lmg<G! uiB?!Nluikl<?! sf<K! uikl<?!
$jzgm<M?!sf<kqg!sqOz]<l!Ovigl<?!uik$jz?!uiBOvigl</!!
“kieie!gQz<uik!Ovig!Ohjv!
six<XgqOxe<!fQbxqb!uqhvlig!
lieie!uib<UOvigl<!uik!Ovigl<!
lgk<kie!LmgG<uiB!Lmg<G!uikl<!
Okeie!sf<kQg!sqOzm<Ml!Ovigl<!
oktquie!jggizqz<!hqch<H!Ovigl<!
Deie!vsuikl<!$jzgg<m<M!
dk<klOe!sf<kquikl<!uik$jz!biOl!
Nole<x!-k<kjeBl<!nkxGh<!Ohvil<”!
.!ngk<kqbI!G{uigml<< << << <!!
! !
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giv{!ohbIgt<;!!<<< !
Ofib<!giv{l<!!!!!!!!!!!;!!!! Olg!$jz!
Lg<Gx<x!fqjz!liXhiM!!!;!!!!!uik!$jz?!sf<kqg!sqOz]<l!Ovigl<!
-mk<jkg<!ogi{<M!!!!!! ;!!!!!sf<K!uikl<?!&m<Muzq?!sf<K!uzq?!Nl!uikl<!
Gxq!G{r<gjtg<!ogi{<M!;!!!!!$jzg<gm<M?!Lmg<G!uikl< 
 
-bz<<<< (DEFINITION):  
               “utqB!jlBf<!ke<eqjz!ogm<M!
!!!!!!!!!!uzqBme<!uQg<gs<!SvLl<!gibf<K!
!!!!!!&m<Mg!OmiXl<!LMg<gqOb!ofif<K!
!!!!!!!!!!&m<Mg!me<eqe<!fQVl<!Svf<K!
!!!!!!kir<ogi{i!uzqBme<!ofif<kqM!ll<Ol”!!
. shihkq!jgObM!!!!!!!
               According to Sabapathy Manuscript: In Keel Vayu, the following 
symptoms are produced, that is painful joints, swelling associated with fever, 
restriction of joint movements, finally produce deformity and systemic illness.  
Ofib<!<<< uVl<!<<< upq!)AETIOLOGY*;!!
!!!!!!!!!!“uiklziK!Oleq!ogmiK”!
. Okjvbi<<<<!!
              According to Siddha system, any modifications (or) disturbances in Uyir 
thathugal, especially in Vatham, is a major role to produce Keel Vayu. 
According to Sabapathy manuscript , 
                       “utqkV!gib<gq!pr<G!
!!!!!!!!!!!!!!!!!!!!ujvuqzi!kbqzz<!Ogijp!
!!!!!!!!!!!!!!Htqkbqi<!Ohie<lq!!Gg<G!
!!!!!!!!!!!!!!!!!!!!Ljxbqzi!U{<c!Ogimz<!
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!!!!!!!!!!!!!!Gtqi<kV!utqbqx<!Oxgr<!
!!!!!!!!!!!!!!!!!!!!Geqh<Hx!Uzuz<!oh{<ci<!
!!!!!!!!!!!!!!gtqk<kV!lbg<gl<!ohx<Oxii<!
!!!!!!!!!!!!!!!!!!!!gcosbz<!gVuqbiliz”<!
!!!!!!!!!!!!!!!!!!!!!!!!!!!.shihkq!jgObM.!sqk<k!lVk<Ku< << << < l<< <<!)ohiK)!!!!!!!!!!!!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!)hg<gl</w{</735*< < << < << < < !
There are various number of factors,  that play a major role in modification of 
Vatham.Excessive intake of rhizomes and vegetables that can increase the risk of  
Vatha diseases.Irregular food intake, prolonged exposure to cold air, staying in hilly 
area,excessive sexual activity and hereditary factors produce Keel Vayu. 
                           “Ncbikqbib<!Jh<hsq!=xib<!!
!!!!!!!!!!!!!!!!Neqzlkx<!Ogivvsqbz<!gizl<”!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!skgfic!)Ofib<!fimz<< << << <*!!!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!)higl</2?!hg<gl<!w{</278?279< < < << < < << < < < *!!
         According to Sathaganaadi,  the Vatha diseases are predominant in the months 
of Aadi to Iypasi (July to November).  
                              “uik!uIk<kje!gizOlOki!oue<eqz<!!!
!!!!!!!!!!!!!!!!!!!!!!!!!lVUgqe<x!Neq!gx<gmgliGl<!!
!!!!!!!!!!!!!!Nkjuh<!hsqObiM!giIk<kqjg!ke<eqz<!
!!!!!!!!!!!!!!!!!!!!!!!!!nVmOl///////////////////////////////////////////////”!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!b,gq!juk<kqb!sqf<kil{q< << << < .911!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!)himz<!<<< w{</356?!hg<gl<!w{</87< < < << < < << < < < *!!
                      In Yugi Chinthamani, Vatham provokes in its own site in Aani and Aadi 
(ke<eqjz!utIs<sq). But it provokes and spread beyond the site, in the month of 
Iypasi and Karthigai (Oux<Xfqjz!utIs<sq). And reassumes normal in the rest of the 
months (ke<eqjz!njmkz<*/      
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  According to this Poem,   
            “hKlk<jkh<!h,g<g!jug<Gl<!hiElqg<g!giBl<!!
!!!!!!!!!!LKOueq!zqx<H!uqfQI!Lx<Xl<!.!gKole!
!!!!!!ux<Xl<!ghGl<!uiBlqGl</////////////////////////////////////////”!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!lVk<KuI!keqh<himz<!< < << < << < < !
 !!!! LKOueqx<! gizk<kqz<?! $iqb! ouh<hk<kqe<! giv{lig! ohVuiiqbig! fQI!
Nuqbig<gh<hm<M!h,lqbqz<!uxm<sq!fqzUl</!nKOhiz<!flK!dmzqz<!uxm<sq!Wx<hm<M!
utqOfib<!uVukx<G!WKuigqxK/!!
In pararasa Sekaram , 
! gi{Ou!lqgU{<miZl<!gVKhm<ceq!uqm<miZl<!!
! liej{!biv<g{<!Oliglxg<gqE!.!lqGf<kqm<miZl<!!
! N{u!lz!gml<jlbOe!uqmikziZl<!!
! uiEke<!lmfz<ziOt!uikr<Ogihqg<G!giO{.!343!!
! nkqg! ntU! d{U! dm<ogit<tz<! )Excessive food intake), ! hm<ceq!
gqmk<kz<!)Starvation)/!
According to Agasthiyar in Agasthiyar Gunavagadam,  
                                “kieie!!gQz<uik!Ovigl<!Ohjv!
!!!!!!!!!!!!!!!!!!!!!///////////////////////////////////////////////////////////////////!
!!!!!!!!!!!!!!!OhiOl!kie<vs!K~]qbk<!kqeiOz!!!
!!!!!!!!!!!!!!!!!!! ohiz<zik!-f<k!Ofib<!gi[l<!hiV”!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!ngk<kqbI!G{uigml<!!< << << < !
              Keel Vayu occurs due to dietary substances which degrade the quality of 
chyle (ne<evsl<– chyle).  
In Pararasa Sekaram,  
“hivqeqx<!!hbh<hm<miZl<!hzVme<!!Ogihqk<kiZl<!!
! gioveg<!gVgqObicg<!!gPlvk<!!Kvk<kqeiZl<!!
 11 
 
! Wv<ohX!keK!ovsqe<!lqgk<Kg<g!ljmk<kqm<miZl<!!
! hivqb!gix<xqeiZl<!hmvqEl<!uikr<gi[l<”!!.!himz<!w{<!;!< << << < 344!!
! hbl<! )Fear) ?! wz<OzivqmLl<! Ogihl<! ogit<tz<! )Arrogant towards all 
people)?! lqGkqbig! Ymz<! )Excessive running)?! Kg<gl<! )Sadness)?! kqeLl<!!
dmzqe<!Olz<!gix<X!hmz</   !
 
According to Theraiyar in Theriyar Vagadam text,   
 “oub<bqzqz<!fmg<jgbiZl<!lqgk<!k{<{QI!Gcg<jgbiZl<! 
! ! Osb<bqjp!lgtqjvs<!OsIf<ke!huqg<jgbiZl<!!
! !jhbOe!d{<jlbiZl<!higx<gib<!kq{<jgbiZl<!!!
! ! jkbOz!uikOvigl<!seqg<G!ole<xxqf<K!ogit<t”!!!!!
!! ! ! ! ! OkjvbI!uigml<!!!!!!<<< !
!! ! ! ! ! )himz<!w{</27?!hg<gl<!w{</6< < < < << < < < << < < < < *!!!
            Excessive exposure in sun rays, excessive intake of water, excessive sexual 
activity, Excessive intake of bitter guard etc…, may disturb the normal functions of 
Vatham. 
Vatha Kanma Varalaru says,   
 “F~oze<x!uikl<!uf<k!ujgkiOeK!! 
! ! K{<jlbib<g<!ge<lk<kqe<!ujgjbg<!OgT!!
!! gizqOz!Okie<xqbK!gMh<hOkK!!!
! ! !jggizqz<!Lpg<gqbK!uQg<glK!
! !OgizqOz!hMgqe<x!uqVm<slie!!!
!! ! Gpf<jk!lvf<kje!oum<mz<!Olz<Okiz<sQuz<!
! !F~zqOz!sQu\f<K!giz<!Lxqk<kz<!!!
! ! !fz<zogil<H!!kjpLxqk<kz<!fzqk<kz<!kiOe”!!!!!!
! ! ! ! ! !ngk<kqbI!ge<lgi{<ml<!!!!!!< < < << < < << < < < !
! ! ! ! ! !(himz<!w{</67?!hg<gl<!w{</34< < < < << < < < << < < < < )  
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 Psychological factors such as removing the bark of living trees, injuring the 
animals, cutting the branches in the living trees and plucking the leaves may produce 
Vatha diseases.  !
 According to Yugi Muni in Yugi Vaidhya Chinthamani,    
 “kioee<x!gsh<OhiM!KuIh<H!jgh<H!
! ! sikglib<!lqR<SgqEl<!sjlk<k!u{<{l<!!
! Noee<x!NxqeK!Hsqk<k!ziZl<!
! ! Ngibk<!OkxzK!Gck<kziZl<!!
!!!!!!hioee<x!hgZxg<g!lqviuqpqh<H!! !
! ! hm<ceqOb!lqgUXkz<!hivolb<kz<!!
! Okoee<x!olipqbiI!Olx<sqf<jk!bikz<!!
! ! sQg<gqvlib!<uiklK!oseqg<Gf<kiOe”!!!
! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!!!!!!
! ! ! ! ! !)himz<!w{</355?!hg<gl<!w{</87< < < < << < < < << < < < < *!!
 Excessive intake of bitter, astringent and salty foods, drinking polluted rain 
water, irregular sleep pattern, undue starving, excessive weight lifting and sexual 
perversion can induced  Vatha diseases. 
According to pararasa sekaram, 
  “okipqz<ohX!jgh<Hg<!gii<k<kz<!!Kui<k<kz<!!uqR<SgqER<!OsiXl<!
! ! hjpbkil<!uvG!lx<jxh<!jhf<kqj{!bVf<kq!eiZl<!
! !wpqz<ohxh<!hgZ!xr<gq!-vuqeq!Zxr<gik!kiZl<!
! ! ljpfqgi<!Gpzq!eiOt!uikr<Ogi!hqg<Gr<!giO{”!
        -hvvis!Osgvl<<<<!
!! jgh<H,! gii<h<H,! Kui<h<Ht<t! hkii<k<kr<gjt! nkqgligs<! Osi<k<Kg<!
ogit<tz<,! hjpb! OsiX,! uvG,! kqje! d{<{z<?! hgzqz<! dxr<gq! -vuqz<!
uqpqk<kqVk<kz</!
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According to Yugi Muni in Yugi Vaithya Chinthamani,  
 “hgvOu!uiklK!Ogihqk<kh<Ohi 
! ! h{<hig!oh{<Ohigl<!nKkie<!osb<bqz< 
! fgvOu!ouGK~v!upqfmg<gqz<!
! ! ftqvie!gix<XOl!eqOlz<!hm<miz<!!
! lqgvOu!gib<gt<!geqgqpr<G!ke<je!!!
!!!!!!!!!!!lqguVf<kq!lQxqOb!kbqIkie<!ogi{<miz<! !
! LgvOu!LKogZl<jh!LXg<gq!ofif<K!!
! ! Lpr<giZl<?!g[g<giZl<!gMh<H{<miOl”!!!
! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!
! ! ! ! ! !)himz<<<<!w{</326?!hg<gl<!w{</9:< < < << < < << < < < *!!
 Excessive sexual activity (or) desire, walking for a long distance, prolonged 
exposure to cold, harmful consumption like taking excessive curd after eating fruits, 
vegetables and tubers produces toxic factors which affects bones and muscles, 
produce Vatha diseases.    
As per Karmic Law:   
   In Siddha system, many diseases are said to be precipitated by Kanmam, 
which means the deeds good (or) bad committed, by an individual in his / her 
previous and the present births. According to Agasthiyar Kanma Kandam-300, Vatha 
diseases may also be precipitated by Kanmam.  
 “nf<k{I!gx<H!likI!nVtqb!sihk<kiZl<!!!
! ! Lf<kqb!uqjebiZl<!LkqIgIh<h!Olgk<kiZl<!
! sqf<jkbqx<!ogiMjlbiZl<!squGV!fqf<jkbiZf<!!
! ! okif<klil<!uqbikqbiZl<!Okie<xqMl<!$jzkiOe”!!!!!!!!
! ! ! ! ! ! .!ngk<kqbI!!!<<<   
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            Soolai may occur by the curse of well characterized people and ladies or due 
to evil deeds in the previous births or due to megam produced by their parents or due 
to bad thoughts and curse of Guru.   !
Individual derangements in Mukkutram i.e., Vatham, Pitham and Kapham:   
 Abanan and Viyanan are affected in Vatham. 
 In Pitham, Sathaga Pitham is affected. 
 In Kapham, Santhigam is affected.  
Classification of Keel vayu:   
According to Sabapathy manuscript the Keel vayu is classified into 10 types. 
 They are:  
2/utq!gQz<!uiB 
3/npz<!gQz<!uiB 
4/Jb!gQz<!uiB 
5/utqnpz<!gQz<!uiB 
6/utqJb!gQz<!uiB 
7/npz<!utq!gQz<!uiB 
8/npz<!Jb!gQz<!uiB 
9/Jb!utq!gQz<!uiB 
:/Jb!npz<!gQz<!uiB 
21/Lg<Gx<x!gQz<!uiB! 
General clinical features of keel vayu:   
1. Painful joints 
2. Swelling  
3. Restricted joint movements 
4. Stiffness  
5. Fever  
6. Loss of appetite 
7. Synovial effusion  
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 VALI AZHAL KEEL VAYU:   
               Vali Azhal Keel Vayu is one among the ten types of keel vayus.  
               When the Vadha dosham is in vitiated condition,some untold activity,food 
stuffs,kanmam which provoke the Pitha dosham which is the causative factor of Vali 
Azhal Keel Vayu.  
utq!)uik*!ucuk<ke<jl;< << << < ! 
 “l{<{q!vez<gi!oze<E!fie<Gl<!
!! ! fqvOz!fix<xf<!km<hf<!kqm<hl<!
! !dVuq!Zix<x!Ljmb!uigq!
! ! !olb<h<ohiVt!pqohiV!oteuqV!ujgb!
!!! nEg<gt<!olb<ohiVt<!giiqb!lpqohiVt<”/!
uikk<kqe<!-bx<jg!ucul< < << < << < < <!F{<jl< << << < )nEk<Kul<*ofib<jlgTl<;< < < << < < << < < < !
 “uqmb!lvLk!zjskx<!OgK”!
!! ! we<hkiz<!-bg<gLl<!
 “Okozie<!xiOe!gui<G{!LxK!
! ! km<hl<!ouh<h!lux<xqe<!Ouoxe<!
! xl<L!ujtgk<ki!biBr<!gijz!
! ! fqzfq!vez<giz<!fie<gqE!fqjzBl<”/!
! we<hkiz<! ke<jl! oul<jl! -u<uqv{<mie<! uVl<!
yh<hvuqe<jlBl<)sVs<sjvBl<*!Ngqb!utqucuk<!ke<jlgtil</!
uikk<kqe<!-bx<jg!h{<H< < < << < < << < < < : 
! yPr<Gme<!kiOkp<!Ls<!Osir<gq!-br<g!
! ! wPs<sqohx<!wh<h{qBlix<x.wPf<kqiqb!
!!!!!Ougl<!Hze<gTg<G!Olus<!SXSXh<H!
! ! uigtqg<Gl<!lif<ki<g<G!uiB/!
     -(sqk<k!lVk<Kuir<gs<Vg<gl< < < < << < < < << < < < < <*< << !
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        The normal structure and functions of Vatham (ucuk<ke<jl< << << < ) is:  
 Dry (uxm<sq) 
 Cold (GtqIs<sq) 
 Rough (gcel<) 
 Motion (njskz<) 
 Light (-zG) 
        The normal structure and functions of Pitham (ucuk<ke<jl< << << < ) is:   
 Heat (ouh<hl< ) 
 Sharpness (%Ijl) 
 Lubrication (ofb<h<H) 
 Relaxation (ofgqp<s<sq) 
 Motion (-bg<gl<) 
         The normal structure and functions gets modified in Vali Azhal Keel Vayu.   
uik!lqG!G{l<<<<:!   
 “nxqbuql<!&e<xqe<!ke<jl!osie<eiIff<kq!
! ! Wxqb!fz<uik!olxqg<Gr<!G{r<OgT!
! Gxqobeg<!jggiz<!Gjts<S!uqziss<f<K///”!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!kqV&zI!gVg<gqjm!juk<kqbl<!711!< < << < << < < !
!! uikuQX!ne<elqxr<!giK!gMh<H{<mil<!u{<{L{<mil<!
! ! OliKgm<G!Ovigl<!SvL{m<i!lqVlZli!Lxr<gioke<Xl<!
! YKkiqb!uikleziG!fMg<gL{<mil<!ohiVt<!gtbIf<k!
! ! kQokeOu!fvl<hqk<K!sf<Kgt<!OkiXr<!gMg<Gf<!kqeLf<kiOe”!
. OkjvbI!uigml<<<<!)himz<!w{</321?!hg<gl<!w{</69< < < < << < < < << < < < < *!
 “kg<g!uiB!Ogihqk<kiz<!sf<Kjtk<K!$jzOfiui!
! ! lqg<g!ogim<miuq!uqm<mr<!ogiqB!lzr<ogm<Ml<!
! yg<g!fvl<H!kie<!Lmr<G!lzIf<K!uib<!fQ'xquVl<!
! ! lqg<g!GtqVl<!fMg<glib<!Oleq!Ge<xq!uVr<giOe”!
. OkjvbI!uigml<!)himz<< << << <!w{</54?!hg<gl<!w{</24*!< < < << < < << < < < !
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!
! uikl<!lqGl<OhiK!hsqbqe<jl?!dmz<!gMh<H?!Svl<?!-Vlz<?!dxg<glqe<jl?!
dmz<! fMg<gl<?! fvl<Hk<! ktIs<sq?! sf<Kgt<! OkiXl<! Gjmkz<?! uqzis<sf<Kgt<!
Ofikz<?!ubqX!ohiVlz<?!Gmzqjxs<sz<?!lzs<sqg<gz<?!lqGf<k!ogim<miuq!Ohie<x!
Gxq!G{r<gt<!Okie<Xl</!
hqk<kl<!lqG!G{l<< < << < << < <:!  
 g{<,! lzl<?! sqXfQI?! Okiz<! -jugt<! lR<st<! fqxl<! njmkz<?! hsq?!
fQIOum<jg! lqGkqh<hmz<?! dmz<! Lx<Xl<! wiqs<sz<! d{<mikz<?! Gjxf<k! K~g<gl<!
Ohie<x!Gxq!G{r<gt<!Okie<Xl</!! 
            So, In Vali Azhal Keel Vayu, Vatha Pitha dosham, it produce stiffness, 
swelling, restriction of movements in the affected joints.  
! kieie!gQz<uik!Ovigl<!Ohjv!
! ///////////////////////////////////////////////////////////////////////////////!
! ohiz<zik!-f<k!Ofib<!gi[l<!hiV!
! fiOlkie<!Lpr<giz<!ohiqbgQz<gt<!
! fe<jlBme<!njks<!Sx<xq!-Vg<Gl<!su<uqe<!
!!!!!///////////////////////////////////////////////////////////////////////////////”!!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!ngk<kqbI!G{uigml<!< << << <   
         According to Agasthiyar Gunavagadam, Vali azhal keel vayu affects all joints 
and their periarticular surface.  So, the Vali Azhal Keel Vayu is affecting major, 
minor joints and end stage it can  produce the disability.  
Prodromal symptoms of Keel Vayu (Lx<Gxq!G{r<gt<< < << < << < <):   
              Nasal block, running nose, hoarseness of voice, low grade fever, painful 
arthralgia are common symptoms of Vali azhal Keel vayu.   
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CLINICAL FEATURES OF VALI AZHAL KEEL VAYU:   
In pararasa Sekaram , 
! osiv<sQOk!Ukqvuik!SOvi{qk!Lpr<giz<!kiEl<!
 ohix<gj{g<!giZf<!sf<Kl<!Hxuc!kiEl<!uQr<gq!
 fx<g[!uqvz<g!oeif<K!!fMh<hbqk<kqb!uikk<kqz<!
 dx<hug<!G{L{<mi!LXF~zqx<!osie<ekiOl!
 - Swelling of ankles and knee joint  
 - Swelling of hind foot 
 - Pain in the interphalangeal joints 
 - characters of  paithya vatham are seen  
 According to Sabapathy Manuscript,   
 “uik!hqk<kg<!gQz<!uiBuqe<!
! ! uVr<Gxqs<!six<xg<!Ogtib<!
! WkliI!lf<k!Olh<hl<!
! ! -jvs<sZl<!ubqx<xqx<!gi[l<!
! YkVr<!Gk<kz<!uQg<gl<!
! ! Yb<kzqz<!wiqs<s!Z{<mil<!
!!!!!!!!gikX!Lxg<g!lqe<jl!!
!!!!!!gib<s<sZr<!gi[r<!g{<mib<” 
Sapapathy  manuscript  
 Vali azhal keel vayu have the symptom of indigestion ( i.e ) 
Mantham,Aeppam, Eraichal ( Borborygmus of the abdomen . This disease occur due 
to excessive intake of foods which increases vatha and pitha ( e.g, mutton egg, fish 
potato ) and frequent intake of liquers .Laziness may also be produce this disease. 
 In this disease first eruction due to indigestion then the formation of gas in the 
abdomen, constipation and obesity also occur. 
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 Wrist, ankle and phalangeal joints are mainly affected, there is redness, pain 
and burning sensation in the affected joints. It is difficult to relieve from the disease . 
 Even though it gets relieved it repeatedly occurs in the same joints and 
produce ankylosis and hence all the movements of the joints become restricted. It may 
be associated  with insomnia, restlessness and mild fever.    
i) According to Yugi Muni,   
 “jugqklib<g<!gj{g<giZ!Lpr<giz<!kiE!
! ! lx<gmR<!sf<KHx!ucBl<!uQr<gqs<!
! osb<gqkliR<!sqXuqvz<gt<!lqgU!ofif<K!
! ! sqf<jkkG!lixqOb!szqh<H{<miGl<!
! jhgqklib<!hbqk<kqbk<kqz<!uik!lqR<sqh<!
! ! hivli!Bx<huqk<!kpZ{<!miGl<!
! db<gqkil!lselK!kiEl<!Ou{<mi!
! ! dkqvuiks<!SOvi{qkk<kq!E{Is<sq!biOl”!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!.!sqk<klVk<Kul<< < << < << < <!(ohiK)!(hg<gl<!w{</< < << < << < < 609)  
 Vali azhal keel vayu,  one of the 80 Vatha disease characterized by swellings 
especially in ankle, knee joints. Secondary it can produce depression, fatigueness, 
anorexia, because it is deranged (or) altered Vatha and Pitha dosham.   
Vaidhya sara sankiragam , 
jg!giz<gt<!ohiVk<Kgtqz<!gvMgm<c!Oleqobz<zil<!
kck<Kh<!H{<{il<!uikhqk<k!S,jz!weh<hMl<!
 Vatha pitha soolai cause ankylosis of the joints along with it some extra 
articular  structure like skin may be involved with the formation of ulcers . 
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ii) According to Theriyar in Theriyar Vagadam,    
              “olipq!uikl<!olipqgOmiXr<!gvj{gm<Ml<!!
!!!!!!///////////////////////////////////////////////////////lqsqf<K!OfiGl;”    
                            - OkjvbI!uigml<!&zLl<?!djvBl<!< < << < << < < !
                               (himz<!w{</326?!hg<gl<!w{</6:< < < < << < < < << < < < < )  
               Theriyar defines,  Mozhi Vatham is one among the 81 Vatham. The 
characteristic features of joint pain, erosion and fusion of joints, causing deformity 
leading to inability to use the joints.   
 “Lxqf<k!uikl<!uf<kiz<!
! ! wPf<kKOl!fmg<g!ouim<miK”!
!!!!!!!!!!!!!!!!!!!-!uikOfib<!lVk<Kul< << << < << <<!(hg<gl<!w{</275< < << < << < < ) 
     “uiiqfQI!ohVGl<!OhiOz!dzIf<kqMl<!&mMl?<!giZl<!
! ! hiGx!sf<K!OkiXl<!hvf<Kmz<!Stqk<Kg<!Gk<Kl<!
! giiqjg!dkqvolz<zil<!fbf<KOl!uVf<kquiMl<!
! ! %iqb!uikole<X!ogix<xuI!uVk<kiI!kiOl//.” 
    - uikOfib<!lVk<Kul<!< < << < << < < (hg<gl<!w{</279< < << < << < < )  
              Kooriya Vatham is one among the 80 types of Vatha disease.  It is 
characterized by painful interphalangeal joints and swelling.  
             All the above features described in various texts closely resembles the clinical 
features of Vali Azhal Keel Vayu (Rheumatoid Arthiritis).   
iii). According to Panditharathna Dr. S. Chidambarathanu Pillai, Siddha 
Medical Literature Research Centre,  
 “dmzK!ouKl<hq!jg!giz<gt<!
! ! djtUme<!gMk<K!ofif<K!
! gmzjz!kie<!hqv{<mih<!OhiOz!
! ! gek<KOl!nbIf<K!gi[l<!
! smlK!uqPf<K!kigl<!
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! ! sR<szl<!Oki]l<!d{<mib<!
! Lmlkil<!jggiz<!ke<je!
! ! Lmg<gqb!uikole<Ox” 
DIAGNOSIS IN SIDDHA:  
 A). Piniyari Muraigal (Methods of Diagnosis) is based upon three main topics 
namely,  
 Poriyal Aridhal (Physical Examination, Perception)  
 Pulanal Aridhal (Palpation)  
 Vinadhal (Interrogation)   
Poriyal Aridhal (Inspection):   
       ‘Poriyal Aridhal’ means examining the ‘Pori’ of the patient by the ‘Pori’ of the 
physician for proper diagnosis.  Pori is considered as the ‘five sensory organs’ of 
perception namely.   
 Mei (Skin) 
 Vai (Tongue) 
 Kan (Eye)  
 Mooku (Nose) 
 Sevi (Ear)  
RiOef<kqiqgtqe<!Nb<U< < << < << < <  
Hze<gt<< << << < okipqz<gt<< << << <! utq!npz<!gQz<!uiBuqz<!< Q < << Q < << Q < < hikqh<H<<<  
osuq! yzqjb!nxqb!osb<b! -bz<H!
olb<! Dmzqz<!Dx<jx!nxqkz;! &m<Mg<gtqz<!uzq,!uQg<gl<!
g{<! ytqjb!nxqbs<!osb<kz<! -bz<H!
fig<G! Sjujb!nxqbs<!osbz<! -bz<H!
&g<G! uisjejb!Fgvs<!osb<kz<! -bz<H!
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geOlf<kqiqbr<gtqe<!Nb<U< < < << < < << < < <  
Hze<gt<< << << < okipqz<gt<< << << <! utq!npz<!gQz<!uiBuqz<!< Q < << Q < << Q < < hikqh<H<<<  
uib<! Ohss<!osb<Bl<! -bz<H!
jg! -MkZl<,!Wx<xZl<!osb<Bl<! hikqh<H!
giz<! fmg<gs<!osb<Bl<! &m<Mg<gtqz<!uzq,!fmg<gs<!!sqvll<!
wVuib<! lzk<jkg<!gpqg<Gl<!! lzs<sqg<gz<!
gVuib<! gV,!Sg<gqzk<jkg<!gpqg<Gl<! -bz<H!
!  
Pulanal Aridhal (Palpation):   
        The five sense are given below:  
 Smell 
 Taste 
 Vision 
 Sensation of touch  
 Hearing         
        By examining the ‘Pulan’ of the patient the physician can diagnose the disease.  
Vinadhal (Interrogation):  
           Vinadhal is questioning and gathering information regarding the previous 
history of disease and clinical features which is much essential for diagnosis.  
b). Envagai Thervugal (Eight Diagnostic Tools):   
                         The excellent and unique method in the Siddha system is the Envagai 
Thervugal. 
 They are,   
 “okiMg<gZx<x!nm<muqkh<!hvqm<js!ke<je!
! ! Kzg<gLXl<!h{<ckOv!oktq!ukigh<!
! hGg<gvqb!ficOb!fQhqck<Kh<!hiV!
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! ! hgi<gqe<x!uii<k<jkh<!hii<!fiju!hiV!
! uGg<gvqb!Okgolek<!okim<Mh<!hiV!
! ! sgqg<gvqb!lzk<jkh<!hii<!szk<jk!hiV!
! sii<f<k!uqpqkjeh<!hii<k<K!oktquib<!giO{”/!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
! ! ! ! ! ! -!ngk<kqbi<!juk<kqb!uz<zikq!711< < < << < < << < < < !
1. Naadi (Pulse):    
  Among the Envagai Thervugal, Naadi is the  most important. Naadi is felt as 
Vatham, Pitham and Kapham with the tip of the index, middle and ring fingers 
respectively over the end of the radius.    
      Normally Vatham, Pitham and Kapham are held in the ratio of 1:1/2:1/4. 
Derangement in this will reflect as disease. Naadi Nadai in Keel Vayu is,  
! ! uikk<kqe<!G{Ol!ke<eqz<!
! ! ubqX!ohiVlqg<!ogit<Tl<!
! ! kigk<kqz<!Oleq!jggiz<!
! ! sf<KOl!gMh<Hk<!Okie<Xl<!
!!!!!!!!!!!!!! ! ! ! !.!Gxq!bjmbie<!fic!<<< !
! ! nxqBl<!uikk<kqz<!nMk<k!hqk<klibqe<!
! ! GxqbKkie<!uiBr<GpXl<!ofxqbig!
! ! GtqVr<!!giz<uQr<Gl<!Gmz<!Hvm<Ml<!uql<lqk<!
! ! oktquqz<jz!Hk<kqobes<!osh<H!
. g{<[silqbl<we<El<juk<kqb! !< < < < << < < < << < < < < –!
Osgvl<!!!!!!!!!!!!!!<<< !
! ! “uim<cMl<!Osk<K!lk<kqz<!uf<kqMl<!uikligqz<!
! ! !! fim<cb!giz<gt<!Ohiz!fvl<ohz<zil<!uzqk<K!fqx<Gl<” 
       -(n/L/fic) 
!
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  “kqVk<klil<!uikk<!OkiOm!kQr<ogiM!hqk<kR<!Osiqz<!
! ! ! !ohiVk<K!gt<OkiXl<!ofif<K!OhikOu!hqcg<Gl<!$jz”!
! ! ! ! ! Ofibqe<!sivl<!< << << < .!sqk<k<<< lVk<Kul<!)ohiK*< << << < !
! ! ! ! ! ! ! ! )hg<<<<gl<!w{</745*< << << < !
  “uib<k<kqMl<!uiklq{<M!oliVsqOzk<l!OliMligqz<!
!!!!!!!!! ! !!dbk<kqMl<!jgiz<!ofif<K!dbi<gek<!kqMh<HOfiGl”<!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! ! !!-)skgfic*!!
  “gi{h<hi!uik!lQxqz<!
! ! ! giz<jggt<!ohiVk<K!OfiGl<”!
!!!!!!!!!!!!!!!!!!!!!!!.!giuqbfic!.!sqk<k!lVk<Kul<!)ohiK*!!!!!< < << < << < < !
!!!!!!!!!!!!!!!!!!!!!!!!!!!!(hg<<<<gl<!w{</74< << << < 5)  
In Vali Azhal Keel Vayu,  the following Naadi is commonly felt.   
 Vatham 
 Vatha Pitham  
 Pitha Vatham  
 2. Sparisam (Sensation to touch):    
           In Vali Azhal Keel Vayu,  heat is noticed over the affected joints.   
3. Naa (Tongue):   
           In Vali Azhal Keel Vayu,  no abnormality is seen in Naa.   
4. Niram (Colour):   
           In Vali Azhal Keel Vayu,  some skin colour changes are seen in affected area 
due to inflammatory mechanism.  
5. Mozhi (Voice):   
            In Vali Azhal Keel Vayu, no abnormality is seen in mozhi. 
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6. Vizhi (Eyes):   
            In Vali Azhal Keel Vayu,  Eye pallor is reported in some cases.  
7. Malam (Faeces):    
            In Vali Azhal Keel Vayu,  Constipation is reported in some cases.   
8. Moothiram (Physical appearance of Urine):   
            In urine, Neer kuri and Nei kuri examinations are done.   
Nei kuri (Oil Examination):   
            Prior to the day of urine examination the patient is instructed to take a 
balanced diet and quantities of food must be proportionate to his / her appetite.  The 
patient should have no disturbed sleep. After waking up in the morning, the first urine 
voided is collected in a clear wide mouthed glass dish or china clay bowl and is 
subjected to analysis of Neer kuri and Nei kuri within one and a half an hour of its 
collection.   
            The collected urine specimen is kept in a glass dish or china clay container and 
observed under direct sunlight without shaking the vessel.  Then add one drop of 
gingelly oil and observe the spreading pattern and conclude as follows:  
   “nvoue!fQ{<ce!n0Ok!uikl<!
! ! NpqOhix<!hvuqe<!n0Ok!hqk<kl<!
! ! Lk<okik<K!fqx<gqe<!olipqu!oke<!ghOl” 
                              - Ofib<<<<!fimz<<<<!higl</2<<<       
!!!!!!!!!!!!!!!!!!!!!!!!!!!!! ! ! (hg<<<<gl<!w{</3:9?!3::< << << < )  
Neer kuri:   
                 “ uf<k!fQi<g<giq!objm!l{l<!Fjv!wRs<oze<!
!!!!!!!!!!!! !jxf<kqbZtju!bjxGK!LjxOb”!!!!!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!-!sqk<k!lVk<Kuir<g!SVg<gl<!!!< < < < << < < < << < < < < !
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! !)hg<<<<gl<!w{</621*!!!< << << < !
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! In urine examination the following characteristic features were observed namely.    
  Niram   -  Colour  
           Edai      -  Specific gravity  
           Manam -  Smell  
           Nurai    -  Frothy nature   
           Enjal     -  Quality of urine voided    
 Apart from these, frequency of micturition, abnormal constituents such as sugar, 
protein, blood stains, pus, crystals also to be found out.  
 In Vali Azhal Keel Vayu, Straw or Hay coloured urine was noticed in Neer kuri.   
c. hVugizl<<<<< <<:!!
u/w{<<<<! !!!!!!!!!!!Gx<xl<< << << <! gizl<<<<!
     1. uikl<!ke<eqjz!njmkz<! Le<heq! gizl<! ,hqe<heq!
gizl<,! %kqi<! gizl<,!
-tOueqz<!gizl<!
     2. uikl<!ke<eqjz!uti<s<sq LKOueqz<!gizl<!
     3. uikl<!Oux<Xfqjz!uti<s<sq! gii<gizl<!
 
!!! LKOueqx<!gizk<kqz<!flK!dmzqz<!uxm<sq!Wx<hm<M!utqOfib<!uVukx<G!
WKuigqxK/!
d). kqj{ (Geographical distribution):  
GxqR<sq!<<< ;!ljzBl<?!ljz!siIf<k!hGkqBl<!
Lz<jz!<<< ;!giMl?<!giM!siIf<k!hGkqBl<!
 “Lz<jz!fqzk<kbOl!&iqfqjv!OleqElu<!
! ! ouz<jz!fqjzk<khqk<k!olr<GXr<gi{<!.!uz<jzobeqe<!
! uikolipq!bikkE{<!le<E!ljuupqOfib<h<!
! ! Ohkolipq!bikjxbh<!hqe<H”!
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)ohipqh<Hjv*;<<< !
Lz<jz!fqzk<kqz<!NM,!hS,!wVjl!Lkzqbju!-Vh<hqEl<!nf<fqzk<kqx<G!diqb!
hqk<kOfib<! wu<uqmk<kqx<! Ohib<! fqx<Gl<@! ne<xqBl<! uz<jzOfib<! d{<miGl</!
-keiz<!uik!OfiBl<!uf<KXl<!Njgbiz<!-f<fqzk<kqz<!uiks<!sii<hie!Ofib<gt<!
hzUl<!d{<miGl</!
lVkl<!!<<< ;!ubZl<?!ubz<!siIf<k!hGkqBl<!!
ofb<kz<!< << << < ;!gmZl<?!gmz<!siIf<k!hGkqBl<!
“ofb<keqOz!OlZh<jh!fQr<gi!KxqElK!
ofb<keqOz!Olkr<G!uQmiGl<!.!ofb<kz<!
lVr<Gmjz!lqg<gig<Gl<!uz<ZXh<jh!uQg<Gl<!
gVr<Gmjzg<!gQpqxr<Gr<!gi{</”!
)ofb<kz<! fqzk<kqz<-lqg<g! dh<H! uqjt! ohiVtibqVh<! hqEl<! nf<fqzk<kqz<!
ogiMjlbie!uikOfib<gOt!d{<miGl<*!
!hijz!!;!l{Zl<?!l{z<!siIf<k!hGkqBl<!!! !
!Lz<jz!lx<Xl<!ofb<kz<!fqzr<gtqz<!uik!Ofib<gt<!ohVltuqz<!Wx<hMl</!
e). WP!dmz<!kiKg<<< << <<gtqe<!Nb<U< << << <   (Seven Udal Thathukal Examinations):  
Seven Thathus  
1. Saaram – Strengthens the body and mind  
2.  Senner – gives power, knowledge and boldness to the mankind  
3. Oon – It strengthens the body 
4. Kozhuppu – It lubricates the joints 
5. Enbu – It protects all the internal organs and gives the structure to the body 
6. Moolai – It is present in the bones  
7. Sukkilam and suronitham- Mean for reproduction ( male and female 
gonads )  
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SI.No. Udal  
Thathukal 
Increased conditions Decreased 
condition 
1. Saaram Loss of appetite , excessive salivation Tiredness , fatigue , 
diminished activity 
of the sense organs. 
2.  Senneer Boils and tumours in different parts of 
the body, spleenomegaly, colic pain, 
increased blood pressure reddish eyes 
and skin, jaundice, leprosy, 
haematuria.  
 
Tiredness, lassitude, 
anemia. 
 
3. Oon Tumours or extra growth around the 
neck, face, abdomen, thigh, genitalia 
etc., with dyspnoea.  
Muscle wasting  
 
Muscle wasting 
4. Kozhuppu 
 
Pain 
5. Enbu Extra growth of bone and teeth Weak bones , teeth , 
nails and hair. 
6. Moolai Heaviness, swollen eyes, swollen 
phalanges, oliguria and non healing 
ulcers.  
Osteoporotic changes.  
 
Osteoporotic 
changes. 
7. Sukkilam or 
Suronitham 
Increased sexual activity and 
symptoms as that of urinary calculi.  
 
Infertility , pain in 
genitalia. 
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In Vali Azhal Keel Vayu:  
 Saaram, Seener, Kozhuppu, Enbu, Moolai thathukal are commonly affected.    
          Saaram : Weakness, pain in all major and minor joints.  
          Seneer: Tiredness anemia 
          Kozhuppu : Early morning stiffness occurs in affected joints.  
          Enbu  : Joint space narrowing, marginal erosions and deformities.  
          Moolai  : Joint effusion and oedema are seen in the joints.   
MUKKUTRAM:   
  Uyir thathukal i.e., Vatham, Pitham and Kapham responsible for normal 
physiological conditions of the body. Vatham is mainly responsible for proper 
locomotor functions.  Bones and joints are the major site of Vatha. 
Vatham:- 
 Locations of  Vatham 
 Vatham is located in abana vayu , faeces , idakalai , spermatic cord , pelvic 
bone , skin,  nerves, joints etc., 
Types of vatham  
1. Piranan ( uyirkkal )  
 This controls knowledge,  mind and five objects of senses which are helpful 
for breathing and digestion  
2. Abanan ( Keezh Nokkukal ) 
 This is responsible for all downward movements such as passing of urine, 
stools, sperm,  menstrual flow, etc.,  
3.  Samanan ( Nadukkal )  
 This aids for proper digestion. 
4. Viyanan ( Paravukkal)  
 This is responsible for movements of all parts of the body   
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5. Uthanan ( Mel Nokukkal ) 
 Responsible for all upward visceral movenments such as cough, hiccup, 
vomiting, nausea etc., 
6. Nagan 
 Responsible for opening and closing of the eyes.  
7. Koorman 
 Responsible for vision and yawning  
8.Kirukaran 
 Responsible for salivation, nasal secretion and appetite  
9. Dhevathathan 
 Responsible for laziness, sleep and anger 
10.Dhananjeyan  
 Produces bloating of body after death and escapes on the third day by bursting 
the cranium 
   In vali azhal keel vayu Abanan, Viyanan, Samanan, Koornan and Kirukaran 
are affected and they produce symptoms as follows  
- Affected Abanan produces constipation, 
- Affected Samanan produces loss of appetite and indigestion 
- Affected Viyanan produces pain and restriction of movements of the 
Affected joints 
- Affected Koorman produces disturbed sleep 
- Affected Kirukaran produces loss of appetite 
Pitham 
 Locations of Pitham 
 Pitham is located in pirana vayu, bladder, moolaakini, heart, umbilical, region, 
abdomen, stomach, sweat glands,eyes, saliva, blood etc., 
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Types of pitham 
 Analapitham- It gives appetite and helps digestion  
 Pirasagapitham – It gives complexion to the skin 
 Ranjagapitham – It gives colour to the blood 
 Alosagapitham – It brightens the eye 
 Sathagapitham – it controls the whole body 
 In vali azhal keel vayu Analapitham, Pirasagapitham, Ranjagapitham, and 
Sathagapitham maybe affected. 
 Affected Analapitham produces loss of appetite  
 Affected Ranjagapitham produces anemia 
 Affected Sathagapitham produces disability to carry out regular works  
 Affected  Pirasagapitham produces pallor of skin 
Kabam  
 Kabam is located in samana vayu , sperm, head, tongue, vulva etc., 
Types of Kabam 
 Kilethagam – Lies in stomach, makes food soft and helps in digestion 
 Avalambagam – Lies in lungs, controls the heart and other kabas, 
 Pothagam – responsible for indentifying tastes  
 Tharpagam – present in the head and responsible for the coolness of both 
eyes 
 Santhigam – responsible for the lubrication and free movement of the joints. 
 In vali azhal keel vayu, Kilethagam and Santhigam may be affected  
 Affected Kilethagam causes loss of appetite   
 Affected Santhigam causes pain in the joints . 
 
 32 
 
 
Noi Varum Vali (Aetiology) is tabulated below:  
  
   !
!
!
!
!!!
!!
!!
!!
!!
!!
!!
!!
!!
!
!
!
!
!
!!
   In Vali Azhal Keel Vayu, the Vatha kutram and Pitha kutram is mainly 
affected.  The symptoms and signs are,  
  Deranged Viyanan leads to painful stimuli and difficulty in movements with 
early morning stiffness.  
  Deranged Abanan leads to constipation.  
 ge<l!uqje! d{U!
hpg<g!
upg<gr<gt<!
giz!liXhiM!
uik!hikqh<H! hqk<k!hikqh<H!
nhiee<!, gqVgve<!
!uqbiee<!, %i<le<!
sliee<?!Okukk<ke<!
nezhqk<kl<?!!!
-vR<sg!hqk<kl<?!
sikgl<, hqvisgl<!
gqOzkgl<?!sf<kqgl<!
!
utq!npz<!gQz<uiB!!
ghl<!hikqh<H 
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  Inflammatory changes of the joints, heat, redness and swelling are developed 
due to altered Pitham. Ranjaga Pitham is reduced haemoglobin level. Sathaga 
Pitham is hindering of the locomotor functions. 
  Along with Vatham, Kapham is also deranged, Santhigam is affected and this 
leads to abnormality in joint movements. 
  Erosion, loss of joint space, increased secretion of synovial fluid may lead to 
synovial effusion due to increased Kapham.  
SI.No Name Location Physiological function 
1. Abanan 
Lower abdomen 
and extremitis 
Responsible for urination, defecation, 
parturition, menstruation and ejaculation of 
the sperm. 
2. Viyanan Heart, Skin 
Responsible for movements of all parts of the 
body and sensation. 
3. Samanan Stomach Responsible for proper digestion. 
 
NOI KANIPPU VIVATHAM (Differential Diagnosis):   
 Vali Azhal Keel Vayu is differentiated from the following diseases,  
2/!sf<K!uikl<)< << << < Santhu Vatham*!)Infective Arthritis) 
 “osb<jg!kie<!sf<KgT!lqgk<!kqlqi<f<K!
! ! smolr<Gl<!ofik<KOl!lqgu!px<xq!
! jfjgbib<!fZk<KOl!lbqi<g<!s<szqm<M!
! ! fi{qOb!Le<Ohiz<!fjm!ogimiK!
! jljgkie<!lbg<goliM!uib<!fqVXl<!
! ! uv{<cMOl!fiUkiecg<g!cg<Gg<!
! jggiz<kie<!kv{qkeqx<!xvqg<!ogi{iK!
! ! sR<siqg<GR<!sf<Kuil<!uikr<!OgOt”/!
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 Pain in joints ,body pain, inability to walk, giddiness,dryness of tongue, 
excessive salivation and unable to stand in floor is a characteristic features of the 
disease.  
2. Azhal Keel Vayu:   (Osteoarthritis) 
 “hqk<kg<gz<!uibU!ke<eix<!hqxr<GgQe<!Lm<M!uQr<gqs<!
! ! sqk<kI!lVk<K!uk<KR<!sQvhmik<!ke<jlk<!kigqk<!
! kk<kX!gib<s<sz<!g{<M!sizOu!kjekie<!kf<Ok!
! ! olk<kX!sqgqs<js!ke<eiz<!ole<olz!fQr<G!lh<hi”!
!!!!!!!!!!!!! ! !.!shihkq!jgObM!sqk<k!lVk<Kul<!)ohiK*!!!!!< < << < << < < !
!!!!!!!!!!!!!!!!!!!! ! ! ! ! !!)hg<g<<< l<!w{</737*!< << << < !!
        It is characterized by swelling of joint associated with severe pain and fever. In 
later stages joints gets fused, resulted in disability.    
3. Iya Keel Vayu:  (Tubercular arthritis) 
! “gVkVr<!ghg<gqz<!uiB!g{<cce<!dmzqjtg<Gl<!
! ! dVolzquig<Gr<!ogit<Tl<!d{<cjbs<!SVg<G!lqehf<!
! kVKbqz<!fr<G!Lm<cx<!xir<ogi{i!uZjubig<Gl<!
! ! -VlOz!uqg<gz<!uif<kq?!Osijh!hi{<omPh<Hl<!hiOv”!
!!!!!!!!!!!!!!!!! !!.!shihkq!jgObM!sqk<k!lVk<Kul<!< < << < << < < (ohiK) 
!!!!!!!!!!!!!!!!!!!!!! ! ! !!(hg<<<<gl<!w{</738< << << < )!!
  It is characterized by severe pain in the joints associated with loss of weight, 
anorexia, insomnia, cough, hiccough, vomiting, anemia and dropsy.  
5/!fiqk<kjz!uikl<< << << <!)Narithalai Vatham* (Gonococcal arthritis) 
 “Li<g<glib<!Lbe<X!Lpr<giz<kie<!uqr<gq!
! ! Lkqi<f<Kvk<k!Lf<kqv{<M!Lbx<sq!bigq!
! fqg<glib<!kqe<xqmoui!{ilx<!xiEl<!
! ! fqlqi<f<kqMgqz<!sf<Kf<kie<!Lmg<!ogi{ilz<!
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! osPjl!fiqk<!kjz!Ohiz!lqgOu!uqr<gq!
! ! fii<g<glib<!ficBOl!hmhmg<Gl<!
! fiqk<kqjzbqe<!uikole<Ox!fuqz!ziOl”/!
 Swelling of the knee joint with hyperemia, difficulty  to stand,palpitation will 
be seen, the swelling looks like the head of the fox are the features of this disease. 
5. Vali Iya Keel Vayu: (Synovial effusion)    
 “njubl<!uikg<!ghg<gQz<!uiBuie<!uzq!lqGf<Ok!
! ! dbr<G!fQI!Ogik<K!gQz<gt<!yiqbqe<!kjzOhix<!gi[l<!
! fbr<ogit<t!Lmg<gz<!fQm<mz<!f{<{qmiolb<!Br<giBl<!
! ! lbg<GX!Lxg<glqe<eil<!le<eqb!ofiqg<gm<!miOl”!
!!!!!!!!!!!!!!!!!! !.!shihkq!jgObM!sqk<k!lVk<Kul<!)ohiK*!!!!!!< < << < << < < !
!!!!!!!!!!!!!!!!!!!! ! ! ! !!)hg<<<<gl<!w{</739*!< << << < !
  It is characterized by pain in the joints associated with effusion of joint fluid, 
swelling, restricted joint movements, pyrexia, fainting, insomnia, asymmetrical 
presentation lymphadenopathy, generalized malaise, atrophy of the affected limb etc.,    
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MODERN ASPECTS 
RHEUMATOID ARTHRITIS 
             Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease 
where the body's immune system attacks normal joint tissues, causing inflammation 
of the joint lining. This inflammation of the joint lining can cause pain, stiffness, 
swelling, warmth, and redness that can eventually result in bone erosion and joint 
deformity.   
EPIDEMOLOGY:   
            Rheumatoid arthritis is affecting approximately 1.3 million people in the 
developed countries. The disease is three times more common in women as in men. 
The individuals with HLA-D4 and HLA-DR4 are more prone to Rheumatoid 
arthiritis. It afflicts people of all races equally. The disease can begin at any age and 
even affects children (juvenile idiopathic arthritis), but it most often starts after 40 
years of age and before 60 years of age. Though uncommon, in some families, 
multiple members can be affected, suggesting a genetic basis for the disorders.   
CAUSES AND RISK FACTORS:   
            The cause of rheumatoid arthritis is unknown. 
            The risk factors may be:    
 Infections.  
 Hereditary. 
 Environmental factors.    
              
 Smoking    
 Tobacco chewing  
 Exposure to Silica Mineral    
 Periodontal diseases  
  Even though infectious agents such as viruses, bacteria, and fungi have long 
been suspected, none has been proven as the cause. The cause of rheumatoid arthritis 
is a very active  area of worldwide research.   
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           Rheumatoid arthritis is a chronic multi system, inflammatory, autoimmume 
disease that affects the synovia and cartilages of small and large joints as well as other 
organ system.It is a destructive disease that involves boyh cell mediated and humoral 
immune responses. 
             The initial underlying causes of RA is still unknown. Cartilage damage is 
because of the CD4+  T-cells recognition of antigens with in the joint that triggers the 
release of inflammatory cytokines that lead to the accumulation of neutrophils and 
macrophages. 
          Within the inflamed synovia or B cells,plasma cells,CD4+ T cells, and various 
types of inflammatory cytokines,such as tumor necrosis factor(TNF),IL-1,IL-8,and 
IFN-α  
          Rheumatoid factors are formed that facilitate the formation of immune 
complexes.In the most  patients with RA, antibodies to cyclic citrullinated peptide 
(anti-CCP) are detected before RA symptoms develop.   
          In advanced stages of RA,deposition and complement fixation of the immune 
complexes may contribute not only to joint destruction but also to 
vasculitis,carditis,and pleuritis.  
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PATHOGENESIS:  
                                                    Genetic  Susceptibility 
                                     MHC class II (Major Histocompatibility Complex) 
                                                                 (or) 
                                                 HLA( Humen Leucocyte Antiens) 
                                                                                         Antigenic Stimulation 
                                                                                                (Infection Agent) 
 
                                                                           CD4+T-cells 
                                                                                  
 
                                                                         Cytokines 
                                                                       (TNF-,TNF-,IL-1) 
  
 
 
                                 Activate                             Activate Activate 
 
 
  
                                  B-cells                      Endothelial cells                           
Macrophages 
                                    
  
                   Anti-IgG antibody            Release of adhesim molecules Cytokines  
proteases 
               ( Rheumatoid factor) 
 
                                                        
                           Formation of immune complex,inflammatory cells,pannus 
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Synovium:   
  The synovium, in normal joints, is a thin delicate lining that serves several important 
functions. The synovium serves as an important source of nutrients for cartilage since 
cartilage itself is a vascular. In addition, synovial cells synthesize joint lubricants such 
as hyaluronic acid, as well as collagens and fibronectin that constitute the structural 
framework of the synovial interstitium.  
1. Synovial lining or intimal layer: Normally, this layer is only 1-3 cells 
thick. In RA, this lining is greatly hypertrophied (8-10 cells thick). Primary 
cell populations in this layer are fibroblasts and macrophages.  
2. Subintimal area of synovium: This is where the synovial blood vessels 
are located this area normally has very few cells. In RA, however, the 
subintimal  area is heavily infiltrated with inflammatory cells, including T 
and B lymphocytes, macrophages, macells,andmononuclear cells that 
differentiate into multinucleated osteoclasts.  
            The intense cellular infiltrate is accompanied by new blood vessel growth 
(angiogenesis). In RA, the hypertrophied synovium (also called pannus) invades and 
erodes contiguous cartilage and bone. As such, it can be thought of as a tumor-like 
tissue, although mitotic figures are rare and of course, metastasis does not occur.   
Cartilage:   
   Composed primarily of type II collagen and proteoglycans, this is normally a 
very resilient tissue that absorbs considerable impact and stress. In RA, its integrity, 
resilience and water content are all impaired. This appears to be due to elaboration of 
proteolytic enzymes (collagenase, stromelysin) both by synovial lining cells and by 
chondrocytes themselves.    
   Cytokines including IL1 and TNF drive the generation of reactive oxygen and 
nitrogen species and while increasing chondrocyte catabolic pathways and matrix 
destruction, also inhibit  new cartilage formation. Polymorphonuclear leukocytes in 
the synovial fluid may also contribute to this degradative process.   
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Bone:   
   Composed primarily of type I collagen, bony destruction is a characteristic 
of  RA. This process is primarily driven by the activation of osteoclasts. Osteoclasts 
differentiate under the influence of cytokines especially the interaction of RANK with 
its ligand. The expression of these are driven by cytokines including TNF and IL1, as 
well as other cytokines including IL-17.  There may also be a contribution to bony 
destruction from mediators derived from activated synovial cells.    
Synovial Cavity:   
  The synovial cavity is normally only a “potential” space with 1-2ml of highly 
viscous (due to hyaluronic acid) fluid with few cells. In RA, large collections of fluid 
(“effusions”) occur which are, in effect, filtrates of plasma (and therefore, exudative – 
i.e., high protein content). The synovial fluid is highly inflammatory. However, unlike 
the rheumatoid synovial tissue in which the infiltrating cells are lymphocytes and 
macrophages but not neutrophils, in synovial fluid the predominant cell is the 
neutrophil.   
Disease Initiation:   
a) Genetic Susceptibilities:  
  Class II MHC on the surface of an antigen presenting cell interacts with a T 
cell receptor in the context of a specific antigen, usually a small peptide sequence 
from a protein. A sequence of amino acid residues with highly conserved sequence 
and charge characteristics within the hypervariable region of HLA-DR4 remains the 
largest genetic risk factor described for RA, estimated to contribute approximately 
30% of the genetic risk for the disease. It is hypothesized that a triggering peptide (or 
peptides) with a tight conformational fit for the pocket formed by these residues is an 
early event leading to the activation of T lymphocytes. More recently, it has been 
found that modified citrullinated peptides may have significant binding specificity for 
shared epitope alleles, with some data now suggesting that citrullinated sequences 
from different proteins are associated with allelic restriction.   
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            Other genetic susceptibilities include peptidyl arginine deiminase-4 (PAD-4) 
which may  lead to increased citrullination, PTNP22, STAT4, and CTLA4 which may 
be involved in T cell activation, TNF receptors, and others.  That RA has a genetic 
component is also borne out through monozygotic (from the same embryo, thus nearly 
identical DNA) and dizygotic (from different embryos) twins. In Research studies the 
concordance rates between twins was higher in monozygotic twins ranging from 15-
35% compared with dizygotic twins in which the concordance was in the 5% range.  
Even the dizygotic RA prevalence was higher than the general population estimates of 
approximately 1%. It is important to emphasize however that even in twins with 
nearly identical DNA, there was far from perfect correlation of the development of 
RA, implicating many other factors related to the development of disease than genetic 
factors.   
b) Citrullination:    
   Citrulline is a post-translational modification that occurs on arginine residues 
contained within proteins and peptides. There are a number of enzymes that can cause 
citrullination to occur, present in various cell types and tissues known as Peptidyl 
Arginine Deiminases (PADs).  Citrullination is a normal process, required for normal 
skin formation and other physiologic functions. The triggering factors of RA results in 
increase CITRULLINATION of Proteins. However, in rheumatoid arthritis an 
autoimmune response develops against citrullinated peptides detected as 
anticitrullinated peptide antibodies (ACPA).     
   The mechanisms to citrullination that lead to RA remain unclear.  A 
polymorphism in the PAD4 gene which may lead to increased citrullination has been 
described in few populations.  In RA patients, autoantibody responses also develop 
against the PAD4 protein, associated with a more aggressive disease course.  One 
species of oral bacteria Porphyromonas gingivalis has a PAD enzyme.  Given the 
relationships described with periodontal disease and RA, it has been hypothesized that 
this bacteria may also serve to initiate citrullination in the preclinical phases of RA.  
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 c) Propagation of Disease:   
i) T cell activation   
   Upon encounter with antigen in the context of MHC on an antigen presenting 
cell, a T lymphocyte is positioned for 3 possible fates: activation, anergy /tolerance, or 
apoptosis (death). T cell activation is only possible if the T cell receives a “second 
signal” through engaging additional cellular receptors.  One of the most important of 
these second signals is delivered through the CD28 molecule on the surface of the T 
cell but many other second signals are involved in this process of “costimulation”.  
Upon engagement of these receptors, a T cell usually becomes activated.  Failure to 
engage the stimulatory receptors, or engagement of a downregulator receptor will 
cause the cell to become tolerant to the antigen or to undergo programmed cell death 
through apoptosis. The process of T-cell costimulation is interrupted by abatacept, a 
biological therapy used to treat RA.   
   When T cells become activated, they will in turn proliferate and begin to 
secrete additional cytokines including IL-2 which furthers their proliferation, and 
depending on other exposures, cytokines such as IFN-γ, TNF, and IL-4.  It is the 
effect of these T-cell derived cytokines that additional cells become activated.  T cells 
also directly interact through surface receptors with other cells to generate additional 
activation signals.   
 ii) B Cell Activation and Autoantibodies 
   B cells become activated through interactions with T cells and through soluble 
cytokines that enhance their proliferation and differentiation.  B cells express a 
number of receptors on their surfaces during their differentiation, including the 
molecule CD20, which is lost upon terminal differentiation to antibody-forming 
plasma cells.  B cells and plasma cells can be found in rheumatoid synovium 
sometimes as lymphoid aggregates in the subsynovium.  The effects of B cells extend 
beyond their roles in forming plasma cells including cytokine production, direct 
cellular interactions, and they themselves serve as antigen-presenting cells to T 
lymphocytes.  The role of B cells in RA has been clearly demonstrated with the 
efficacy of rituximab which eliminates circulating B cells, though with  limited impact 
on autoantibody formation.   
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  Rheumatoid arthritis is characterized by the presence of autoantibodies known  
as rheumatoid factors (RF) and anti-citrullinated peptide antibodies (ACPA, which 
includes the anti-cyclic citrullinated peptide antibody or anti-CCP).These are 
autoantibodies in the classical sense; they are antibodies directed against native 
antibodies, most classically described as IgM antibodies that recognize the Fc portion 
of IgG molecules, but RF may also be of the IgG or IgA isotypes.     
iii) Effector Cell Activation  
   While T cells and B cells represent the immunological aspects of RA, most of  
the damage from the disease is driven through effector cells and their products 
including cytokines and other mediators.  The synovial lining in RA represents an 
expansion of fibroblast like cells and macrophages.  It is the macrophage that has been 
seen as one of the master orchestrators of the effector damage in RA. Macrophages 
are rich sources and major producers of pro inflammatory cytokines including TNF, 
IL-1, IL-6, IL-8, and GMCSF. These  cytokines further stimulate the macrophage, as 
well as other cells in the microenvironment in a including fibroblasts and osteoclasts, 
and finally at distant sites in the body through cell surface receptors including the 
hepatocyte which is responsible for the generation of acute phase response proteins 
(such as C-reactive protein).  Macrophages are also producers of prostaglandins and 
leukotrienes, nitric oxide, and other pro-inflammatory mediators with local and 
systemic effects.  The synovial fibroblast also secretes cytokines including IL-6, IL-8 
and GM-CSF, and other mediators including destructive proteases and collagenases.  
  Neutrophils are recruited in very large numbers to the rheumatoid cavity 
where they can be aspirated in the synovial fluid. The recruitment of 
neutrophils to the joint is likely driven by IL-8, leukotriene B4, and possibly 
localized complement activation through C5a.  Neutrophils in the synovial 
fluid are in an activated state, releasing oxygen-derived free radicals that 
depolymerize hyaluronic acid and inactivate endogenous inhibitors of 
proteases, thus promoting damage to the joint. 
   
  Chondrocytes like synovial fibroblasts, are activated by IL1 and TNF to 
secrete proteolytic enzymes. They may, therefore, contribute to the dissolution 
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of their own cartilage matrix, thus explaining the progressive narrowing of 
joint spaces seen radiographically in this disease.   
d) Inflammatory Mediators in RA:   
Cytokines:   
   One of the most important group of mediators in RA are cytokines. The most 
prominent of these are TNF, IL-1, and IL-6.  These cytokines, released in the synovial 
micro environment have autocrine (activating the same cell), paracrine (activating 
nearby cells), and endocrine (acting at distant sites) effects and accounting for many 
systemic manifestations of disease.  There are many shared functions of TNF, IL-1, 
and IL-6, and these cytokines in turn upregulate the expression of the others.  Among 
the important effects of these cytokines are: 
 Induction of cytokine synthesis 
 Upregulation of adhesion molecules 
 Activation of osteoclasts   
 Induction of other inflammatory mediators including prostaglandins, 
nitric oxide, matrix metalloproteinases 
 Induction of the acute phase response (Increased C-reactive protein, 
increased ESR) 
 Systemic features ( Fatigue, fever, Cachexia)  Activation of B cells                  
(IL-6)   
   Soluble mediators of inflammation that may diffuse in from blood and/or be 
formed locally within the joint cavity include prostaglandins, leukotrienes, matrix 
metalloproteinases. Prostaglandins are involved in pain sensitization, localized 
inflammation and some effects on bone. Leukotrienes play roles in vascular 
permeability and chemotaxis.  Matrix metalloproteinases (MMPs) are potent in their 
ability to enzymatically degrade  the collagen matrix of cartilage. Kinins cause release 
of prostaglandins from synovial fibroblasts, and are also potent algesic 
(painproducing) agents.     
   Complement may be available for interaction with immune complexes to 
generate additional chemotactic stimuli. The neuropeptide substance P is a potent 
vasoactive, pro inflammatory peptide that has also been implicated in RA.   
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SIGNS AND SYMPTOMS:   
• RA symptoms come and go, depending on the degree of tissue inflammation. 
• When body tissues are inflammed, the disease is active.  
• When tissue inflammation subsides, the disease is inactive (in remission).  
• Remissions can occur spontaneously or with treatment and can last weeks, 
months, or years.  
• During remissions, symptoms of the disease disappear, and people generally 
feel well.  
• When the disease becomes active again (relapse), symptoms return.  
• The return of disease activity and symptoms is called a Flare.  
• The course of rheumatoid arthritis varies among affected individuals, and 
periods of flares and remissions are typical.   
When the disease is active, RA symptoms can include   
  Fatigue 
  Insomnia 
  Lack of appetite.  
  Low-grade fever 
  Muscle and joint pain  
  Stiffness  
  Muscle and joint stiffness are usually most notable in the morning and after 
periods of inactivity. This is referred to as morning stiffness and post-sedentary 
stiffness. Arthritis is common during disease flares. Also during flares, joints 
frequently become warm, red, swollen, painful, and tender. This occurs because the 
lining tissue of the joint (synovium) becomes inflammed, resulting in the production 
of excessive joint fluid (synovial fluid). The synovium also thickens with 
inflammation (synovitis).  
         Rheumatoid arthritis usually inflammes multiple joints and affects both sides 
of the body. In its most common form, therefore, it is referred to as a symmetric 
polyarthritis. Early RA symptoms may be subtle. The small joints of both the hands 
and wrists are often affected. Symptoms in the hands with rheumatoid arthritis include 
difficulty with simple tasks of daily living, such as turning door knobs and opening 
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jars. The small joints of the feet are also commonly involved, which can lead to 
painful walking, especially in the morning after arising from bed.     
         Chronic inflammation can cause damage to body tissues, including cartilage and 
bone. This leads to a loss of cartilage and erosion and weakness of the bones as well 
as the muscles, resulting in joint deformity, destruction, and loss of function. Rarely, 
rheumatoid arthritis can even affect the joint that is responsible for the tightening of 
our vocal cords to change the tone of our voice, the cricoarytenoid joint. When this 
joint is inflammed, it can cause hoarseness of the voice. Symptoms in children with 
rheumatoid arthritis include limping, irritability, crying, and poor appetite. 
Extra- articular manifestations of Rheumatoid  Arithiritis 
Systemic 
• Fever 
• Fatigue 
• Weight loss 
• Susceplibility to infection 
Musculoskeletal 
• Muscle wasting 
• Bursitis 
• Tenosynovitis 
• Osteoporosis 
Haematological 
• Anamia - NSAID – GIT blood loss leads to anaemia 
• Eosinophila 
• Thrombocytosis 
Lymphatic 
• Felty’s syndrome 
• Spleenoonegely 
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Nodules 
• Scleritis 
Vasculitis 
• Digital arteritis 
• Venous ulcer 
• Visceral arteritis 
• Pyoderma gangrenosum 
• Mono Neuritis Multiplex 
Cardiovascular system 
• Pericarditis 
• Myocarditis 
• Endocarditis 
• Conduction defects 
• Coronary vasculitis 
• Granulomatous  aortitis 
Pulmonary system 
• Nodules 
• Plereral offusions 
• Caplan’s syndrome 
• Bronchiolitis 
• Fibrosing alveotitis 
Central Nervous system 
• Cervical and compression 
• Compressive myelora radiculopathy 
• Periphral neuropathies 
• Mono Neuritis multiplex 
  Amyloidosis is a rare complication of prolonged active disease and usually 
presents with Nephrotic syndrome. 
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Subcutaneous  Rheumatoid  Nodules 
   Subcutanneous and intracutaneous nodules are the hall mark of the disease. 
  It develop in 20 to 30% of patients with Rheumatoid  Arthritis. 
  They are usually found on peri articular structures,extensor or other areas 
subject to Mechanical pressure. 
  Common locations include a olecranon bursa, the proximal ulnar, the achilles 
tendon, the occipital bone etc., They are also found in the flexor tendon,the 
scalar,with in the aortic value,myocardium,larynx and vocal cord. 
Histologically, the nodules consist of a central zone of necrotic material,including 
collagen fibrils,non-collagenous filaments and cellular debris,mid zone of palisading 
macrophages that express HLA-DR antigens and an outer zone of granuloma tissue. 
Rheumatoid vasculitis  
      It can affect nearly any organ system and is seen in patients with severe from 
and high titres of circulating rheumatoid factors. 
  Neurovascular disease presenting either as distal sensory neuropathy or as 
mononeuritis multiplex may be the only sign of vasculitis. 
  Custaneous vasculitis usually presents as crops of small brown spots in the 
nail bed, nail folds and digital pulp,large ischaemic ulcers especially in the lower 
extremity may also develop. 
  Vasculitis also involves the lungs,bowel,liver,spleen,pancreas,lymphnodes and 
testes. 
Renal Involvement  
  Renal papillary necrosis and interstitial nephritis occasionally occur IgA 
nephropathy associated with elevated serum levels of IgG and IgA is described in 
Rheumatoid Arthritis. 
Liver Involvement 
  This is evident in about 10% of patients with active disease. 
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  There may be mild hepatospleenomegaly and asympatamatic elevation of the 
serum alkaline phosphatase. 
  Kupffer cell hyperplasia and lymphocytic infilteration of the portal tracts may 
be seen. 
Pulmonary Manifestations  
  This is more in men. 
  Pleuro pulmonary nodule may occur as singly or in clusters when they appear 
in individual with the pneumoconiosis and diffuse nodular fibrotic nodules 0.5-5 cm 
in diameter are seen mainly in the periphery of the lung fields. This association is 
known as Caplan’s syndrome. These nodules may produce pneumothorax or 
broncho pleural fistula. 
Interstitial fibrosis. 
 Pleurisy and pleural effusion produce frank synovitis. 
 Pulmonary fibrosis is common in rheumatoid arthritis but is often subclinical. 
 Pulmonary hypertension due to vasculitis. 
 Obliterative bronchiolitis is a rare but rapidly progressive and fatal process. 
 Cardiovascular  Manifestations 
 Asymptamatic pericarditis 
 Pericardial effusion 
 Constructive pericarditis 
 Cardiomyopathy 
 Coronary artery occlusion 
 Acute aortic regurgitation 
 Valvulitis 
Hematological Manifestations 
Felty’s syndrome 
   This syndrome describes the association between rheumatoid arthritis, 
spleenomegaly and leucopenia with normochromic normocytic aneamia, 
thrombocytopenia,lymphadenopathy,cutaneous pigmentation, chronic skin ulceration 
and weight loss. 
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Thrombocytosis 
Eosinophilia 
Neuro Muscular Mainfestations 
  Peripheral neuropathies - usually sensory or occasionally motor. 
  Atlanto axial or mid cervical spine subluxation may produce Vertibro Basilar 
Insufficiency(VBI) and neurological manifestation due to direct compression of the 
cord. 
  Entrapement neuropathy e.g. Median never compression at wrist – carpal 
tunnel syndrome. 
Posterior tibial nerve compression at ankle – Tarsal tunnel syndrome. 
Ulnar nerve compression at elbow. 
Cervical myelo radiculopathy. 
Tenosynovitis and Bursitis 
  “Triggering” of the fingers may be associated with nodules in the flexor 
tendon sheaths which can progress to permanent flexion contractures or tendon 
rupture if left untreated. 
Muscular Changes  
  Muscle atrophy in Rheumatoid patients is usually attributed to reflex 
inhibition and disuse because of articular inflammation. 
Ocular manifestations 
  Episcleritis which is mild and transient. 
  Scleritis which involves the deeper coat of the eye and is a more serious 
inflammatory condition. 
  Keratolysis(corneal melting) 
  Sclero malacia 
  Sclero malacia perforans. 
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  Sjogren’s syndrome – Keratoconjunctivitis sicca, Xerophthalmia and 
Rheumatoid Arthritis or other connective tissue disorder with the lack of tear and 
salivary secretions. 
  The symptoms are gritty sensations in the eyes, dryness of the mouth, 
photophobia,dysphasia,recurrent otitismedia,chronic respiratory disease and dryness 
of the skin. 
The following are less common: 
Osteoporosis  
  Spontaneous fractures occuring in the long bones, neck of the femur and pelvis 
are well recognised in patients with Rheumatoid arthritis. 
  A small   proportion of patients may develop Oseomalacia. 
Lymphnode  enlargement 
  Chronic positive RA or the neutropenic patient with felty’s syndrome is 
particularly susceptible to infection. 
  It has been estimated that death from infections occurs at 8 to 10 times more 
the rate for the normal population. 
Peripheral Oedema 
  Recurrent oedema of the lower limb is commonly found. 
  In some cases it develops around the acutely inflamed ankle joint. 
STAGES OF RHEUMATOID ARTHIRITIS   
   The American College of Rheumatology has developed a system for 
classifying rheumatoid arthritis that is primarily based upon the X-ray appearance of 
the joints. This system classify the severity of Rheumatoid arthritis with respect to 
cartilage, ligaments, and bone.   
Stage-I   
• No damage seen on X-rays, although there may be signs of bone thinning  
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Stage-II   
• On X-ray, evidence of bone thinning around a joint with or without slight bone 
damage 
• Slight cartilage damage possible  
• Joint mobility may be limited; no joint deformities observed  
• Atrophy of adjacent muscle  
• Abnormalities of soft tissue around joint possible  
Stage-III   
• On X-ray, evidence of cartilage and bone damage and bone thinning around 
the joint 
• Joint deformity without permanent stiffening or fixation of the joint  
• Extensive muscle atrophy 
• Abnormalities of soft tissue around joint possible  
Stage-IV   
• On X-ray, evidence of cartilage and bone damage and osteoporosis around 
joint 
• Joint deformity with permanent fixation of the joint (referred to as ankylosis) 
• Extensive muscle atrophy 
• Abnormalities of soft tissue around joint possible.  
CRITERION:                                                       
JOINTS AFFECTED SCORE 
1 Large joint      0 
2-10 Large joints 1 
1-3 Small joints   2 
4-10 Small joints      5 
SEROLOGY    
Negative RF and ACPA        0 
 53 
 
Low Positive RF or ACPA     2 
High Positive RF or ACPA    3   
DURATION OF SYMPTOMS  
<6 weeks               0 
>6 weeks      1   
ACUTE PHASE REACTANTS    
Normal CRP and ESR      0 
Abnormal CRP or ESR     1    
 
 Patient with a score greater than or equal 6 are considered to have definite 
Rheumatiod Arthritis.   
INVESTIGATIONS:   
HAEMATOLOGICAL:   
Total RBC Count  
            Haemoglobin Concentration 
            Total WBC count  DC – Polymorphs  
1. Lymphocytes  
2. Eosinophils  
3. Monocytes  
4. Basophils    
ESR   
  ½ Hr 
   1 Hr  
Blood Sugar 
     RBS 
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   FBS 
    PPBS  
Serum:  Cholesterol. 
   Urea 
   Creatinine  
Uric acid   
 URINE     
 Albumin  
    Sugar  
    Deposits   
SPECIFIC INVESTIGATIONS   
  CRP 
   ASO Titre   
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Antinuclear antibody (ANA)     
Rheumatoid factor (RF):  
  Designed to detect and measure the level of an antibody that acts against the 
blood component gamma globulin, this test is often positive in people with 
Rheumatoid arthritis.   
Anti-cyclic citrullinated peptide (anti-CCP):  
  Also called anti-citrullinated protein  antibodies (ACPA)   
HLA tissue typing: 
  This test, which detects the presence of certain genetic markers in the blood, 
can often confirm a diagnosis of ankylosing spondylitis (a disease involving 
inflammation of the spine and sacroiliac joint) or reactive arthritis (a disease involving 
inflammation of the urethra, eyes and joints). The genetic marker HLA-B27 is almost 
always present in people with either of these diseases.  
  Lyme serology – This test detects an immune response to the infectious agent 
that causes Lyme disease and thus can be used to confirm a diagnosis of the disease.  
  
 Skin biopsy  
 Muscle biopsy  
 Joint fluid tests         
RADIOLOGICAL INVESTIGATIONS:   
   The radiographic hallmarks of Rheumatoid arthritis are:   
• Soft tissue swelling: Fusiform and Periarticular; it represents a combination of 
Joint Effusion, Oedema and Tenosynovitis   
• Osteoporosis: initially juxta-articular, and later generalised. 
• Joint space narrowing: Symmetrical or Concentric  
• Marginal Erosions: Due to erosion by pannus of the bony “bare areas”   
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IN HANDS AND WRISTS:   
 There is a predilection for:   
• PIP and MCP joints (especially 2nd and 3rd MCP)    
• Ulnar –Styloid Process  
• Triquetrum   
 As a rule, the DIP joints are spared.   
Late changes include:   
• Subchondral cyst formation: Destruction of cartilage presses synovial fluid 
into the bone 
• Subluxation causing: Ulnar deviation of the MCP joints  
• Boutonniere, Swan neck and Hitchhikers thumb deformities 
• Carpal instability: Scapholunate dissociation, Ulnar translocation 
• Ankylosis    
FEET:   
   Similar to the hands, there is a predilection for the PIP and MTP joints 
(especially 4th and 5th MTP).   
• Involvement of Subtalar joint 
• Posterior Calcaneal tubercle erosion  
• Hammer toe deformity  
• Hallux valgus  
 SHOULDER:   
• Erosion of the distal clavicle 
• Marginal erosions of the Humeral head: The superolateral aspect is a typical 
location  
• Reduction in the Acromio humeral distance: "High-riding shoulder" due to 
Sub acromial-Subdeltoid bursitis and high incidence of rotator cuff tear     
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HIP:    
• Concentric loss of joint space where there is a tendency for superior loss of 
joint space 
• Acetabular protrusion   
KNEE:   
• Joint effusion  
• typically involves the lateral or non-weight bearing portion of the joint 
• loss of joint space involving all three compartments 
• lack of subchondral sclerosis and osteophytes, compared with OA  
• Prepatellar bursitis   
IN SPINE:   
        The Cervical spine is frequently involved in RA , whereas a Thoracic and 
Lumbar involvement are rare. Findings include:   
• Erosion  
• Atlanto axial subluxation-atlanto axial distance in more than 3 mm on a 
flexion radiograph Atlanto axial impaction (cranial settling).  
• Erosion and fusion of uncovertebral (apophyseal joints ) and facet joints  
• Osteoporosis and osteoporotic fractures  
• Erosion of spinous processes   
Ultrasound:     
 Sonography can assess the soft tissue manifestations of RA, 
• Synovial proliferation and inflammation of the superficial joints   
• Tenosynovitis: Extensor carpi ulnaris tendon involvement is common in early 
disease and may lead to erosion of the ulnar styloid 2  
• Bursitis  
CT:   
   CT is not routinely used in the evaluation of peripheral RA. It has applications 
in imaging of the spine, and perioperative assessment.   
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  MRI    MRI is particularly sensitive to the early and subtle features of RA.   
 Features of RA best demonstrated with MRI include:   
• Synovial hyperaemia: indication of acute inflammation  
• Synovial hyperplasia (rice bodies) 
• Pannus formation 
• Decreased thickness of  
• Subchondral cysts and erosions  
• Juxta-articular bone marrow oedema 
• Joint effusions   
Differential diagnosis   
 The differential for the skeletal manifestations of RA includes:   
• Osteoarthritis involving the: DIPs, PIPs, 1st CMC joints, Nonuniform joint space 
loss, subchondral sclerosis and osteophyte, soft tissue swelling, Heberdons node 
(DIPs) and Bouchard node (PIPs), no Erosions and no anklylosis.   
• Erosive osteoarthritis: Clinically an acute inflammatory attacks (swelling, 
erythema, pain) in post menopausal woman typically includes the DIPs, PIPs 1st 
CMC joint 6, but not the metacarpo phalangeal (MCP) joints and large joints. Classic 
central erosions, possible ankylosis.   
• Psoriatic arthritis (PsA): Commonly involves the hands and there is an 
interphalangeal predominant distribution in PsA. MCP joint pre dominance in 
rheumatoid arthritis (RA) starts with erosions in the margins and eventually involves 
the whole joint. Classic: “pencil in cup” and bone proliferation (unlike RA). 
Osteoporosis not a feature in PsA. MRI dynamic enhancement pattern may 
differentiate PsA from RA at 15 minutes  
• Reactive arthritis (Reiter’s syndrome): Predilection for the lower limb Osteopenia 
and then Osteoporosis, uniform joint space loss, subchondral cyst formation, 
subluxations, marginal erosions but no bone formation, symmetrical involvement of 
the: PIPs, MCPs, and carpal bones.  
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 • Systemic lupus erythematosus (SLE)/Jaccoud arthropathy: Joint space loss, 
subchondral sclerosis, osteophyte, and ulnar deviation of the phalanges without 
erosions   
• Calcium pyrophosphate dihydrate (CPPD) arthropathy: usually only affects the 
MCP's: symmetric joint space narrowing, subchondral cysts, and osteophytes. unlike 
RA: chondrocalcinosis and no erosions.   
• Gout usually in older men : Punched out erosions usually with a sclerotic border and 
overhanging edges, tophi, most commonly involves the 1st MTP known as podagra.   
COMPLICATIONS:    
   Since rheumatoid arthritis is a systemic scleritis disease, its inflammation can 
affect organs and areas of the body other than the joints.  
   Inflammation of the glands of the eyes and mouth can cause dryness of these 
areas and is referred to as Sjögren's syndrome. Dryness of the eyes can lead to 
corneal abrasion.  
   Inflammation of the white parts of the eyes (the sclerae) is referred to as and 
can be very dangerous to the eye.   
   Rheumatoid inflammation of the lung lining (pleuritis) causes chest pain with 
deep breathing, shortness of breath, or coughing. The lung tissue itself can also 
become inflammed and scarred, and sometimes nodules of inflammation (rheumatoid 
nodules) develop within the lungs.  
   Inflammation of the tissue (pericardium) surrounding the heart, called 
pericarditis, can cause a chest pain that typically changes in intensity when lying 
down or leaning forward. Rheumatoid arthritis is associated with an increased risk for 
heart attack.   
   Rheumatoid disease can reduce the number of red blood cells (anemia) and 
white blood cells. Decreased white cells can be associated with an enlarged spleen 
referred to as Felty's syndrome and can increase the risk of infections.  
   The risk of lymph gland cancer (lymphoma) is higher in patients with 
rheumatoid arthritis, especially in those with sustained active joint inflammation.   
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   Firm lumps or firm bumps under the skin, subcutaneous nodules called 
rheumatoid nodules can occur around the elbows and fingers where there is frequent 
pressure. Even though these nodules usually do not cause symptoms, occasionally 
they can become infected.   
 Caplan’s syndrome (or) Rheumatoid pneumoconiosis still disease.  
   Nerves can become pinched in the wrists to cause carpal tunnel syndrome.    
   A rare, serious complication, usually with longstanding rheumatoid disease, is 
blood vessel inflammation (vasculitis). Vasculitis can impair blood supply to tissues 
and lead to tissue death (NECROSIS) leading to leg ulcers.  
Factors which suggest poor prognosis 
1. Young age 
2. Female gender 
3. positive family history 
4. positive RA factor,Anti – CCP 
5. Raised ESR 
6. Extraarticular lesions 
7. The presence of noduless 
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CHAPTER-IV 
MATERIALS AND METHODS 
 
   The clinical study of “Vali Azhal Keel Vayu” is carried out in the Department 
of Pothu Maruthuvam, Government Siddha Medical College and Hospital, 
Palayamkottai under observation and guidance by the Head of the Department, 
Department of Pothu Maruthuvam.   
 
Selection of the cases:  
   For this clinical study, 40 patients were selected according to the inclusion 
and exclusion criteria. 20 Out patients and remaining 20 In patients were treated in 
Out patient department and admitted in the In patient ward of the Government Siddha 
Medical College and Hospital, Palayamkottai.  
 
Aetiological Factors:  
   The seasonal variations and precipitating factors like emotional stress, trauma, 
occupation and food habits were enquired and recorded.  The socio economic status, 
family history and other significant diseases already treated, were thoroughly 
registered.   
 
Inclusion criteria:  
 Age  :  18-50 years  
 Sex  :  Both sex  
Symmetrical joint involvement, painful small joints, florid morning stiffness 
more than hours per day, joint swelling especially in the interphalangeal joints, pain 
criteria score should be greater on equal to 6.  
 
Exclusion criteria:  
 Systemic Hypertension  
 Diabetes mellitus  
 Chronic Alcoholic and Smokers  
 Pregnancy and lactating mothers 
 Other locomotor disorders  
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 Pulmonary / Extra pulmonary Tuberculosis  
 Psoriatic arthritis  
 Gouty arthritis  
 Chronic kidney disease  
 Ischemic heart disease  
 SLE  
 
Diagnosis:  
 The diagnosis is made by following Siddha diagnostic methods:  
   Poriyal Aridhal  
 Pulanal Aridhal  
 Vinnadhal   
 Envagai Thervugal 
 Udal Thathukal  
 Kaalam  
 Nilam  
The following investigations were done in modern medicine aspects.  
 
Haematological investigations:  
 Total RBC Count 
 HB%  
 Total WBC count  
 Differential count   
 Erythrocyte sedimentation rate  
 Blood sugar  
 Serum Cholesterol   
 Serum Urea  
 Serum Creatinine  
 Serum Uric acid  
 
Urine analysis:  
a. Albumin  
b. Sugar  
c. Deposits  
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Specific investigations:  
a. CRP  
b. RA factor  
c. ASO titre  
Radiological investigations (for selected cases):  
X-ray of affected joints (AP and lateral view)  
 
Assessment of results:  
   The results were assessed on the basis of symptomatic relief and DISEASE 
ACTIVITY SCORE OF 28 JOINTS (DAS 28). 
   The difference in the score before and after treatment represents the 
improvement in the treatment.  
 
Treatment:  
   The clinical trial drug “AKKINI CHOORANAM” 4.2gm two times after 
food with sugar is given for 30 days till the end of the course.  The Biochemical, 
Pharmacological and Acute toxicity studies were done in  K.M.College of Pharmacy, 
Madurai, Tamilnadu. 
 All the patients admitted for the study were given uniformly regular hospital 
diet. After discharge all the patients were advised to attend the Out patient  
Department of Pothu Maruthuvam, Government Siddha Medical College and 
Hospital, Palayamkottai for further follow–up.  
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CHAPTER-V  
RESULTS AND OBSERVATIONS  
 
 The results were observed regarding the following criteria by clinical trial study on 
40 patients: Out of 40, 20 In patients and 20 Out patients of both sex.  
 
 The criteria were:  
 
1. Sex Distribution  
2. Age Distribution  
3. Kaalam  
4. Constitution of body  
5. Gunam  
6. Religion  
7. Paruva Kaalam  
8. Thinai  
9. Socio – Economical status  
10. Food habits  
11. Family History   
12. Occupation  
13. Clinical Manifestation  
14. Duration of Illness  
15. Kanmenthiriyam  
16. Kosam  
17. Gnanendrium  
18. Condition of Mukkutram  
a). Condition of Vatham  
b). Condition of Pitham  
c). Condition of Kapham  
19. Involvement of Udal Kattugal (or) Udal thathukal  
20. Conditions of Envagai Thervugal  
21. Neer kuri  
22. Nei kuri  
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23. Disease activity score 
24. Assessment of outcome  
25. Gradation of results  
26. Laboratory Investigations  
a). Out patients  
b). In patients  
27. Diseases activity pain score  
a). Out patients  
b). In patients  
28. Case summary  
a). Out patients  
b). In patients  
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1. SEX DISTRIBUTION:  
 
Table-1 Illustrates the Distribution of Sex and its percentage.  
 
TABLE-1  
DISTRIBUTION OF SEX  
 
Sl.  
No.  
Sex  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Male  - - 4 20%  
2.  Female  20 100%  16 80%  
 Total 20  100%  20  100%  
 
   Among 20 Out patients 0% were Male and 100% were Female. Among 20 In 
patients, 20% were Male and 80% were Female.  
FIGURE-1  
DISTRIBUTION OF SEX 
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2. AGE DISTRIBUTION:  
 Table-2 Illustrates the Distribution of Age and its percentage.  
TABLE-2  
DISTRIBUTION OF AGE  
Sl.  
No.  
Age group in 
years  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  11 to 20  -  -  1 5% 
2.  21 to 30  1 5%  1  5%  
3.  31 to 40  7 35%  4 20%  
4.  41 to 50  12 60%  14 70%  
 Total 20 100%  20  100%  
   From the above table it is observed that the highest incidence of Vali Azhal 
Keel Vayu in Out patients is among the age group of 41 to 50 with 60% and 31 to 40 
with 35%, 5% were in the age group of 21 to 30 years. Among 20 In patients 5% were 
in the age group of 11 to 20 years  and 21 to 30 years , 20% were in the age group of 
31 to 40 years , 70% with the highest incidence in the age group of 41 to 50 years.  
FIGURE-2 
DISTRIBUTION OF AGE  
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3. KAALAM DISTRIBUTION:  
 Table-3 Illustrates the Distribution of Kaalam and its percentage.  
TABLE-3  
DISTRIBUTION OF KAALAM  
Sl.  
No.  
Kaalam  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Vatham  2 10% 3 15% 
2.  Pitham  18 90%  17 85%  
3.  Kapham  - - - - 
 Total 20  100%  20  100%  
 
   Among 20 Out patients, 90% were affected in Pitha Kaalam and 10% were 
affected in VathaKaalam. Among 20 In patients, 85% were affected in Pitha Kaalam 
and 15% were affected in Vatha Kaalam.  
FIGURE-3  
DISTRIBUTION OF KAALAM  
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4 CONSTITUTION OF BODY:  
 Table-4 Illustrates the Distribution of Constitution Body and its percentage.  
TABLE-4  
DISTRIBUTION OF CONSTITUTION OF BODY  
Sl.  
No.  Constitution of body  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Vatham  -  -  -  -  
2.  Vatha Pitham  16 80%  15 75%  
3.  Vatha Kapham  -  -  -  -  
4.  Pitham  -  -  -  -  
5.  Pitha Vatham  4 20%  3 15%  
6.  Pitha Kapham  -           - 2 10% 
7.  Kapham  -  -  -  -  
8.  Kaba Vatham  -  -  -  -  
9.  Kaba Pitham  -  -  -  -  
 Total 20  100%  20  100%  
 
   Vatha Pitha Thegi register high incidence of Vali Azhal Keel Vayu with 80% 
OP and 75% IP. Remaining Pitha Vatha Thegi of 20% OP and 15% IP, Pitha Kapham 
Thegi of 10% In patients.  
 
FIGURE-4 DISTRIBUTION OF CONSTITUTION OF BODY  
 
 
 
.  
70 
 
0
60
40
0
75
25
0
10
20
30
40
50
60
70
80
Sathuva Gunam Rajo Gunam Thamasa Gunam
P
e
rc
e
n
ta
g
e
 (
%
)
GUNAM
OP 
IP 
5.GUNAM:  
 Table-5 Illustrates the Distribution of Gunam and its percentage.  
TABLE-5    DISTRIBUTION OF GUNAM  
Sl.  
No.  Gunam  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Sathuva Gunam  -  -  -  -  
2.  Rajo Gunam  12  60%  15  75%  
3.  Thamasa Gunam  8 40% 5 25% 
 Total 20  100%  20  100%  
 
Among 20 Out patients, 60% were Rajo gunam and 40% were Thamasa gunam. 
Among  20 In patients, 75% were Rajo gunam and 25% were Thamasa gunam. 
 
FIGURE-5 DISTRIBUTION OF GUNAM 
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6. RELIGION:  
 Table-6 Illustrates the Distribution of Religion and its percentage.  
TABLE-6  
DISTRIBUTION OF RELIGION  
Sl.  
No.  Religion  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Hindu  17 85%  16 80%  
2.  Christian  - - 3 15% 
3.  Muslim  3 15% 1  5%  
 Total 20  100%  20  100%  
 
   Among 20 Out patients, 85% were Hindus, 15% were Muslims. Among 20 In 
patients, 80% were Hindus,15% were Christians and 5% were Muslims .  
 
FIGURE-6 DISTRIBUTION OF RELIGION  
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7. PARUVA KAALAM:  
Table-7 Illustrates the Distribution of Paruva Kaalam and its percentage.  
TABLE-7  DISTRIBUTION OF PARUVA KAALAM  
Sl.  
No.  Paruva Kaalam  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Elavenil Kaalam  -  -  3 15%  
2.  Muthuvenil Kaalam  5 25% 6 30% 
3.  Kaar Kaalam  -  -  3 15% 
4.  Koothir Kaalam  3 15% 4 20% 
5.  Munpani Kaalam  6 30%  2 10%  
6.  Pinpani Kaalam  6 30%  2 10%  
   
  Among 20 Out patients, 30% of cases were in Munpani Kaalam and  Pinpani 
Kaalam,25% of cases were in Muthuvenil Kaalam and 15% of cases were in Koothir 
Kaalam. Among 20 In patients, 30% of cases were in Muthuvenil Kaalam, 20% of 
cases were in Koothir Kaalam and 15% of cases were in Elavenil Kaalam and Kaar 
Kaalam,10% of cases were in Munpani and Pinpani Kaalam.  
 FIGURE-7 DISTRIBUTION OF PARUVA KAALAM  
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8. THINAI:  
 Table-8 Illustrates the Distribution of Thinai and its percentage.  
TABLE-8  
DISTRIBUTION OF THINAI  
Sl.  
No.  Thinai  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Kurinji  -  -  1 5% 
2.  Mullai  5 25% 4 20% 
3.  Marutham  10  50%  11 55%  
4.  Neithal  5 25%  4 20%  
5.  Paalai  -  -  -  -  
 Total 20  100%  20  100%  
 
 Among 20 Out patients, 50% were in Marutham and 25% were in Neithal and 
Mullai.  
Among 20 In patients, 55% were in Marutham and 20% were in Neithal and Mullai, 
5% were in Kurinji 
FIGURE-8 DISTRIBUTION OF THINAI  
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9. SOCIO - ECONOMICAL STATUS:  
 Table-9 Illustrates the Socio – Economical Status of patients and its percentage.  
TABLE-9  
SOCIO – ECONOMICAL STATUS  
Sl.  
No.  
Socio – Economical 
Status  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Low income class  7 35%  8  40%  
2.  Middle income class  8  40%  9 45%  
3.  High income class  5 25%  3 15%  
 Total 20  100%  20  100%  
 
   Among 20 Out patients, 35% were in Low income class, 40% were in Middle 
income class and 25% were in High income class. Among 20 In patients, 40% were in 
Low income class, 45% were in Middle income class and 15% were in High income 
class.  
FIGURE-9 SOCIO – ECONOMICAL STATUS  
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10 FOOD HABITS:  
 Table-10 Illustrates the Distribution of diet among the patients and its percentage.  
TABLE-10  
FOOD HABITS  
Sl.  
No.  
Food Habits  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Vegetarian diet  3 15% - - 
2.  Non – Vegetarian diet  17 85%  20 100%  
 Total 20  100%  20  100%  
 
Among 20 Out patients, 15% were Vegetarian and 85% were non – vegetarian.   
Among 20 In patients, 0% were vegetarian and 100% were non – vegetarian.  
 
FIGURE-10  FOOD HABITS  
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11. FAMILY HISTORY:  
 Table-11 Illustrates the Family History and its percentage.  
TABLE-11  
FAMILY HISTORY  
Sl.  
No.  
Family History  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Positive   11 55%  10 50%  
2.  Negative  9 45%  10 50%  
 Total 20  100%  20  100%  
 
 Among 20 Out patients, 55% have positive Family History and 45% don’t have any 
positive Family History.  Among 20 In patients, 50% have positive Family  
History and 50% don’t have any positive Family History.  
 
FIGURE-11 FAMILY HISTORY  
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12 OCCUPATION:  
 Table-12 Illustrates the Occupation and its percentage.  
TABLE-12  
OCCUPATION  
Sl.  
No.  
Occupation  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Agricultural labours  2  10%  4  20%  
2.  Coolie  3 15%  5 25%  
3.  House wife  11 55%  4 20%  
4.  Tailor  2 10%  2 10% 
5.  Loadman  - - 1  5%  
6.  Driver  - - 1 5% 
7.  Beedi Worker 1  5%  - - 
8.  Business  - - 1 5%  
9. Sales Women 1 5% - - 
10. Flower Maker -          - 1 5% 
11. Mason - - 1 5% 
 Total 20  100%  20  100%  
 
 Among 20 Out patients, 10% Agricultural labours, 15% Coolie, 55% House Wife, 
10% Tailor, 5% Beedi worker and Sales women. 
 
Among 20 In patients, 20% Agricultural labours, 25% Coolie, 20% House Wife, 5% 
Loadman, 5% Driver,5% Business,5% Flower Maker,5% Mason, 10% Tailor were 
observed.  
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FIGURE-12 
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13 CLINICAL MANIFESTATION:  
 Table-13 Illustrates the Clinical Manifestation and its percentage.  
TABLE-13  
CLINICAL MANIFESTATION  
Sl.  
No.  
Symptoms  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Arthritis involving 
more than 3 joints  20  100%  20  100%  
2.  Severe pain and 
swelling  
20  100%  20  100%  
3.  Symmetrical joint 
involvement  
20  100%  20  100%  
4.  Morning stiffness  17 85%  10 50%  
5.  Anorexia  4 20%  7 35%  
6.  Rheumatoid nodules  3 15%  5 25%  
7.  Depression  9 45%  11 55%  
 
   Among 20 Out patients, 100% cases have arthritis involving more than 3 
joints, severe pain and swelling, symmetrical joint involvement,85% have morning 
stiffness , 45% have depression, 20% have Anorexia, 15% have Rheumatoid nodules. 
Among 20 In patients, 100% cases have arthritis involving more than 3 joints, severe 
pain and swelling, symmetrical joint involvement,50% have morning stiffness, 55%% 
have depression, 25% have rheumatoid nodules, 35% have anorexia.  
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FIGURE-13  
CLINICAL MANIFESTATION  
 
 
 
  
100 100 100
85
20
15
45
100 100 100
50
35
25
55
0
20
40
60
80
100
120
P
e
rc
e
n
ta
g
e
 (
%
)
CLINICAL MANIFESTATION
OP 
IP 
.  
81 
 
14 DURATION OF ILLNESS:  
 Table-14 Illustrates the Duration of Illness and its percentage.  
TABLE-14  DURATION OF ILLNESS  
Sl.  
No.  Duration of illness  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Below 1 year  1 5%  1  5%  
2.  1 to 2 years  2 10%  3 15%  
3.  2 to 3 years  -         - 2 10%  
4.  3 to 4 years  16 80%  13  65%  
5.  Above 4 years  1  5%  2 10% 
 Total 20  100%  20  100%  
 
   Among 20 Out patients, Duration of Illness was 5% below 1 year, 10% in 1 to 
2 years,80% in 3 to 4 years and 5% in above 4 years.  Among 20 In patients, Duration 
of Illness was 5% below 1 year, 15% in 1 to 2 years, 10% in 2 to 3 years and 65% in 3 
to 4 years,10% above 4 year.  
 
FIGURE-14 DURATION OF ILLNESS  
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15 KANMENTHIRIYAM:  
 Table-15 Illustrates the Kanmenthiriyam and its percentage.  
TABLE-15 KANMENTHIRIYAM  
Sl.  
No.  Kanmenthiriyam  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Kai  20  100%  20  100%  
2.  Kaal  20  100%  20  100%  
3.  Vai  -  -  -  -  
4.  Eruvai  8 40%  11 55%  
5.  Karuvai  -  -  -  -  
 
   Among 20 Out patients, 100% cases were affected in Kai, Kaal, 40% cases 
were affected in Eruvai. Among 20 In patients, 100% cases were affected in Kai, 
Kaal, 55% cases were affected in Eruvai.  
 
FIGURE-15 KANMENTHIRIYAM 
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16 KOSAM  
 Table-16 Illustrates the Kosam and its percentage.  
TABLE-16   KOSAM  
Sl.  
No.  Kosam  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Annamaya Kosam  4 20%  7 35%  
2.  Pranamaya Kosam  20 100% 20 100% 
3.  Manomaya Kosam  20  100%  20  100%  
4.  Vinganamaya Kosam  20  100%  20  100%  
5.  Anandamaya Kosam  -  -  -  -  
 
 Among 20 Out patients, 20% were affected in Annamya Kosam, 100% were affected 
in Pranamaya Kosam,Manomya Kosam and Vinganamaya Kosam. Among 20 In 
patients, 35% were affected in Annamya Kosam and 100% were affected in 
Pranamaya Kosam,Manomya Kosam and Vinganamaya Kosam.   
 
FIGURE-16 KOSAM  
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17 GNANENDRIUM:  
 Table-17 Illustrates the Gnanendrium and its percentage.  
TABLE-17    GNANENDRIUM  
Sl.  
No.  Gnanendrium  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Mei  13 65% 9 45% 
2.  Vaai  -  -  -  -  
3.  Kan  3 15% 2 10% 
4.  Mookku  -  -  -  -  
5.  Sevi  -  -  -  -  
 
 
Among 20 Out patients, 65% of the patients were affected in Mei, 15% of the patients 
were affected in kan. 
Among 20 In patients, 45% of the patients were affected in Mei, 10% of the patients 
were affected in kan. 
 
 
FIGURE-17 GNANENDRIUM  
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18 CONDITION OF MUKKUTRAM:  
 
18 (a) Condition of Vatham.  
 
Table-18 Illustrates the Condition of Vatham and its percentage.  
 
TABLE-18 (a)  
CONDITION OF VATHAM  
Sl.  
No.  
Condition of 
Vatham  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Piraanan  -  -  -  -  
2.  Abaanan  8 40%  11 55%  
3.  Viyaanan  20  100%  20 100%  
4.  Uthaanan  -  -  -  -  
5.  Samaanan  20  100%  20  100%  
6.  Naagan  -  -  -  -  
7.  Koorman  3 15% 2 10% 
8.  Kirukaran  4 20% 7 35% 
9.  Devathathan  18 90%  17 85%  
10.  Dhananjayan  -  -  -  -  
 
   Viyaanan, Samaanan,  were affected in 100% of both Out patients and In 
patients. Abaanan was affected in 40% of Out patients, and 55% of the In patients, 
Kirugaran was affected in 20% of Out Patients, and 35% of In patients. Devathathan 
was affected in 90% of Out patients, and 85% of In patients.  Koorman was affected 
in 15% of Out patients and 10% of In patients, 
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FIGURE-18 (a) 
CONDITION OF VATHAM 
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18 (b). CONDITION OF PITHAM  
 Table-18 (b) Illustrates the Condition of Pitham and its percentage.  
TABLE-18 (b)  
CONDITION OF PITHAM  
Sl.  
No.  Pitham  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Anala Pitham  4 20%  7 35%  
2.  Ranjagam  11 55%  10 50%  
3.  Sathagam  20  100%  20  100%  
4.  Prasagam  -  -  -  -  
5.  Aalosagam  3 15% 2 10% 
 
Among 20 Out patients, 20% affected in Anala Pitham, 55% in Ranjaga Pitham and 
100% in Sathaga Pitham, 15% in Aalosagapitham.  Among 20 In patients, 35% 
affected in Anala Pitham, 50% in Ranjaga Pitham and 100% in Sathaga Pitham, 10% 
in Aalosagapitham. 
FIGURE-18 (b) CONDITION OF PITHAM  
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18 (c) CONDITION OF KAPHAM  
 Table-18 (c) Illustrates the Condition of Kapham and its percentage.  
TABLE-18 (c)  
CONDITION OF KAPHAM  
Sl.  
No.  Kapham  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Avalambagam  -  -  -  -  
2.  Kilethagam  4 20%  7 35%  
3.  Pothagam  -  -  -  -  
4.  Tharpagam  -  -  -  -  
5.  Santhigam  20  100%  20  100%  
 
   Kilethagam was affected in 20% of Out patients and 35% of In patients.  
Santhigam was affected in 100% of both Out patients and In patients.  
 
FIGURE-18 (c) CONDITION OF KAPHAM  
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19. INVOLVEMENT OF UDAL KATTUGAL (OR) UDAL THATHUKAL  
   Table-19 Illustrates the involvement of Udal Kattugal (or) Udal Thathukal 
and its percentage.  
TABLE-19  
INVOLVEMENT OF UDAL KATTUGAL (OR)  
UDAL THATHUKAL  
Sl.  
No.  
Udal Kattugal  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Saaram  20 100%  20  100%  
2.  Senneer  11 55%  10 50%  
3.  Oon  -  -  -  -  
4.  Kozhuppu  - - - - 
5.  Enbu  20  100%  20  100%  
6.  Moolai  - - - - 
7.  Sukkilam / Suronitham  -  -  -  -  
 
Among 20 Out patients and In patients Saaram, Enbu were affected in 100% of the 
cases.  senneer was affected in 55% of OP and 50% of IP. 
 
FIGURE-19 INVOLVEMENT OF UDAL KATTUGAL 
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20 CONDITIONS OF ENVAGAI THERVUGAL  
 Table-20 Illustrates the conditions of Envagai Thervugal and its percentage.  
TABLE-20  
CONDITION OF ENVAGAI THERVUGAL  
Sl.  
No.  
Envagai Thervugal  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Naadi (Thontha Naadi)  20  100%  20  100%  
 1). Vatha Pitham  16 80%  15 75%  
 2). Vatha Kapham  -  -  -  -  
 3). Pitha Vatham  4 20%  3 15%  
 4). Pitha Kapham  -           - 2 10% 
 5). Kapha Vatham  -  -  -  -  
 6). Kapha Pitham  -  -  -  -  
2.  Sparisam  13 65%  9  45%  
3.  Naa  -  -  -  -  
4.  Niram  -  -  -  -  
5.  Mozhi  -  -  -  -  
6.  Vizhi  3 15%  2 10%  
7.  Malam  8 40%  11 55%  
8.  Moothiram  -  -  -  -  
 
 Among 20 Out patients,15 % were affected in  Vizhi, 40% were affected in Malam, 
65% was affected in Sparisam, Naadi-80% with Vatha Pitham, 20% with Pitha 
Vatham . Among 20 In patients, 10% were affected in Vizhi, 55% was affected in 
Malam, 45% was affected in Sparisam, Naadi-75% with Vatha Pitham ,15% with 
Pitha Vatham and 10% with Pitha Kapham. 
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FIGURE-20 CONDITION OF ENVAGAI THERVUGAL  
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21 NEER KURI  
 Table-21 Illustrates the Neer kuri condition and its percentage.  
TABLE-21  
NEER KURI  
Sl.  
No.  
Neer kuri  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Niram  4 20%  7 35%  
2.  Manam  -  -  -  -  
3.  Edai  -  -  -  -  
4.  Nurai  2 10%  3  15%  
5.  Enjal  -  -  -  -  
 
   Niram was ffected in 20% of Out patients and 35% of In patients. Nurai was 
affected in 10% of  Out patients and 15% of In patients.  
 
FIGURE-21  
NEER KURI 
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22. NEI KURI  
 Table-22 Illustrates the Nei Kuri conditions and its percentage.  
TABLE-22  
NEI KURI  
Sl.  
No.  
Nei Kuri  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Vatha Neer / 
spreading like snake  
16 80%  15 75%  
2.  Pitha Neer / spreading 
like ring  
4         20% 5  25%  
3.  Kapha Neer / 
spreading like pearl  
- - - - 
4.  Thontha Neer /  
Asthiya Neikurigal   
- - - - 
 
 Among 20 Out patients, 80% had Vatha Neer, 20% had Pitha neer. 
Among 20 In patients, 75% had Vatha Neer, 25% had Pitha Neer.  
FIGURE-22 NEI KURI  
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23. DISEASES ACTIVITY SCORE
 Table-23 Illustrates the 
Sl. 
No. 
Disease 
activity 
score 
Out
Patients
(OP)
No. 
of 
Cases 
Percentage 
1. 
Low DAS 
Score 
(Tenderness) 
20 
2. 
Moderate  
DAS score 
(Swelling) 
20 
3. High DAS 
score (VAS) 20 
 Lower disease activity 2.6<DAS28
 Moderate disease activity 3.2<DAS28
 High disease activity DAS28>5.1. 
  
Reference:  
 Prevoo ML, Van’t Hof MA Kuper HH, Van Leeuwen MA, Van de Putte LB, Van 
Rie / PL (1995). “Modified disease activity scores that include twenty
counts. Development and validation in a prospective longitudinal study of patients 
with rheumatoid arthritis”. Arthritis Rheum. 38 (1):44
 
Before Treatment:  
 Among 20 Out patients, and 20 In patients 100% of cases were with High disease 
activity.  
After Treatment:  
 Among 20 Out patients, 50% of cases with Low disease activity 30% of cases with 
Moderate disease activity and 20% of cases with High disease activity.  Among 20 In 
94 
 
Diseases activity score.  
TABLE-23 
DISEASES ACTIVITY SCORE 
Before Treatment After Treatment
 
 
 
In Patients (IP) 
Out 
Patients
(OP) 
(%) 
No. 
of 
Cases 
Percentage 
(%) 
No. 
of 
Cases 
Percentage 
(%)
100% 20 100% 10 50%
100% 20 100% 6 30%
100% 20 100% 4 20%
 
3.2.  
5.1.  
 
-8.  
 
 
In 
Patients 
(IP) 
 
No. 
of 
Cases 
Percentage 
(%) 
 12 60% 
 4 20% 
 4 20% 
-eightjoints 
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patients, 60% of cases with Low disease activity, 20% of cases with Moderate disease 
activity and 20% of cases with High disease activity.  
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24 ASSESSMENT OF OUTCOME: 
 Table-24 Illustrates the Assessment of Outcome and its percentage. 
Sl.  
No.  
Assessment 
of 
Outcome 
Out 
Patients 
(OP) 
No. 
of 
Cases 
Percentage 
(%)
1.  Low  -  
2.  Moderate  -  
3.  High  20  100% 
 
 Lower disease activity
 Moderate disease activity 3.2<DAS28
 High disease activity DAS28>5.1. 
  
Reference:  
 Prevoo ML, Van’t Hof MA Kuper HH, Van Leeuwen MA, Van de Putte LB, Van 
Rie / PL (1995). “Modified disease activity scores that include twenty
counts. Development and validation in a prospective longitudinal study of patients 
with rheumatoid arthritis”. Arthritis Rheum. 38 (1):44
 
Before Treatment:  
 Among 20 Out patients, and 20 In patients 100% of cases were with High disease 
activity.  
After Treatment:  
 Among 20 Out patients, 50% of cases with Low disease activity 30% of cases with 
Moderate disease activity and 20% of cases with High disease activity.  Among 20 In 
patients, 60% of cases with Low disease activity, 20% of cases with Moderate disease 
activity and 20% of cases with High disease activity. 
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TABLE-24 
ASSESSMENT OF OUTCOME 
Before Treatment  After Treatment 
 
 
 
In Patients (IP)  
Out  
Patients 
(OP)  
 
No. 
of 
Cases 
Percentage 
(%) 
No. 
of 
Cases 
Percentage 
(%) 
-  -  -  10 50% 
-  -  -  6 30% 
 20  100%  4  20% 
 2.6<DAS28 3.2.  
5.1.  
 
-8.  
 
 
 
 
In  
Patients  
(IP)  
No. 
of 
Cases 
Percentage 
(%) 
 12 60%  
 4  20%  
 4 20%  
-eightjoints 
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FIGURE-24  
ASSESSMENT OF OUTCOME 
 
 
 
 
  
  
0 0
100
0 0
100
50
30
20
60
20 20
0
20
40
60
80
100
120
Low Moderate High
P
e
rc
e
n
ta
g
e
 (
%
)
ASSESSMENT OF OUTCOME
Before Treatment OP
Before Treatment IP
After Treat ment OP
After Treat ment IP
 98 
 
25 GRADATION OF RESULTS:  
 Table-25 Illustrates the Gradation of results and its percentage.  
TABLE-25  
GRADATION OF RESULTS  
Sl.  
No.  
Results  
Out Patients (OP)  In Patients (IP)  
No. of 
Cases  
Percentage 
(%)  
No. of 
Cases  
Percentage 
(%)  
1.  Good response  10 50%  12 60%  
2.  Moderate response  6 30%  4  20%  
3.  Poor response  4  20%  4 20%  
 Total 20  100%  20  100%  
 
 Among 20 Out patients, 50% of cases showed Good response, 30% of cases showed 
Moderate response and 20% of cases showed Poor response.  
 Among 20 In patients, 60% of cases showed Good response, 20% of cases showed 
Moderate response and 20% of cases showed Poor response.  
 
FIGURE-25 GRADATION OF RESULTS  
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TABLE-26(a)  
i) LABORATORY INVESTIGATION OF OUT PATIENTS  
Sl.  
No.  
Out  
Patient No.  
HAEMATOLOGICAL REPORT  URINE ANALYSIS  
BEFORE TREATMENT  AFTER TREATMENT  BEFORE TREATMENT  AFTER   TREATMENT  
TC  DC  
ESR 
 (mm)  Hb%  (gms)  TC  
DC  ESR  (mm)  Hb%  (gms)  Alb  Sug  
Dep-  
Epi.cells /  
Pus cells  
Alb  Sug  
Dep-  
Epi.cells /  
Pus cells  P  L  E  1 Hr. P  L  E  1 Hr.  
1. 59037 8000 64 38 8 32 13.00 9500 60 37 3 10 13.40 NIL NIL 1-2 Epi.cells NIL NIL NAD 
2. 59417 9200 68 26 2 40 7.00 8600 66 35 4 12 9.00 NIL NIL NAD NIL NIL NAD 
3. 63452 8000 62 34 4 18 12.60 9000 62 32 6 22 10.40 NIL NIL NAD NIL NIL NAD 
4. 63573 6700 68 30 2 20 13.20 6400 60 25 2 13 10.20 NIL NIL NAD NIL NIL NAD 
5. 73028 6000 60 31 9 40 9.80 5000 52 30 8 24 9.40 NIL NIL NAD NIL NIL NAD 
6. 109410 7800 54 40 6 16 12.50 8000 60 45 5 8 12.80 NIL NIL NAD NIL NIL NAD 
7. 11640 8000 64 33 3 20 10.20 7800 62 30 2 10 10.20 NIL NIL NAD NIL NIL NAD 
8. 113090 7800 65 30 5 50 12.80 8000 66 32 4 7 13.00 NIL NIL NAD NIL NIL NAD 
9. 3237 8200 60 36 8 18 11.00 6200 31 7 9 10 11.20 NIL NIL NAD NIL NIL NAD 
10. 7590 8100 64 30 5 20 12.60 9800 60 35 5 6 12.90 NIL NIL NAD NIL NIL NAD 
11. 12172 9400 65 28 7 30 13.00 8700 63 32 5 5 13.20 NIL NIL NAD NIL NIL NAD 
12. 12554 9100 60 30 2 40 10.00 8900 62 28 3 10 11.00 NIL NIL NAD NIL NIL NAD 
13. 18807 8400 67 28 5 21 13.50 8100 65 33 2 8 13.70 NIL NIL 1-2 Epi.cells NIL NIL NAD 
14. 19600 8900 64 34 2 30 10.10 9000 62 36 6 24 10.40 NIL NIL NAD NIL NIL NAD 
15. 22078 8100 60 35 5 20 11.40 8400 64 30 6 10 12.80 NIL NIL NAD NIL NIL NAD 
16. 22519 8400 67 30 3 30 10.20 8000 59 38 3 30 10.60 NIL NIL NAD NIL NIL NAD 
17. 243320 9200 60 36 4 50 11.50 8700 60 39 1 6 12.00 NIL NIL NAD NIL NIL NAD 
18. 22120 8200 61 30 9 40 10.60 8100 54 39 7 10 13.00 NIL NIL 2-4 Epi.cells NIL NIL NAD 
19. 25588 8900 58 34 8 60 13.00 8600 58 36 6 6 13.50 NIL NIL NAD NIL NIL NAD 
20. 30928 8800 73 25 2 40 11.00 9800 60 36 4 4 12.00 NIL NIL NAD NIL NIL NAD 
  
TABLE-26(a) 
i). LABORATORY INVESTIGATION (OUT PATIENTS) 
Sl. 
No. 
OP 
No. 
 Before treatment   After treatment  
Blood 
sugar 
(R) 
Blood 
urea 
Serum 
Cholesterol 
Uric 
acid 
Serum 
Creatinine Bilirubin 
Blood 
sugar 
(R) 
Blood 
urea 
Serum 
Cholesterol 
Uric 
acid 
Serum 
Creatinine Bilirubin 
1. 59037 92 20 136 4.10 0.5 0.7 87 20 130 3.80 0.3 0.4 
2. 59417 103 19 175 2.20 0.7 0.6 100 21 177 2.80 0.6 0.7 
3. 63452 98 19 200 4 0.5 0.4 96 17 200 3.80 0.4 0.4 
4. 63573 84 38 190 3.4 0.9 0.5 83 30 180 3.2 0.6 0.4 
5. 73028 72 21 120 4.2 0.6 0.7 70 20 118 4 0.5 0.6 
6. 109410 93 33 149 4 0.8 0.5 80 15 120 2 0.4 0.3 
7. 11640 109 18 189 4.20 0.7 0.6 106 16 186 4 0.6 0.4 
8. 113090 81 35 156 3.90 0.6 0.8 70 15 140 3.10 0.2 0.4 
9. 3237 103 18 180 3.40 0.7 0.7 100 16 160 3.20 0.4 0.5 
10. 7590 116 20 186 3.60 0.5 0.6 100 10 146 2 0.3 0.4 
11. 12172 97 23 170 3.3 0.9 0.4 90 20 140 2.5 0.4 0.2 
12. 125554 102 19 198 3.90 0.6 0.3 98 18 190 3.60 0.5 0.3 
13. 18807 75 20 186 3.60 0.4 0.6 70 15 160 3.20 0.3 0.4 
14. 19600 97 25 176 4.50 0.6 0.5 99 22 171 4.20 0.5 0.6 
15. 22078 65 26 160 3.60 0.4 0.3 60 20 140 3 0.2 0.2 
16. 22519 74 30 186 5.30 0.7 0.5 70 33 179 5 0.5 0.4 
17. 24320 70 23 170 3.30 0.5 0.4 60 15 120 2 0.2 0.1 
18. 22160 91 20 143 3.0 1,0 0.7 90 18 130 4 0.1 0.6 
19. 25588 83 36 162 5.20 0.6 0.5 65 30 140 4.60 0.4 0.3 
20. 30928 75 24 170 3.80 0.8 0.3 68 20 159 2.40 0.7 0.2 
  
Table-26 (a) 
iii). LABORATORY INVESTIGATIONS (OUT PATIENTS) 
Sl. 
No. 
OP 
No. 
BEFORE TREATMENT AFTER TREATMENT 
RA Factors  (IU / ml) ASO titre  (IU / ml) 
C – reactive 
Protein 
(mg / dl) 
RA 
Factors 
(IU / ml) 
C – reactive Protein 
(mg / dl) 
1. 59037 62.5 90.4 7.8 82.3 7.2 
2. 59417 42.6 20.4 9.3 18.4 8.4 
3. 63452 54.6 32.8 6.9 30.6 6.8 
4. 63573 63.0 18.3 5.2 17.4 5.0 
5. 73028 39.6 40.6 8.9 37 8.5 
6. 109410 19.00 80.9 6.7 6.2 6.4 
7. 11640 70 19.6 3.0 18.4 2.8 
8. 113090 18.4 30.4 4.4 15.4 4.2 
9. 3237 57.8 5.1 7.9 4.8 6.4 
10. 7590 15.7 6.8 8.0 6.9 6.3 
11. 12172 256 3.0 4.0 2.8 3.6 
12. 12554 49.6 7.4 6.4 6.9 5.3 
13. 18807 13.7 46 4.8 30 3.6 
14. 19600 16.2 52.3 6.3 51.3 6.2 
15. 22078 20.4 9.3 5.3 6.4 3.2 
16. 22519 14.3 101.4 6.5 98.2 4.8 
17. 24320 18.4 90 5.2 86 4.00 
18. 22160 5.8 535 13.6 526 12.4 
19. 25588 19.6 120 7.4 102 6.5 
20. 30928 15.3 99 13 60 5.4 
Reference range:  
Rheumatoid factor  :  Upto 20 IU/ml   Serum for ASO  :  Upto 200 IU/ml        CRP  :  Upto 6 mg/dl  
  
TABLE-26 (b) 
i). LABORATORY INVESTIGATION OF IN PATIENTS 
 
 
HAEMOTOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT BEFORE TREATMENT AFTER  TREATMENT 
TC 
DC ESR (mm) 
Hb% 
(gms) TC 
DC ESR (mm) 
Hb% 
(gms) Alb Sug 
Dep- 
Epi.cells / 
Pus cells 
Alb Sug Dep- Epi.cells / Pus cells P L E 1 Hr. P L E  1 
Hr. 
1. 1676 11500 74 16 0.6  100 9.6 12000 74 20 0.3  6 13.4 Nil Nil 6-8 puscells Nil Nil NAD 
2. 1833 8400 64 34 0.2  30 11.2 9300 60 38 0.2  5  Nil Nil NAD Nil Nil NAD 
3. 1891 9300 60 38 0.2  50 12.4 8100 62 36 0.4  6  Nil Nil NAD Nil Nil NAD 
4. 1951 13000 78 17 0.3  92 9.8 9800 64 32 0.6  10  Nil Nil NAD Nil Nil NAD 
5. 1996 8100 60 34 0.4  20 13.5 8400 56 30 0.5  7  Nil Nil 2 – 3 puscells Nil Nil NAD 
6. 2044 9800 63 28 0.5  30 10.6 8600 52 34 0.4  15  Nil Nil NAD Nil Nil NAD 
7. 2138 8400 65 24 0.3  44 12.9 8600 58 33 0.2  5  Nil Nil NAD Nil Nil NAD 
8. 2178 8900 61 36 0.2  50 11.6 9300 60 36 0.3  25  Nil Nil NAD Nil Nil NAD 
9. 2312 9200 70 22 0.4  20 12.4 8400 63 38 0.6  6  Nil Nil NAD Nil Nil NAD 
10. 2522 8400 68 24 0.5  30 9.10 8400 65 34 0.2  20  Nil Nil NAD Nil Nil NAD 
11. 2711 9200 64 30 0.2  40 13.6 7500 62 34 0.3  6  Nil Nil NAD Nil Nil NAD 
12. 2775 8300 70 26 0.4  20 11.5 8600 63 36 0.5  20  Nil Nil 3 – 2 puscells Nil Nil NAD 
13. 3010 8100 61 34 0.5  50 12.4 7800 66 35 0.4  6  Nil Nil NAD Nil Nil NAD 
14. 3060 9400 67 28 0.3  40 9.8 8900 58 34 0.2  20  Nil Nil NAD Nil Nil NAD 
15. 3066 8100 63 22 0.5  30 13.3 8600 62 38 0.3  8  Nil Nil NAD Nil Nil NAD 
16. 3158 9400 69 28 0.4  50 11.5 9000 56 34 0.5  30  Nil Nil NAD Nil Nil NAD 
17. 262 8200 70 26 0.6  40 10.4 8500 60 30 0.4  15  Nil Nil NAD Nil Nil NAD 
18. 427 8100 66 30 0.4  30 12.8 8100 54 33 0.6  5  Nil Nil NAD Nil Nil NAD 
19. 598 8300 62 34 0.4  40 11.2 8700 62 34 0.3  7  Nil Nil NAD Nil Nil NAD 
20. 1056 8400 70 24 0.3  20 13.0 9200 56 30 0.2  10  Nil Nil NAD Nil Nil NAD 
In 
Pat
ien
t 
No. 
 
Sl. 
No. 
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26 (b) 
ii). LABORATORY INVESTIGATION (IN PATIENTS) 
Sl. 
No. 
OP 
No. 
Before treatment After treatment     
Blood 
sugar 
(R) 
Blood 
urea 
Serum 
Cholesterol 
Uric 
acid 
Serum 
Creatinine Bilirubin 
Blood 
sugar 
(R) 
Blood 
urea 
Serum 
Cholesterol 
Uric 
acid 
Serum 
Creatinine Bilirubin 
1. 1676 98 20 189 4.20 0.70 0.80 94 16 187 4.20 0.60 0.40 
2. 1833 90 20 146 3.40 0.60 0.90 98 20 147 3.40 0.70 0.90 
3. 1891 95 21 182 5.0 0.50 0.40 90 20 180 5.00 0.50 0.40 
4. 1951 97 21 191 4.50 0.80 0.70 96 20 180 4.20 0.60 0.40 
5. 1996 104 20 188 3.0 0.70 0.90 97 17 159 3.00 0.70 0.80 
6. 2044 90 24 189 2.50 0.80 0.50 91 20 183 2.50 0.60 0.50 
7. 2138 89 22 179 4.40 0.50 0.60 80 20 160 4.20 0.40 0.30 
8. 2178 102 20 150 3.80 0.90 0.50 98 19 138 3.60 0.80 0.60 
9. 2312 99 26 160 3.90 0.80 0.40 90 20 150 3.10 0.60 0.20 
10. 2522 101 19 148 3.20 0.60 0.70 100 18 147 3.00 0.50 0.60 
11. 2711 90 21 160 3.60 0.40 0.30 82 18 148 3.20 0.30 0.10 
12. 2775 112 24 158 6.0 0.50 0.40 110 22 150 4.30 0.40 0.30 
13. 3010 90 22 148 3.40 0.60 0.80 78 20 120 3.00 0.30 0.40 
14. 3060 95 29 180 4.20 0.80 0.30 93 26 178 4.00 0.70 0.20 
15. 3066 129 30 184 3.80 0.40 0.70 110 28 169 3.20 0.30 0.60 
16. 3158 101 19 147 3.70 0.80 0.60 100 18 146 3.60 0.40 0.50 
17. 262 90 24 189 2.50 0.80 0.70 85 22 180 2.00 0.50 0.40 
18. 427 104 36 168 4.0 0.40 0.40 100 38 150 3.80 0.30 0.20 
19. 598 99 24 199 3.20 0.60 0.30 90 20 180 3.00 0.50 0.20 
20. 1056 89 38 158 4.30 0.50 0.90 80 34 148 4.00 0.30 0.50 
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26(b) 
iii). LABORATORY INVESTIGATIONS (IN PATIENTS) 
Sl. 
No. IP No. 
BEFORE TREATMENT AFTER TREATMENT 
RA Factors  (IU / ml) ASO titre  (IU / ml) 
C – reactive 
Protein 
(mg / dl) 
RA 
Factors 
(IU / ml) 
C – reactive Protein 
(mg / dl) 
1. 1676 60 285 1.0 20 1.0 
2. 1833 17.2 103 3.3 17.1 3.1 
3. 1891 11.4 89 2.3 11.2 2.7 
4. 1951 19 320 4 16.4 4.6 
5. 1996 17.9 140 4.6 17.9 4.6 
6. 2044 19.6 60.4 4.7 18.4 4.4 
7. 2138 62.4 89 8.6 62.4 7.3 
8. 2178 73.6 110.6 8.3 73.2 8.6 
9. 2312 18 93 2.4 17.8 2.0 
10. 2522 12.6 46.3 2.6 13.9 2.6 
11. 2711 19 90.2 2.9 18 2.3 
12. 2775 56.3 50 7.2 54.6 6.7 
13. 3010 34.6 109 6.8 30.2 6.3 
14. 3060 18.2 65.4 1.9 18 1.6 
15. 3066 40.6 78.3 5.6 39 6.8 
16. 3158 20.8 79.6 8.7 50.6 5.6 
17. 262 11.2 88.6 2.3 11.4 2.0 
18. 427 250 50 12.6 236 10.6 
19. 598 16.4 79.4 3.2 15.6 2.8 
20. 1056 20 80.6 2.8 19.7 2.0 
Reference range:  
Rheumatoid factor  :  Upto 20 IU/ml   Serum for ASO  :  Upto 200 IU/ml        CRP  :  Upto 6 mg/dl  
   
Sl. 
No. 
OP 
No. 
1. 59037 
2. 59417 
3. 63452 
4. 63573 
5. 73028 
6. 109410 
7. 11640 
8. 113090 
9. 3237 
10. 7590 
11. 12172 
12. 12554 
13. 18807 
14. 19600 
15. 22078 
16. 22519 
17. 24320 
18. 22160 
19. 25588 
20. 30928 
Interpretation:  
 Low disease activity 2.6<DAS
Reference range   ESR 5
 
 
27 (a) DISEASE ACTIVITY PAIN SCORE (OUT PATIENTS)
 Before treatment 
TJC 
28 SJC 28 
ESR mm 
 / Hr. VAS 
4 12 32 70 
12 10 40 50 
10 9 18 60 
12 8 20 50 
20 18 40 80 
11 10 16 50 
13 9 20 60 
18 20 50 80 
10 9 18 70 
14 18 20 50 
13 15 30 60 
9 12 40 70 
13 8 21 50 
8 9 30 80 
10 11 20 60 
15 14 30 50 
13 10 50 40 
12 16 40 70 
16 10 60 40 
14 16 40 60 
3.2  Moderate disease activity 3.2<DAS28
-15mm / hr.   
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  After treatment
DAS 
28 
TJC 
28 SJC 28 
5.51 2 4 
6.11 7 9 
5.48 14 16 
5.53 8 7 
7.41 12 10 
5.39 4 4 
5.8 3 7 
7.5 4 3 
5.62 8 12 
6.09 2 4 
6.33 5 3 
6.23 4 4 
5.65 2 4 
5.94 12 10 
5.65 3 6 
6.3 12 10 
6.21 6 2 
6.63 5 4 
6.55 4 4 
6.65 5 2 
5.1  High disease activity DAS28.>5.1  
 Sl. 
No. IP No. TJC
28
1. 1676 
2. 1833 10
3. 1891 
4. 1951 13
5. 1996 20
6. 2044 12
7. 2138 16
8. 2178 18
9. 2312 
10. 2522 12
11. 2711 
12. 2775 14
13. 3010 11
14. 3060 16
15. 3066 
16. 3158 18
17. 262 10
18. 427 12
19. 598 11
20. 1056 10
Interpretation:  
 Low disease activity 2.6<DAS
Reference range   ESR 5
 
27 (b) DISEASE ACTIVITY PAIN SCORE (IN PATIENTS)
Before treatment 
 
 
SJC 28 ESR mm 
 / Hr. VAS
8 12 100 
 14 30 
9 12 50 
 10 92 
 14 20 
 16 30 
 10 44 
 13 50 
9 12 20 
 18 30 
9 8 40 
 16 20 
 10 50 
 14 40 
8 10 30 
 12 50 
 14 40 
 10 30 
 14 40 
 8 20 
3.2  Moderate disease activity 3.2<DAS28
-15mm / hr
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DAS 
28 
TJC 
28 SJC 28
40 5.22 4 3 
60 6.05 6 4 
40 5.96 4 3 
60 5.77 11 9 
50 6.35 3 4 
70 6.43 9 8 
50 6.48 4 6 
40 6.69 10 14 
60 5.6 6 4 
40 6.08 10 12 
50 5.76 5 3 
30 5.74 10 6 
40 6.05 3 3 
30 6.29 12 14 
50 5.56 3 4 
40 6.64 14 10 
50 6.11 8 8 
40 5.77 4 3 
50 5.2 2 6 
40 5.22 3 4 
5.1  High disease activity DAS28.>5.1  
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TABLE-28 (a) 
CASE SUMMARY - OUT PATIENTS 
Sl. 
No. 
OP 
No. Name 
Age / 
Sex Occupation 
Duration of 
illness 
Treatment 
starting date 
End of the 
treatment date 
Total 
Days 
Results 
1. 59037 &g<gl<lit<! 40F Beedi worker 2 Years 11.07.2017 11.08.2017 30 Good 
2. 59417 LjgkQe<!lQvit<! 34F Housewife 4 Months 12.07.2017 12.08.2017 30 Fair 
3. 63452 hik<kqli! 43F Housewife 1 Year 25.07.2017 25.08.2017 30 Poor 
4. 63573 uq\bi! 45F Coolie 1 Year 25.07.2017 25.08.2017 30 Fair 
5. 73028 ds<sqligitq! 40F Coolie 2 Months 25.08.2017 25.09.2017 30 Poor 
6. 109410 zzqki! 50F Housewife 4 Months 11.12.2017 11.01.2018 30 Good 
7. 11640 usf<kq! 50F Agricultural labour 2 Months 18.12.2017 18.01.2018 30 Fair 
8. 113090 fivib{q! 37F Housewife 4 Months 22.12.2017 22.01.2018 30 Good 
9. 3237 Ouz<osz<uq! 30F Housewife 2 Months 08.01.2018 08.02.2018 30 Fair 
10. 7590 ngqzit<! 40F Housewife 2 Years 22.01.2018 22.02.2018 30 Good 
11. 12172 gif<kqlkq! 42F Sales women 6 Months 05.02.2018 07.03.2018 30 Good 
12. 12554 dlilOg^<uiq! 47F Housewife 5 Years 06.02.2018 08.03.2018 30 Fair 
13. 18807 liiqbl<lit<! 44F Coolie 6 Months 23.02.2018 25.03.2018 30 Good 
14. 19600 fi%i<lQvi! 50F Housewife 4 Years 26.02.2018 28.03.2018 30 Poor 
15. 22078 Vg<l{q! 50F Agriculutral labour 2 Months 05.03.2018 05.04.2018 30 Good 
16. 22519 sv^<ukq! 49F Tailor 1 Year 07.03.2018 07.04.2018 30 Poor 
17. 24320 vi{q! 40F Housewife 2 Months 12.03.2018 12.04.2018 30 Good 
18. 22160 lQei! 50F Tailor 3 Months 14.03.2018 14.04.2018 30 Fair 
19. 25588 Sf<kiq! 33F Housewife 3 Months 16.03.2018 16.04.2018 30 Good 
20. 30928 sif<kqfigvi{q! 50F Housewife 3 Months 03.04.2018 03.05.2018 30 Good 
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TABLE-28 (b) 
CASE SUMMARY - IN PATIENT 
 
Sl. 
No. 
IP No. Name 
Age / 
Sex 
Occupation 
Duration 
of illness 
DOA DOD 
Total Days 
Total 
Days 
Results 
OP IP 
1. 1676 -sg<gqbl<lit<! 18F Coolie 1 Year 06.06.2017 03.07.2017 2 28 30 Good 
2. 1833 zm<Slq! 50F Agricultural labour 2 Years 24.06.2017 02.07.2017 21 9 30 Good 
3. 1891 sOzilq! 50F Agricultural labour 6 months 29.06.2017 01.08.2017  34 30 Good 
4. 1951 Sf<kiq! 30F Housewife 4 months 05.07.2017 01.08.2017 2 28 30 Fair 
5. 1996 \ie<! 44M Loadman 4 years 10.07.2017 11.08.2017  33 30 Good 
6. 2044 lOg^<uiq! 48F Housewife 8 months 17.07.2017 26.07.2017 20 10 30 Fair 
7. 2138 ohiqbkib<! 47F Coolie 5 years 28.07.2017 22.08.2017 4 26 30 Good 
8. 2178 w^<gzqe<! 50F Agricultural labour 1 year 02.08.2017 30.08.2017 1 29 30 Poor 
9. 2312 uQvl<lit<! 50F Housewife 6 months 18.08.2017 21.09.2017  35 30 Good 
10. 2522 Sh<Hozm<Slq! 49F Coolie 1 year 09.09.2017 24.10.2017  46 30 Poor 
11. 2711 sqk<kqvg<g{q! 45F Tailor 3 years 06.10.2017 15.11.2017  41 30 Good 
12. 2775 Ohs<sqbl<lit<! 46F Housewife 7 months 12.10.2017 23.11.2017  43 30 Fair 
13. 3010 gitqvi\i! 31M Driver 3 years 09.11.2017 12.12.2017  34 30 Good 
14. 3060 hQli\ie<! 40F Tailor 5 months 15.11.2017 23.12.2017  39 30 Poor 
15. 3066 nb<bl<lit<! 48F Agricultural labour 2 years 16.11.2017 17.12.2017  32 30 Good 
16. 3158 hqvgi]<! 42M Business 5 months 30.11.2017 24.12.2017 5 25 30 Poor 
17. 262 G{ukq! 35F Flower maker 3 months 01.02.2018 13.03.2018  41 30 Fair 
18. 427 ut<tqbl<lit<! 45F Coolie 1 year 17.02.2018 19.03.2018  31 30 Good 
19. 598 sf<keGlii<! 35M Mason 2 months 06.03.2018 10.04.2018  36 30 Good 
20. 1056 zqr<gl<lit<! 50F Coolie 2 years 18.04.2018 27.04.2018  40 30 Good 
.  
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CHAPTER - VI 
DISCUSSION 
 
  Vali Azhal Keel Vayu is described in Sabapathy manuscript it is nearly 
correlated in modern science with Rheumatoid Arthritis (RA). In this clinical trial 
study totally 40 patients were selected, 20 were treated as Out patient and 20 were 
treated as In patients with clinical trial drug ‘AKKINI CHOORANAM’.  
 The follwing results were discussed and given below, 
1. Sex distribution: 
  Among 20 Out patients 0% were Male and 100% were Female. Among 20 In 
patients, 20% were Male and 80% were Female.  
2. Age distribution: 
  From the above table it is observed that the highest incidence of Vali Azhal 
Keel Vayu in Out patients is among the age group of 41 to 50 with 60% and 31 to 40 
with 35%, 5% were in the age group of 21 to 30 years. Among 20 In patients 5% were 
in the age group of 11 to 20 years  and 21 to 30 years , 20% were in the age group of 
31 to 40 years , 70% with the highest incidence in the age group of 41 to 50 years.  
3. Kaalam distribution: 
  Among 20 Out patients, 90% were affected in Pitha Kaalam and 10% were 
affected in VathaKaalam. Among 20 In patients, 85% were affected in Pitha Kaalam 
and 15% were affected in Vatha Kaalam.  
4. Constitution of body 
   Vatha Pitha Thegi registered high incidence of Vali Azhal Keel Vayu with 
80% OP and 75% IP. Remaining Pitha Vatha Thegi of 20% OP and 15% IP, Pitha 
Kapham Thegi of 10% In patients.  
5. Gunam 
  Among 20 Out patients, 60% were Rajo gunam and 40% were Thamasa 
gunam.  
Among  20 In patients, 75% were Rajo gunam and 25% were Thamasa 
gunam. 
 
 
.  
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6. Religion 
  Among 20 Out patients, 85% were Hindus, 15% were Muslims. Among 20 In 
patients, 80% were Hindus,15% were Christians and 5% were Muslims .  
7. Paruvakaalam 
  Among 20 Out patients, 30% of cases were in Munpani Kaalam and  Pinpani 
Kaalam,25% of cases were in Muthuvenil Kaalam and 15% of cases were in Koothir 
Kaalam. Among 20 In patients, 30% of cases were in Muthuvenil Kaalam, 20% of 
cases were in Koothir Kaalam and 15% of cases were in Elavenil Kaalam and Kaar 
Kaalam,10% of cases were in Munpani and Pinpani Kaalam.  
8. Thinai 
   Among 20 Out patients, 50% were in Marutham and 25% were in Neithal and 
mullai.  
Among 20 In patients, 55% were in Marutham and 20% were in Neithal and Mullai, 
5% were in Kurinji. 
 9. Socio economical status 
  Among 20 Out patients, 35% were in Low income class, 40% were in Middle 
income class and 25% were in High income class. Among 20 In patients, 40% were in 
Low income class, 45% were in Middle income class and 15% were in High income 
class.  
10. Food habits 
  Among 20 Out patients, 15% were Vegetarian and 85% were non – 
vegetarian.   
Among 20 In patients, 0% were vegetarian and 100% were non – vegetarian.  
11. Family history 
  Among 20 Out patients, 55% have positive Family History and 45% don’t 
have any positive Family History.  Among 20 In patients, 50% have positive Family 
History and 50% don’t have any positive Family History.  
12. Occupation 
  Among 20 Out patients, 10% Agricultural labours, 15% Coolie, 55% House 
Wife, 10% Tailor, 5% Beedi worker and Sales women. 
.  
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Among 20 In patients, 20% Agricultural labours, 25% Coolie, 20% House 
Wife, 5% Loadman, 5% Driver,5% Business,5% Flower Maker,5% Manson, 10% 
Tailor were observed.  
13. Clinical manifestations 
  Among 20 Out patients, 100% cases have arthritis involving more than 3 
joints, severe pain and swelling, symmetrical joint involvement,85% have morning 
stiffness , 45% have depression, 20% have Anorexia, 15% have Rheumatoid nodules.  
Among 20 In patients, 100% cases have arthritis involving more than 3 joints, severe 
pain and swelling, symmetrical joint involvement,50% have morning stiffness, 55%% 
have depression, 25% have rheumatoid nodules, 35% have anorexia.  
 14. Duration of illness 
  Among 20 Out patients, Duration of Illness was 5% below 1 year, 10% in 1 to 
2 years, 80% in 3 to 4 years and 5% in above 4 years.  Among 20 In patients, 
Duration of Illness was 5% below 1 year, 15% in 1 to 2 years, 10% in 2 to 3 years and 
65% in 3 to 4 years,10% above 4 years.  
15. Kanmenthiriyam 
   Among 20 Out patients, 100% cases were affected in Kai, Kaal, 40% cases 
were affected in Eruvai. Among 20 In patients, 100% cases were affected in Kai, 
Kaal, 55% cases were affected in Eruvai.  
16. Kosam 
   Among 20 Out patients, 20% were affected in Annamya Kosam, 100% were 
affected in Pranamaya Kosam,Manomya Kosam and Vinganamaya Kosam. Among 
20 In patients, 35% were affected in Annamya Kosam and 100% were affected in 
Pranamaya Kosam,Manomya Kosam and Vinganamaya Kosam.   
17. Gnanendrium 
  Among 20 Out patients, 65% of the patients were affected in Mei, 15% of the 
patients were affected in kan. 
Among 20 In patients, 45% of the patients were affected in Mei, 10% of the patients 
were affected in kan. 
18. Condition of Mukkutram 
a) Condition of Vatham 
  Viyaanan, Samaanan,  were affected in 100% of both Out patients and In 
patients. Abaanan was affected in 40% of Out patients, and 55% of the In patients, 
.  
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Kirugaran was affected in 20% of Out Patients, and 35% of In patients. Devathathan 
was affected in 90% of Out patients, and 85% of In patients.  Koorman was affected 
in 15% of Out patients and 10% of In patients, 
b) Condition of Pitham 
  Among 20 Out patients, 20% affected in Anala Pitham, 55% in Ranjaga 
Pitham and 100% in Sathaga Pitham, 15% in Aalosagapitham.  Among 20 In patients, 
35% affected in Anala Pitham, 50% in Ranjaga Pitham and 100% in Sathaga Pitham, 
10% in Aalosagapitham. 
c) Condition of Kabam 
  Kilethagam was affected in 20% of Out patients and 35% of In patients.  
Santhigam was affected in 100% of both Out patients and In patients.  
19. Involvement of Udal Kattugal  (or) Udal thathukkal: 
  Among 20 Out patients and In patients Saaram, Enbu were affected in 100% 
of the cases.  senneer was affected in 55% of OP and 50% of IP. 
20. Conditions of Envagai thervugal 
  Among 20 Out patients,15 % were affected in  Vizhi, 40% were affected in 
Malam, 65% was affected in Sparisam, Naadi-80% with Vatha Pitham, 20% with 
Pitha Vatham . Among 20 In patients, 10% were affected in Vizhi, 55% was affected 
in Malam, 45% was affected in Sparisam, Naadi-75% with Vatha Pitham ,15% with 
Pitha Vatham and 10% with Pitha Kapham.  
21. Neerkuri 
  Niram was affected in 20% of Out patients and 35% of In patients. Nurai was 
affected in 10% of  Out patients and 15% of In patients.  
22. Neikuri 
  Among 20 Out patients, 80% had Vatha Neer, 20% had Pitha neer. 
Among 20 In patients, 75% had Vatha Neer, 25% had Pitha Neer.  
 
23. Disease Activity Score 
Before Treatment:  
   Among 20 Out patients, and 20 In patients 100% of cases were with High 
disease activity.  
 
.  
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After Treatment:  
   Among 20 Out patients, 50% of cases with Low disease activity 30% of cases 
with Moderate disease activity and 20% of cases with High disease activity.  Among 
20 In patients, 60% of cases with Low disease activity, 20% of cases with Moderate 
disease activity and 20% of cases with High disease activity.  
24. Assessment of Outcome: 
Before Treatment:  
   Among 20 Out patients, and 20 In patients 100% of cases were with High 
disease activity.  
After Treatment:  
   Among 20 Out patients, 50% of cases with Low disease activity 30% of cases 
with Moderate disease activity and 20% of cases with High disease activity.  Among 
20 In patients, 60% of cases with Low disease activity, 20% of cases with Moderate 
disease activity and 20% of cases with High disease activity.  
Result: 
  Stastitical analysis has shown DAS 28 score among OP & IP was found to be 
highly significant at  P<0.0001 from Table:  
.  
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 Statistical analysed using student’s paired t-test using the Prism Graph pad 
software. The results were expressed as Mean ± standard deviation and p values 
<0.001 was considered as statistically significant. 
  DAS 28 comparison through statistical analysis 
Sl.No Parameters 
Mean ± SD 
T value P value Result 
BT AT 
1. Outpatient 6.13±0.60 3.91±1.01 8.401 <0.0001 HS 
2. Inpatient 5.99±0.42 3.92±1.04 8.26 <0.0001 HS 
         (n=20) (Listwise) 
BT – Before Treatment 
AT – After Treatment 
HS – Highly significant 
   
25. Gradation of Results: 
  Among 20 Out patients, 50% of cases showed Good response, 30% of cases 
showed Moderate response and 20% of cases showed Poor response.  
   Among 20 In patients, 60% of cases showed Good response, 20% of cases 
showed Moderate response and 20% of cases showed Poor response. 
  All the 40 patients were treated with the clinical trial medicine AKKINI 
CHOORANAM 4.2gms BID with sugar for 30 days. Thus at the end of the result, 
the clinical trial drug showed good clinical improvement of the disease 
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CHAPTER – VII 
SUMMARY 
  An open labeled randomized clinical study on ‘VALI AZHAL KEEL 
VAYU’ with reference to its Aetiology, Pathogenesis, Clinical features, diagnosis, 
investigations and treatment were conducted at Department of Pothu Maruthuvam, 
Government Siddha Medical College and Hospital, Palayamkottai.  
   This clinical study of Vali Azhal Keel Vayu is done on the basis of reference 
in Sabapathi manuscript in Noinadal, Noi mudhal naadal Thiratu Part-II, Pg. No. 
623.  The disease is correlated with Rhematioid arthritis.  
   The trial drug chosen for the clinical study – AKKINI CHOORANAM 
Dosage of 4.2 gms twice a day with  sugar  after food (Ref. Koshayi Anuboga 
Vaithiya Bramma Ragasiyam Part – II, Pg. No. 104).  
   The aetiology, pathology, pathogenesis, clinical features, classification and 
prognosis of the disease were collected from a number of literatures both in Siddha 
system as well as in modern system of medicine.  
   For this study, Out of 40 patients, 20 patients were diagnosed clinically and 
admitted in the In patients ward and treated with trial medicines. Another twenty 
patients was treated Out patients department. 
   The selection of patients and management of patients during admission and 
after treatment is carried out under the supervision of Professor, Associate Professor, 
Lecturers of Department of Pothu Maruthuvam.   
  A case sheet proforma is prepared with particulars focus on Siddha and 
Modern clinical parameters.  
   Separate cases sheets were maintained for each patient in In-patient ward and 
their vital signs and symptoms were monitored and recorded daily.  The patients were 
treated with the trial drug AKKINI CHOORANAM.  
   Routine blood examinations, Urine analysis, other specific investigations and 
radiological investigations were done by modern scientific methods and were 
considered for diagnosis and to follow the progress of the patients.  
   Siddha diagnosis is made up with the help of Ezhu Udal Kattugal and Envagai 
Thervugal.  
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   Since Vali Azhal Keel Vayu is a chronic disease, it requires treatment for 
minimum thirty days to minimize the severe pain, tenderness and swelling with slight 
disappearance of stiffness. The patient is advised to follow up the treatment in Out 
patient Department.   
   From this study the following datas were clear that disease was more common 
in female than male. Maximum incidence was in Pitha Kaalam. Clinically marked 
reduction in the symptoms along with increase sense of well being, decrease in ESR, 
decrease in symptoms, decrease in the DISEASE ACTIVITY PAIN SCORE OF 28 
JOINTS was noted.  
   The patients were observed for a period of 3 months during and after the 
course of treatment.  No signs of complications were observed.  Clinically no toxic 
effects were noticed during the treatment period. The pharamacological evaluation of  
AKKINI CHOORANAM showed significant anti inflammatory and analgesic 
activity.  No acute toxicity, side effects were noted.  
   Bio chemical analysis of AKKINI CHOORANAM showed the presence of 
calcium, sulphate, chloride, ferrous iron, starch, tannic acid, amino acids and 
unsaturated compound  
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CHAPTER-VIII 
 
CONCLUSION 
 
   In Sabapathy Manuscript was described under Vali Azhal Keel Vayu explains 
the clinical conditions as rheumatoid arthritis.  The lines of this version are well 
analysed under Siddha and modern parameters and the cases are thoroughly examined 
with clinical and bio chemical report.  
   Treatment is given on the basis of Mukkutra Theory.  The deranged kutrams 
are made to normal by the trial medicine.  
   The trial medicine, AKKINI CHOORANAM has the taste of kaarupu,  
inippu according to the taste of individual ingredients.  
 
Kaarpu suvai    -  Has its function of relieving indigestion, flatulence and   
   
 
 constipation.  
Inippu suvai   
 
-  Regulates the vitiation of Vatham and Pitham.  
   Thus the trial drug based of its suvai acts as an effective anti-arthritic drug.  
Almost all the cases treated with the trial drug shows considerable improvements.   
Further follow up of all patients showed a significant relief of their symptoms. 
  
 50 % of Out patients and 60% of In patients showed Good response.  
 30% of Out patients and 20% of In patients showed Moderate response.  
 20% of Out patients and 20% of In patients showed Poor response.  
 
   I conclude that this trial drug ‘AKKINI CHOORANAM’ has improved the 
clinical symptoms of the patients and assured them a better standard of living.  
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INGREDIENTS OF AKKINI CHOORANAM 
Seeragam Thippili 
Lavangam Chukku 
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AKKINI  CHOORANAM 
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ANNEXURE-I 
PREPARATION AND PROPERTIES OF TRIAL MEDICINE 
ng<gqeqs<$v{l<< < << < << < <!
. )Reference: Koshayi Anuboga Vaithiya Bramma Ragasiyam, Part-II Page 
No.104) 
Sg<G?! sQvgl<?! kqh<hqzq?! zur<gl<! -jugt<! ujgg<Gh<hzl<! .! 2!
-tuXh<hib<!uXk<K!$v{qk<K!uvigeqjm!uQkl<!kqel<.3!kmju!ofb<bqziuK!
sQeqbqziuK!ogiMk<Kuv!ng<gqeq! lf<kl<?! ubqx<Xuzq?! Ge<ll<?! uikl<!Lkzqb!
ogicb!Ovigr<gt<!G{liGl</!
S.No Drugs Botanical Name Action Dose Part 
used 
Phytochemicals 
01 SEERAGAM Cuminum cyminum 
Linn 
Apiaceae 
Anti 
inflammatory, 
carminative, 
stomachic, 
Astringent 
cooling 
35g Fruits Apigenin-7-
glucoside 
Luteolin-7-0-
glucoside  
Essential oil 
02 THIPPILI Piper longum Linn 
Piperaceae 
Stimulant 
Carminative 
Vermifuge 
35g Flower 
bud 
Resin, Volatile 
oil, starch, 
Fattyoil, Piperine 
03 CHUKKU Zingiber officinalis 
Rose 
Zingiberaceae 
Stimulant 
Stomachic 
Carminative 
35g Rhizome Volatile oil 
Camphene 
Phellandrene 
Zingiberingeineol 
Borneol, oleo 
resin 
04 LAVANGAM Szygium 
aromaticum.Linn  
Myrtaceae 
Antispasmodic 
Carminative 
Stomachic 
35g Flower 
bud 
Alkaloids 
Sapanin 
Flavonoids 
Terpenoids 
Tanin 
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Dose  :  4.2 gms (1 varaganedai) twice a day 
Adjuvant : Sugar, Ghee 
Duration : 30 days 
Seeragam 
 Sju! ;!! giIh<H?!-eqh<H!
! ke<jl!;!! km<hl<!
! hqiqU! ;!! -eqh<H!
ohiKg<G{l<< << << <!
! hqk<kolE!lf<kqiqjbh<!hqe<eh<!hMk<kqbue<!
! sk<KVju!Bf<Kxf<K!sikqk<K!–!lk<koeEl<!
! visjeB!lQoue<X!f{<jhh<!hzh<hMk<kq!
! OhiseG!!miiqosBl<!OhiI/!
-keiz<!npz<Ohil<?!ubqx<Xuzq?!uib<Ofib<?!=vz<Ofib<?!gisl<?!gz<zjmh<H?!
GVkqg<gpqs<sz<?!-jvh<H?!gl<lz<?!&g<GfQIhib<kz<?!ouxq?!utqOfib<gt<!-ju!
uqzGl</!
Thippili 
 Sju! ;! -eqh<H!
! ke<jl!;! km<hl<!
! hqiqU! ;! -eqh<H!
ohiKg<G{l<< << << <!
! gm<c!obkqi<fqe<X!gMOfiobz<!zil<h{qBl<!
! kqm<c!uqjebgZl<!Okgolk<k!–!Hm<cbil<!
! lilEg<G!liloee!lx<xui<g<G!lx<xueir<!
! gilolEf<!kqh<hqzqg<Gl<!jg/!
gMjlbie!Jbh<hq{qgjt!ngx<xq?!dmx<G!ue<jljb!ntqk<kqMl</!
!
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Chukku 
 Sju! ;! giIh<H!
! ke<jl!;! ouh<hl<!
! hqiqU! ;! giIh<H!
ohiKg<G{l<< << << <!
! $jzlf<kl<!ofR<osiqh<H!OkimOlh<!hl<lpjz!
! &zl<!-jvh<hqVlz<!&g<GfQI!–!uizgh!
! Okimlkq!sivf<!okimIuik!Ge<lfQIk<!
! Okiml<N!ll<Ohig<GR<!Sg<G/!
Sg<gqeiz<!osiqbijl?!liIohiqs<sz<?!HtqObh<hl<?!ouh<hl<?!gQp<uib<Ofib<?!-jvh<H?!
-Vlz<?!gpqs<sz<?!fQOvx<xl<?!Ge<ll<?!ubqx<Xh<hqsl<?!giKg<Gk<kz<?!LgOfib<?!
kjzOfib<?!Gjzuzq?!hi{<M?!ubqx<Xg<Gk<kz<?!JbSvl<!Ohil</!
Lavangam 
Sju! ;! giIh<H!
ke<jl!;! ouh<hl<!
hqiqU! ;! giIh<H!
ohiKg<G{l<< << << <!
! hqk<klbg<gl<!OhkqobiM!uif<kqBl<Ohil<!
! Sk<kquqvk<!kg<gMh<Hf<!Okie<XOli!–!olk<k!
! -zur<gr<!ogi{<muVg<!Ogx<!SgliGl<!
! lzlr<Og!gm<Mole!uip<k<K/!
-keiz<!lbg<gl<?!Ohkq?!uif<kq?!GVkqg<gpqs<sz<?!fim<hm<m!gpqs<sz<?!
wVuib<g<gMh<H?!osuqOfib<?!squf<kls<sl<?!gXk<k!ls<sl<?!g{<{iz<!H,?!hjmgt<!
Ngqbux<jx!fQg<Gl</!
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PURIFICATIONS OF RAW DRUGS 
- Seeragam 
Soak in Ca(OH)2 water on 21 hours then sun dried 
- Thippili 
Soak in lime juice and make it dry 
- Chukku 
Peel off the outer layer and cut small pieces allow it to dried on the 
shade light. 
- Lavangam 
Just remove the adulterant and make it dried on the shade light. 
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ANNEXURE-II 
BIO – CHEMICAL ANALYSIS OF AKKINI CHOORANAM 
PREPARATION OF THE EXTRACT 
 5gms of the drug was weighed accurately and placed in 250ml clean beaker. 
Then 50ml of distilled water was added and dissolved well. Then it was boiled well 
for about 10 minutes. It was cooled and filtered in a 100ml volumetric flask and then 
it was makeup to 100ml with distilled water.  This fluid was taken for analysis. 
 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1 
TEST FOR CALCIUM 
2ml of the above prepared extract is 
taken in a clean test tube. To this add 
2ml of 4% Ammonium oxalate 
solution. 
A white precipitate 
is formed. 
Indicates the 
presence of 
calcium. 
2 
TEST FOR SULPHATE: 
2ml of the extract is added to 5% 
barium chloride solution. 
A white precipitate 
is formed. 
Indicates the 
presence of 
sulphate. 
3 
TEST FOR CHLORIDE: 
The extract is added with silver 
nitrate solution 
A white precipitate 
is formed. 
Indicates the 
presence of 
chloride. 
4 
TEST FOR CARBONATE: 
The substance is treated with 
concentrated Hcl 
No brisk 
effervescence is 
formed. 
Absence of 
carbonate. 
5 
TEST FOR STARCH: 
The extract is added with weak 
iodine solution. 
Blue colour is 
formed. 
Indicate the 
presence of 
starch. 
6 
TEST FOR IRON FERRIC: 
The extract is acidified with Glacial 
acetic acid and potassium ferro 
cyanide. 
No blue colour is 
formed. 
Absence of 
ferric iron. 
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7 
TEST FOR IRON FERROUS: 
The extract is treated with 
concentrated Nitric acid and 
Ammonium thio cyanate solution. 
Blood red colour is 
formed. 
Indicates the 
presence of 
ferrous iron 
8 
 
TEST FOR PHOSPHATE: 
The extract is treated with 
Ammonium Molybdate and 
concentrated nitric acid. 
No yellow 
precipitate is 
formed. 
Absence of 
phosphate. 
9 
TEST FOR ALBUMIN: 
The extract is treated with Esbach’s 
Reagent. 
No yellow 
precipitate is 
formed. 
Absence of 
albumin. 
10 
TEST FOR TANNIC ACID: 
The extract is treated with ferric 
chloride. 
Blue black 
precipitate is 
formed. 
Indicates the 
presence of 
tannic acid. 
11 
TEST FOR UNSATURATION: 
Potassium permanganate solution is 
added to the extract. 
It gets decolorized. 
Indicates the 
presence of 
unsaturated 
compound. 
12 
TEST FOR THE REDUCING 
SUGAR: 
5ml of Benedict’s qualitative solution 
is taken in a test tube and allowed to 
boil for 2 mts and added 8-10 drops 
of the extract and again boil it for 2 
mts. 
No colour change 
occurs. 
Absence of 
reducing sugar. 
13 
TEST FOR AMINO ACID: 
One or two drops of the extract is 
placed on a filter paper and dried it 
well. After drying, 1% Ninhydrin is 
sprayed over the same and dried it 
well. 
Violet colour is 
formed. 
Indicate the 
presence of 
amino acid. 
14 
TEST FOR ZINC: 
The extract is treated with potassium 
Ferrocyanide. 
No white 
precipitate is 
formed. 
Absence of 
zinc. 
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INFERENCE: 
Indicates the presence of  Calcium, sulfate, Chloride, Starch, Ferrous iron, 
Tannic acid, Unsaturated compound and Amino acid. 
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ANTI-INFLAMMATORY ACTIVITY OF SIDDHA 
FORMULATION AKKINI  CHOORANAM 
  The anti-inflammatory activities of siddha formulation AKKINI CHOORANAM 
at a dose of 100 and 200mg/kg were evaluated using carrageenan-induced paw edema 
method. The inflammation was readily produced in the form of edema with the help 
of irritant such as carrageenan. Carrageenan is a sulphated polysaccharide obtained 
from sea weed (Rhodophyceae) and when injected cause the release of prostaglandins 
by the way it produces inflammation and edema. 
REQUIREMENTS: 
Animal                                : Albino rat (180-200 g) 
Drugs and chemicals          : Carrageenan (1%w/v), Diclofenac sodium (standard), 
Carboxy methyl cellulose (1%w/v), 
Digital plethysmo meter. U G O Basile (Italy) 
Test compounds                :   siddha formulation AKKINI CHOORANAM 
METHOD: 
  Anti-inflammatory activity was performed by the following procedure of 
Bhandri et al(1) The animals were divided into 4 groups each having six animals. A 
freshly prepared suspension of carrageenan (1% w/v , 0.1 ml) was injected to the 
planter region of left hind paw of each rat. One group was kept as control and the 
animals of the other groups were pretreated with the siddha formulation AKKINI 
CHOORANAM  test Compounds dissolved with 2 ml sterile water given through orally 
30 min before the carrageenan treatment. The paw volumes of the test compounds, 
standard and control groups were measured at 60,240,360 minutes of carrageenan 
treatment with the help of Digital plethysmometer (Ugo basile, Italy). Mean increase 
in paw volume was measured and the percentage of inhibition was calculated. 
% Anti-inflammatory activity = (Vc-Vt / Vc) x 100 
Where, Vt-mean increase in paw volume in rats treated with test compounds, 
Vc-mean increase in paw volume in control group of rats. 
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TABLE No.1 
ANTI-INFLAMMATORY ACTIVITY OF SIDDHA FORMULATION 
AKKINI CHOORANAM 
Treatment Dose (mg/kg) 
Paw volume(ml) 
as measured by 
mercury 
displacement at 6 
hour 
Percentage 
inhibition of paw 
edema 
Group I 
Normal saline 10ml/kg orally 5.63±0.98 - 
Group II 
   Std 
10mg/kg 
I.P.Diclofenac 
sodium 
1.71±0.48 69.62%*a 
Group III 
AKKINI 
CHOORANAM 
100mg/kg.Orally. 2.10±0.48 62.69%*a 
Group IV 
  AKKINI 
CHOORANAM 
200mg/kg.Orally.  1.95±0.51 65.36%*a 
* Data are expressed as Mean ± S.E.M. 
*Data were analyzed by one way ANOVA followed by Newman’s keul’s multiple 
range tests, to determine the significance of the difference between the control group 
and rats treated with the test compounds. 
*a   Values were significantly different from normal control at P< 0.01. 
Results 
Anti- inflammatory activity 
  Both doses of siddha formulation AKKINI CHOORANAM at 100mg/kg and 
200mg/kg were tested for their Anti- inflammatory activity by using carrageenan 
Induced rat paw edema method and the results are tabulated in table no 1.  The results 
reveals that   both doses of siddha formulation AKKINI CHOORANAM at 100mg/kg and 
200mg/kg doses possesses significant Anti- inflammatory activity when compared to 
control group at p<0.01. 
 
  
  
130 
 
ANALGESIC ACTIVITY 
             Analgesic activity of siddha formulation AKKINI CHOORANAM was 
evaluated by acetic acid induced writhing reflux in mice. Painful reaction in animals 
may be produced by the chemicals such as phenylquinone, bradykinin etc.  Like that, 
acetic acid pain reaction which is characterized as a writhing response. Construction 
of abdomen, turning of trunk (twist) and extension of hind legs are taken as reaction 
to chemically induced pain. Analgesics (both narcotic and non-narcotic) inhibit 
writhing response. 
REQUIREMENTS: 
Animal                                : Swiss albino mice (20-25g) either sex 
Drugs and chemicals          : Diclofenac sodium (standard), 
                                              Acetic acid (1%v/v), AKKINI CHOORANAM 
                                            
METHOD: 
TREATMENT PROTOCOL 
Group-1     Treated as normal control received 10ml/kg of normal saline through 
orally. 
Group-2     Treated as Standard control received 10mg/kg of diclofenac sodium 
through                 
                   Intraperitonealy. 
Group-3    Treated as treatment control received 100mg/kg of AKKINI 
CHOORANAM administered through orally.                                     
Group-4    Treated as treatment control received 200mg/kg of AKKINI 
CHOORANAM administered through orally.                           
               Siddha formulation  AKKINI CHOORANAM was  administered one hour 
prior to the acetic acid administration. Note the onset on writhing. Record the 
numbers of abdominal contractions, trunk twist and extension of hind limbs as well as 
the number of animals showing such response during a period of 10 minutes were 
noted. 
 STATISTICS: 
          Data are expressed as mean ± SEM; data analyzed by one way ANOVA 
followed by Newman’s keul’s multiple range tests to determine the significance of the 
difference between the control group and rats treated with the extracts. 
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  *   Values were considered significant at P< 0.01. 
TABLE No.1 
ANALGESIC ACTIVITY OF AKKINI CHOORANAM BY ACETIC ACID 
INDUCED WRITHING REFLUX IN MICE 
Treatment Dose (mg/kg) No. of writhing % reduction in 
reaction time 
Group I 
Normal saline 
Inject 1%v/v acetic 
acid 1ml/100g of 
body weight 
42.3±2.86 - 
Group II 
Std 
10mg/kg  
I.P.Diclofenac 
sodium 
        11.4±0.82 73.04%** 
Group III 
AKKINI 
CHOORANAM 
100mg/kg 
Administered 
through orally. 
15.3±1.54 63.82%** 
Group IV 
AKKINI 
CHOORANAM 
200mg/kg 
Administered 
through orally  
13.7±1.25 67.61%** 
Values are expressed as mean±SEM 
Values were find out by using one-way ANOVA followed by Newman’s keuls 
multiple range tests. 
**   Values were considered significant at P< 0.01. 
 
RESULTS 
  The table values show that analgesic activity of AKKINI CHOORANAM by 
acetic acid induced writhing reflex. The results reveals that both dose of AKKINI 
CHOORANAM possess significant analgesic activity at p<0.01.  
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ACUTE TOXICITY STUDY OF AKKINI CHOORANAM 
  Determination of acute oral toxicity is usually the initial screening step in the 
assessment and evaluation of the toxic characteristics of all compounds. The types of 
toxicity tests which are routinely performed by pharmaceutical manufacturers in the 
investigation of a new drug involve acute, sub-acute and chronic toxicity. Acute 
toxicity is involved in estimation of LD50 (the dose which has proved to be lethal 
(causing death) to 50% of the tested group of animals) 
 (Shetty Akhila, et al., 2007).(1) 
Method:Acute oral toxicity of AKKINI CHOORANAM is carried out as per the 
guidelines Organization of Economic Co-operation and Development (OECD) -423 
guidelines after the animal ethical clearance from Institutional Animal Ethics 
Committee.  
The albino mice are fasted over night and provided only water, after which the 
AKKINI CHOORANAM is administered by gastric intubations to the relevant 
group of animals orally at the dose of 50 mg.kg-1 body weight in Tween-80. The 
animals are then observed for 14 days and maintained with normal food. A mortality 
rate of 2 or 3 animals in 14 days is recorded and the dose is said to be toxic dose. But 
when mortality of one animal is observed, then the same dose is repeated again for 
confirmation. However, if mortality is not observed, the procedure is repeated for 
further higher doses such as 300 and 2,000 mg.kg-1 body weight. Toxic symptoms are 
observed for 72 hrs including behavioral changes, locomotion, convulsions and 
mortality (Shah Ayub, 1997, Bürger, 2005).(2,3). 
Cage Side Observations 
 Observations include changes in skin and fur, eyes and mucous membranes, 
and also respiratory, circulatory, autonomic and central nervous systems, and 
somatomotor activity and behavior pattern. Special attention is directed for the 
observation of tremors, convulsions, salivation, diarrhea, lethargy, sleep and coma. 
Body Weight, Food and Water Intake 
 Body weight, food and water intake are recorded at two-day intervals.  
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Pathology 
 Surviving animals are fasted overnight, weighed and humanely killed on the 
15th day using anesthetic ether. All test animals are subjected to gross necropsy. 
Subchronic test for AKKINI CHOORANAM 
This experiment evaluates the toxicity potential ofAKKINI CHOORANAM. 
Method: Male and female Wistar rats weighing 180 ± 10 g are used for the present 
study. The animals are divided into five groups of six animals each. The dose of the 
preparation is calculated based on the body weight of the animal.   The animals in 
Group I are administered with a single daily dose of 0.5 ml of Tween 80 orally for 20 
days. The animals in Group II are administered with 50 mg.kg-1b.w. of the AKKINI 
CHOORANAMorally once daily for 20 days. The animals in Group III are 
administered with 100 mg.kg-1b.w. of the AKKINI CHOORANAM orally once 
daily for 20 days. The animals in Group IV and V are administered once daily with 
200 and 400 mg.kg-1b.w. of the AKKINI CHOORANAM respectively for 20 days 
orally (Pieme,et al 2006, Joshi, et al 2007, Mythilypriya, et al., 2007).(4,5,6)The 
animals are then weighed every five days, from the start of the treatment, to record the 
weight variation. At the end of the treatment, blood samples are collected by 
puncturing retro orbital plexus after mild anesthesia for biochemical analysis. The 
collected blood sample is centrifuged within 5 min of collection at 4000 g for 10 min 
to obtain plasma, which is analyzed for total cholesterol, total triglyceride, HDL-
cholesterol levels,LDL-cholesterol,plasma glucose, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), creatinine and urea. 
Results 
Acute toxicity study with AKKINI CHOORANAM 
 The acute toxicity of AKKINI CHOORANAMwas evaluated usingOECD- 
423 guidelines. There was no mortality or morbidity observed in animals through the 
15-days period following single oral administration at all selected dose levels of the 
AKKINI CHOORANAM(Table-1).   The animals did not show any changes in the 
general appearance during the observation period. Morphological characteristics such 
as fur, skin, eyes and nose appeared normal. No tremors, convulsion, salivation, 
diarrhea, lethargy or unusual behaviors such as self mutilation, walking backward and 
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so forth were observed.   Gait and posture, reactivity to handling or sensory stimuli, 
grip strength was also normal.  
 Dose (mg.kg
-1
) Sign of Toxicity (ST.NB
-1
) Mortality (D.S
-1
) 
Group I              0                      0/3            0/3 
Group II            300                      0/3            0/3 
Group III           2000                      0/3            3/3 
 
Table.1. Acute toxicity studyof AKKINI CHOORANAM on experimental mice. 
The acute toxicityof AKKINI CHOORANAM on experimental mice was tested 
using OECD-423 guidelines, where ST- sign of toxicity; NB- normal behaviour; D- 
died; S- survive.  Values are expressed as number of animals (n=3). 
Effect of AKKINI CHOORANAM inSubchronic Toxicity  
AKKINI CHOORANAMwere evaluated for subchronic toxicity. 
Effect of AKKINI CHOORANAM on body weight changes in rats 
The effect of AKKINI CHOORANAMwas observed for their effect on the body 
weight changes from the study it was observed that, there was significant increase 
(p<0.05) in body weight in all the animals observed.   The results are shown in 
Table.2. 
Treatment Day 1 Day 5 Day 10 Day 20 
Control 185.14±5.4 190.45  ±6.14 199.10 ±6.30 199.6±6.28 
AKKINI 
CHOORANAM 
 50 mg.kg-1 
196.34 ±6.2 199.35  ±6.45 200.48 ±6.75 200.30±6.82* 
AKKINI 
CHOORANAM 
100 mg.kg-1 
189.36 ±6.0 196.48 ±6.40 198.30  ±6.54 200.89±6.68* 
AKKINI 
CHOORANAM 
200 mg.kg-1 
198.25  ±7.0 200.25±6.32 200.48  ±6.58** 208.35±6.70** 
AKKINI 
CHOORANAM 
189.54  ±6.34 196.40 ±6.60 198.15  ±6.65** 206.52±6.72** 
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400 mg.kg-1 
 
Table.2.The effects of AKKINI CHOORANAM on body weight changes in rats.   A 
study on the effects of AKKINI CHOORANAM on body weight changes in rats was 
carried out.. where, group I animals (GPI) were treated with normal saline (5 ml.kg-1), 
group II animals (GPII) with 50 mg.kg-1 of AKKINI CHOORANAM,  group III 
animals (GPIII)  with 100 mg.kg-1 of AKKINI CHOORANAM, group IV animals 
(GPIV)  with 200 mg.kg-1 of AKKINI CHOORANAM, group V animals (GPV)  
with 400 mg.kg-1AKKINI CHOORANAM. The values are expressed as mean ± 
S.E.M. n=6. The results of group I were compared with other groups such as II, III, 
IV, and V.   The statistical analysis was carried out using one way ANOVA method, 
where **P<0.01 *P<0.05. 
Effect of AKKINI CHOORANAM on kidney,heart, liver and brain in 
rats.The effects of AKKINI CHOORANAM on kidney, heart, liver and brainof the 
rats were observed.From the study it was clear that, significant (p<0.01) changes in 
the weights of various organs of the animals occurred with higher doses of the extract 
(400 mg.kg-1bwt), but macroscopic examinations did not show any changes in colour 
of the organs of the treated animals compared with the control.   The results are 
shown in Table.3. 
Treatment Heart (gms) Kidney (gms) Liver (gms) Brain (gms)   
Control 0.35 ± 0.04 0.72± 0.03 3.33± 0.14 0.74± 0.05 
AKKINI 
CHOORANAM @50 
mg.kg-1 
0.36± 0.05 0.82± 0.05 3.43± 0.19 0.72± 0.03 
AKKINI 
CHOORANAM @100 
mg.kg-1 
0.39± 0.06 0.82± 0.04 3.45±0.21 0.70± 0.08 
AKKINI 
CHOORANAM @ 200 
mg.kg-1 
0.34± 0.03 0.75± 0.02 3.37± 0.22 0.78± 0.09 
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AKKINI 
CHOORANAM @400 
mg.kg-1 
0.37± 0.05 0.74± 0.02 3.38± 0.15 0.77± 0.12 
 
Table.3.The effects of AKKINI CHOORANAMon kidney, heart, liver and brainof 
the rats. A study on the effects of AKKINI CHOORANAMon kidney, heart, liver 
and brainof the rats was tested. where, group I animals (GPI) treated with normal 
saline (5 ml.kg-1), group II animals (GPII)  with 50 mg.kg-1 of AKKINI 
CHOORANAM,  group III animals (GPIII)   with 100 mg.kg-1 of AKKINI 
CHOORANAM, group IV animals (GPIV)   with 200 mg.kg-1 of AKKINI 
CHOORANAM, group V animals (GPV)  with 400 mg.kg-1AKKINI 
CHOORANAM.  The values are expressed as mean ± S.E.M. n=6.   The results of 
group I were compared with other groups such as II, III, IV,  and V.  The statistical 
analysis was carried out using one way ANOVA method, where **P<0.01. 
Effect of AKKINI CHOORANAM on biochemical profiles of rats   
The effect of AKKINI CHOORANAM on various biochemical parameters of the 
experimental animal ‘rats’ were tested.From the study it was evident that, there was 
significant decrease (p<0.05) in the plasma glucose level in treated rats especially at 
higher dose (400 mg.kg-1) compared with control rats.   The control rats were 
administered only with 5 ml of normal saline.   Significant decrease (p<0.05) in the 
plasma total cholesterol (TC), triglyceride (TG) and LDL-cholesterol levels were 
observed.   But a significant increase (p<0.05) in HDL-cholesterol levels were 
observed in all the treated animals compared with the control animals. AST, ALT and 
ALP levels were also normal in the AKKINI CHOORANAM treated animals. From 
the results of biochemical study there was no evidence of severe toxicity associated 
with the administration of higher concentration of AKKINI CHOORANAM. The 
results are shown in Table.4. 
Treatment 
Glucose 
(mg.dl-1) 
Cholesterol 
(mg.dl-1) 
Triglyceride 
(mg.dl-1) 
HDL 
(mg.dl-1) 
LDL 
(mg.dl-1) 
Control 89.42±1.72 34.05± 0.62 29.25±1.43 143.45±3.15 81.30±1.85 
AKKINI 
CHOORANAM @ 50 
87.50±1.60 20.30± 0.33* 12.36± 0.85* 181.40±3.65* 67.75±1.38 
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mg.kg-1 
AKKINI 
CHOORANAM@ 100 
mg.kg-1 
85.44±1.50 18.65± 0.33* 14.32± 0.90* 170.30±3.40* 64.54±1.30 
AKKINI 
CHOORANAM @ 
200 mg.kg-1 
84.30±1.33** 24.20± 0.35 15.40± 0.92* 189.34±3.70* 41.52±1.18 
AKKINI 
CHOORANAM @ 
400 mg.kg-1 
87.28±1.41** 25.45± 0.45 17.30±1.15* 187.24±3.66* 40.30±1.05 
 
 
Table.4.The effect of AKKINI CHOORANAM on biochemical parameters such as 
glucose, cholesterol, triglyceride, HDL and LDL. A study on the  effect of AKKINI 
CHOORANAMon biochemical parameters such as glucose, cholesterol, triglyceride, 
HDL and LDL in rats was tested.where, group I animals (GPI) treated with normal 
saline (5 ml.kg-1), group II animals (GPII)  with 50 mg.kg-1 of AKKINI 
CHOORANAM,  group III animals (GPIII)  with 100 mg.kg-1 of AKKINI 
CHOORANAM, group IV animals (GPIV)  with 200 mg.kg-1 of, group V animals 
(GPV)   with 400 mg.kg-1AKKINI CHOORANAM. The values are expressed as 
mean ± S.E.M. n=6.   The results of group I were compared with other groups such as 
II, III, IV, and V.  The statistical analysis was carried out using one way ANOVA 
method, where **P<0.01 *P<0.05 
 
Treatment 
AST 
(IU.l-1) 
ALT 
(IU.l-1) 
ALP 
(IU.l-1) 
TP 
(g.l-1) 
ALBUMIN 
(g.l-1) 
Control 320.3±11.58 75.4± 3.44 255.35± 8.62 63.36± 3.26 33.30±2.47 
AKKINI 
CHOORANAM
@50 mg.kg-1 
310.4±10.50*
*
 
73.3± 2.92** 267.15±8.73** 63.30±3.18 30.24±2.32 
AKKINI 
CHOORANAM
@ 100 mg.kg-1 
309.5±10.62*
*
 
70.3±2.94** 268.38±8.35** 73.12±3.78 31.30±2.43 
AKKINI 
CHOORANAM 
@ 200 mg.kg-1 
308.5±9.92 67.3± 2.40 268.20±8.41 64.35± 3.67 32.28±2.44 
AKKINI 
CHOORANAM 
@ 400 mg.kg-1 
310.4±9.96 67.6±2.48 268.42±8.49 65.30± 3.74 32.64±2.52 
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Table.5.The effects of AKKINI CHOORANAM on biochemical parameters such as 
AST, ALT, ALP, TP and Albumin in rats. A study on the effects of AKKINI 
CHOORANAM on biochemical parameters such as AST, ALT, ALP, TP and 
Albumin rats was tested. where, group I animals (GPI)  were treated with normal 
saline (5ml.kg-1),  group II animals (GPII) with 50 mg.kg-1 of HAEBD group III 
animals (GPIII)  with 100 mg.kg-1 of AKKINI CHOORANAM, group IV animals 
(GPIV)  with 200 mg.kg-1 of AKKINI CHOORANAM,  and group V animals (GPV)  
with 400 mg.kg-1AKKINI CHOORANAM  The values are expressed as mean ± 
S.E.M. n=6.   The results of group I were compared with other groups such as II, III, 
IV, and V.   The statistical analysis was carried out using one way ANOVA method, 
where **P<0.01 *P<0.05. 
Effect of AKKINI CHOORANAM on haematological parameters in rats   
The effects of AKKINI CHOORANAMwere observed for its effect 
onhaematological parameterson the experimental rats. From the study it was evident 
that, a significant increase (p<0.01) were observed in the haemoglobin contents and  
RBC count  in the group treated with 200 mg.kg-1 body weight of AKKINI 
CHOORANAMand a significant decrease of the parameters occurred in the group 
treated with 400 mg.kg-1 b.w.t compared with the control.   There was no significant 
change in the calcium level in all the treated animals compared to the control. 
Treatment 
Haemoglobin 
(mg.dl-1) 
RBC 
(106 /mm3) 
WBC 
(106 /mm3) 
Calcium 
(mg.dl-1) 
Control 13.52±1.28 9.25± 0.93 11.51± 0.90  9.42 ±0.60 
AKKINI 
CHOORANAM @ 
50 mg.kg-1 
14.33±1.35* 9.38±1.05*   9.34± 0.82*  9.24 ±0.38 
AKKINI 
CHOORANAM @ 
100 mg.kg-1 
14.21±1.84* 9.47±1.20*   8.34± 0.28*  9.24 ±0.45 
AKKINI 
CHOORANAM@ 
200 mg.kg-1 
13.26±1.25* 8.36± 0.85* 11.51± 0.83*  9.58 ±0.56 
AKKINI 
CHOORANAM@ 
400 mg.kg-1 
13.24±1.23* 8.48± 0.92*   10.84±0.75*  9.66 ±0.64 
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Table.6.The effect of AKKINI CHOORANAM on haematological parameters such 
as HB, Calcium, RBC and WBC in rats. A study on the effect of AKKINI 
CHOORANAM on haematological parameters such as Hb, RBC, WBC, Calcium in 
rats was tested. where, group I animals (GPI) treated with normal saline (5 ml.kg1), 
group II animals (GPII)  with 50 mg.kg-1 of AKKINI CHOORANAM,  group III 
animals (GPIII)   with 100 mg.kg-1 of AKKINI CHOORANAM,   group IV animals 
(GPIV)   with 200 mg.kg-1 of AKKINI CHOORANAM, and  group V animals 
(GPV)  with 400 mg.kg-1AKKINI CHOORANAM. The values are expressed as 
mean ± S.E.M. n=6. The results of group I were compared with other groups such as 
II, III, IV and V.   The statistical analysis was carried out using one way ANOVA 
method, where *P<0.05. 
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Discussion 
The evaluation of sub-chronic and chronic dosing in experimental animals 
may be more relevant in determining the overall toxicity of the plant preparation.  The 
highest overall concordance of toxicity in animals in comparison with humans is with 
hematological, gastrointestinal, and cardiovascular adverse effects whiles certain 
adverse effects in humans, especially hypersensitivity and idiosyncratic reactions, are 
poorly correlated with toxicity observed in animals (Olson, et al., 2000).(7) 
 
In the present study, where the acute toxicity study of AKKINI 
CHOORANAM was carried out as per OECD-423 guidelines,no mortality was 
observed in both the animals of control group as well as animals treated with a 
maximum dose of 2000 mg.kg-1.   Hence, 1/10th of 2000 mg.kg-1 i.e. 200 mg.kg-1 of 
dose was selected as a minimum dose for sub-acutetoxicity study (Abu TahaNael, et 
al., 2008).(8) 
The results of sub-acute toxicity study shows that there was no significant 
change in animal behaviour due to the absence of toxicity.   The animals treated with 
AKKINI CHOORANAM showed normal growth pattern and body weight compared 
with control rats treated with normal saline. So the changes in body weight can be 
used as an indicator of adverse effects of drugs and chemicals (Tofovic and Jackson, 
1999; Raza, et al., 2002; Teo, 2002).(9,10,11)  
The changes in enzymes like ALP, AST and ALT levels show liver 
impairment, due to toxicity (Hayes, 1989).(12)   Serum cholesterol and proteins 
mainly regulated via synthesis in the liver and increase or decrease in serum 
concentrations of constituents suggest liver toxicity.   The results of the present study 
were assessed after 28 days of administration of AKKINI CHOORANAM, and it 
was found that AKKINI CHOORANAM at all concentrations do not produce liver 
damage. 
There was a slight decrease in plasma glucose level, when higher doses of 
AKKINI CHOORANAM (400 mg.kg-1) were administered in the treated rats.. 
Analysis of blood parameters is likely to risk evaluation as the change in 
hematological system has a higher predictive value for human toxicity, when data are 
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translated from animal studies (Olson, et al., 2000).(7)   After 28 days of treatment, 
there were no significant changes in the haematological parameters between control 
and treated groups.   No significant changes in the levels of WBC, RBC were 
observed between control and test groups following repeated administration of 
AKKINI CHOORANAM. Interestingly, significant increase in the levels of 
hemoglobin was found in treatment with AKKINI CHOORANAM with a higher 
dose of 400 mg.kg-1.   The possible reason could be that one of the constituents 
AKKINI CHOORANAM may increase absorption of iron.  
The overall results suggest that AKKINI CHOORANAM are non toxic to the 
haaematopoietic and leucopoietic system.   The haematopoietic and leucopoietic 
systems are the most sensitive targets for toxic compounds and an important index of 
physiological and pathological status in man and animal (Adeneye, et al., 2006).(13)   
Therefore, it is possible to assume that the AKKINI CHOORANAMis non 
haematotoxic. 
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PALAYAMKOTTAI, TIRUNELVELI 
DEPARTMENT OF POTHU MARUTHUVAM 
 
A PROSPECTIVE, OPEN LABELLED, RANDOMIZED PHASE – II CLINICAL TRIAL 
ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH EVALUATION OF 
THE TRIAL DRUG “AKKINI CHOORANAM” 
 
 
FORM - I 
 
 
SCREENING AND SELECTION PROFORMA 
 
01. Name of the subject :  
02. S. No. of the Subject :                                    
03. OP No :        04.  IP No :  
05. Date of Admisión :                               
06. Date of Discharge  :                              
07. Address :  
 
08. Contact Number : 
09. Date of Birth  :                                                                     10. Age (in yrs): 
11. Code No (of clinical trial):  
12. Gender :  Male    1    Female    2 
 
13. CRITERA OF INCLUSON Yes 1 No 2 
01 
Age between 18 and 50 years    
18 - 20 1 21 - 30 2 31 - 40 3 41 - 50 4  
02 Both Sex 
Male     
Female  
03 Symmetrical joint involvement     
  
 
14. CRTERIA FOR EXCLUSION 
 
 
 
 
 
 
01 Age below 18 and above 50  
02 Systemic Hypertension   
03 Diabetes  mellitus  
04 Chronic alcoholics, Chronic smokers 
05 Pregnancy and lactating Mothers  
06 Extra pulmonary Tuberculosis  
07 Psoriatic arthritis  
08 Gouty arthritis  
09 Chronic kidney disease  
04 Arthritis of 3 or more joints  
05 Florid Morning stiffness and swelling that lasts for few hours or days  
06 Pain, Joint swelling especially in the inter phalangeal joint  
07 Polyarthritis  
08 
Patients who are willing for admission and stay in IPD for minimum 20-30 days or 
willing to attend OPD 
 
09 
Patient willing to sign the informed Patient who are willing to undergo radiological 
investigation and give blood and urine samples for laboratory investigation. 
 
10 
Patient willing to sign the informed consent stating than he/she will consciously 
stick to the treatment during 30 days but can OPD  out of the trial of his/her own 
conscious discretion. 
 
11 Pain criteria score should be greater than or equal to 6  
12 
DISEASE ACTIVITY PAIN SCORE OF 28 JOINTS’ should be greater than or 
equal to 3.2. 
 
Yes 1 No 2 
 A patient is eligible for admission 
 If “Yes” or “No”  :   
 If admitted: 
 Sr. No. of the Subject:     
 No. of packets issued :          4.1 grm / bd with Ghee or Sugar for 2 days. 
 
 
Date :                     ___________________________ 
Place  : ___________________                       Signature of the Investigator   
 
 
 
 
 
 
 
__________________________                                       ___________________________ 
         Signature of guide                  Signature of Supervisor 
 
Date :                                                              Date :     
 
Place  : ___________________                                              Place  : ____________________   
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI 
DEPARTMENT OF POTHU MARUTHUVAM 
 
A PROSPECTIVE, OPEN LABELLED, RANDOMIZED PHASE – II CLINICAL
TRIAL ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH 
EVALUATION OF THE TRIAL DRUG “AKKINI CHOORANAM” 
 
FORM – I  A 
 
 
HISTORY PROFOMA ON ENROLMENT 
 
01. Name of the subject :  
02. Sr. No. of the Subject :      
03. OP No :        04.  IP No :  
05. Date of Admisión :       
06. Date of Discharge  :    
07. Address :  
 
08. Contact Number : 
09. Date of Birth  :                                                                     10. Age (in yrs): 
11. Code No (of clinical trial) :  
12. Gender :  Male    1    Female    2 
13. Educational status: 
Illiterate 1 High school 5 
Read and write 2 College 6 
Primary 3 Others (specify) 7 
Middle school 4 INA 8 
 
 
 
 
 
 14. Occupation 
Desk work 1 
Field work 2 
Field work with physical labour 3 
Field work with intellectual 4 
 
 
 
      Indicate Nature of work _______________________________________________ 
 
 
13. Religion 
Hindu 1 Christian 4 
Muslim                 2 Parsi 5 
Sikh 3 
14. Total Family members:                        Children        I. Male           II. Female 
 
12. Income per capita per month (in Rs):  
 
 
13. Chief complaint with duration (if any) in 
 
No Chief complaint 1/2 Duration days
01 Severe pain and swelling in small joints    
02 Symmetrical joint involvement   
03 Morning stiffness 
  
04 Anorexia 
  
05 Rheumatoid nodules 
  
06 Depression 
  
07 Others  
 
   If Yes specify :  ________________________________________________________________
 
 
Yes 1 No 2 
14. PERSONAL HISTORY 
1. Diet 
2. Presence of anxiety 
3. Constipation 
 
4. Addiction 
 
15. PERSONAL HABITS 
I. Smoking 
    If yes specify:  (a) Quantity packs  :  
(b) Total Duration in year's :  
II.  Tobacco 
            If yes specify:  (a) Quantity   :  
(b) Total Duration in years :  
III. Alcohol  
            If yes specify:  (a) Quantity (in ml/day) :  
(b) Total Duration in years :  
IV. Any other (specify) : ______________________________________________________
 
16. Drug history: Had the patient been treated before with allopathy drug?  
 
17. MARITAL STATUS :   
 
 
 
18. FAMILY HISTORY :  
       Whether this problem runs in family?              
 
        If yes, mention the relationship of affected person (s) : _____________________________
 
 
 
 
 
Veg 1 Non-veg 2 Mixed 3 
Yes 1 No 2 
Yes 1 No 2 
Yes 1 No 2 
Married 1 Unmarried  2 
Yes 1 No 2 
Normal 1 Abnormal   2 
  
19. BOWEL HABITS & MICTURITION:       
 
 
 History of habitual constipation               
 
 History of frequent diarrhoea                   
 
 History of frequent dysuria                      
 
 
20. PSYCHOLOGICAL STATE:       
 
 
21. PRAKRITI :  
Vatham 1 Kapham 3 Vatha-kapham 5 Sannipatham 7 
Pitham 2 Vatha-pitham 4 Pitha-Kapham 6 
 
22. PHYSICAL EXAMINATION 
1. Height  :          cm 
2. Weight :         kg 
3. Pulse Rate :      per min 
4. Heart Rate :               per min  
5. Blood Pressure (in sitting position) 
 Systolic   :               mm Hg 
 Diastolic  :               mm Hg 
6. Body temperature  :             o F  
7. Respiration rate  :             per min 
8. Signs of dehydration and oedema, if any: _______________________________
 
Yes 1 No 2 
Yes 1 No 2 
Yes 1 No 2 
Normal 1 Anxiety 2 Depression 3 
  
23. SYSTEMC EXAMINATION 
1. Cardio Vascular System 
If abnormal, details : _________________________________________________________
      2. Central Nervous System 
If abnormal, details : _________________________________________________________
3. Digestive system 
If abnormal, details : _________________________________________________________
4. Respiratory system 
If abnormal, details : _________________________________________________________
5. Locomotor System 
If abnormal, details : _________________________________________________________
6. Endocrine System 
If abnormal, details : _________________________________________________________
7. Genito-urinary system 
If abnormal, details : _________________________________________________________ 
  
 
 
Date :                                                                       ___________________________ 
Place  : ___________________                   Signature of the Investigator   
 
 
 
 
 
 
 
 
__________________________                                     ___________________________ 
         Signature of guide            Signature of Supervisor 
Date :                                                Date    :  
 
Place  : ___________________                                        Place   : ____________________ 
Normal 1 Abnormal 2 
 GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI 
DEPARTMENT OF POTHU MARUTHUVAM 
 
A PROSPECTIVE, OPEN LABELLED,RANDOMIZED PHASE – II CLINICAL 
TRIAL ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH 
EVALUATION OF THE TRIAL DRUG “AKKINI CHOORANAM” 
 
FORM – II  A 
 
CLINICAL ASSESSMENT ON ENROLMENT AND ON VISITS 
 
01. Name of the subject :  
02. S. No. of the Subject :       
03. OP No :        04.  IP No :  
05. Date of Admisión :    
06. Date of Discharge  :    
07. Address :  
 
08. Contact Number : 
09. Date of Birth  :                                                                      10. Age (in yrs): 
11. Code No (of clinical trial) :  
12. Gender :  Male    1    Female    2 
 
 
 
SIDDHA SYSTEM OF EXAMINATION 
1. ENVAGAI THERVU: (Eight-Fold Examination) 
I. NAADI  (Pulse perception) 
Naadi 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Vazhi        
Azhal        
Iyyam        
VazhiAzhal        
VazhiIyyam        
AzhalVazhi        
AzhalIyyam        
IyyaVazhi        
IyyaAzhal        
 
 
  
II. NAA (Tongue) 
Colour Taste Mozhi 
Salaiva, Nurai 
Edai 
Volume 
Consistency 
Coating, Dryness 
Glossitis, Baldness 
Fissure, Diarrhoea 
Manam, Enjal 
Dark 1 Sweet 1 High 1 Normal / Nil 1 Solid 1 Present 1 
Yellow 2 Bitter 2 Medium 2 Increased 2 Watery 2 Absent 2 
Red 3 Sour 3 Low 3 Decreased 3 Semisolid 3   
Pale 4 Pungent  4 
Tinted 5 None 5 
 
Naa 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Colour        
Taste        
Coating        
Fissure        
Saliva        
Dryness        
Glossitis        
Baldness        
 
III. NIRAM (Complexion) 
Niram 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Dark        
Yellow        
Tinted        
Pale        
 
 
IV. MOZHI (Voice) 
Mozhi 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Medium        
High        
Low        
Pitched        
 
 
  
V. VIZHI  (Eyes) (Lower Palpebral Conjunctiva) 
Niram 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Dark        
Yellow        
Red        
Pale        
 
 
VI. MALAM (Bowel habits / Stools) 
Naa 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Colour        
Consistency        
Stool bulk        
Constipation        
Diarrhea        
 
 
VII. URINE EXAMINATION 
Neerkuri 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Niram (Colour)        
Manam (Odour)        
Nurai (Froth)        
Edai (weight/10 ml)        
Enjal (Deposits)        
Volume        
 
 
Neikuri 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Serpentine 
fashion  
      
 
Annular/Ringed 
fashion 
      
 
Pearl beaded  
Fashion 
      
 
Mixed fashion        
Other fashion        
  
VIII. SPARISAM (Palpatory perception) 
Sparisam 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Warmth/heat        
Cold        
Sweat        
 
2. THEGI (type of body constitution)  
Vatham predominant 
 
 
 
 
1 
Kabam predominant 2 
Pitham predominant 3 
Thondhaudal 4 
 
 
3. NILAM (land where patient lived most) 
Kurinji (Hilly terrain) 1 
Mullai (Forest range) 2 
Marutham (Plains) 3 
Neithal (Coastal belt) 4 
Palai (Arid regions) 5 
 
 
4. KAALAM 
Kaarkalam 1 Pinpanikalam 
 
 
4 
Koothirkalam 2 Ilavenil 5 
Munpanikalam 3 Muthuvenil 6 
 
 
5. GUNAM 
Sathuvam 1 
Rasatham   2 
Thamasam 3 
 
 
 6. IMPORIGAL (Sensory Organs) 
Organs 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Mei (Skin) 
      
 
Vai (Buccal Cavity) 
      
 
Kann (Eye) 
      
 
Sevi (Ear) 
      
 
Mooku (Nose) 
      
 
 
7. KANMENDRIYAM (MOTOR FUNCTIONS) 
Kanmendriyam 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Kai(Upperlimb) 
      
 
Kaal(lowerlimbs) 
      
 
Vai(buccalcavity) 
      
 
Eruvaai 
(Excretory organs) 
      
 
Karuvaai 
(Reproductive organs)  
      
 
 
8. KOSANGAL (Sheath)   
Kosangal 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Annamaya Kosam 
      
 
Pranamaya Kosam 
      
 
Manomaya Kosam 
      
 
Vignanamaya Kosam 
      
 
Ananthamaya Kosam 
      
 
 
 
 
 
 9. MUKKUTRAM (AFFECTION OF THREE HUMORS) 
A) VATHAM 
Vatham 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Praanan 
      
 
Abaanan 
      
 
Viyaanan 
      
 
Udhaanan 
      
 
Samanan 
      
 
Naagan 
      
 
Koorman 
      
 
Kirukaran 
      
 
Devathathan 
      
 
Dhananjeyan 
      
 
 
B) PITHTHAM 
Piththam 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Analapitham 
      
 
Ranjagam 
      
 
Saathagam 
      
 
Praasagam 
      
 
Aalosagam 
      
 
 
 
C) KAPHAM 
Kapham 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Avalambagam 
      
 
Kilethagam 
      
 
Pothagam 
      
 
Tharpagam 
      
 
Santhigam 
      
 
 
 
 
 
 
 
 10. SEVEN DHATHUS (7 SOMATIC COMPONENTS) 
 
Dhathus 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Saaram (Chyme) 
      
 
Senneer (Blood) 
      
 
Oon (Muscle) 
      
 
Kozhuppu (Fat) 
      
 
Enbu (Bones) 
      
 
Moolai  
(Bone Marrow) 
      
 
Sukkilam / 
Suronitham  
      
 
 
 
 
 
 
 
11. SYSTEMIC EXAMINATION 
Systems 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Locomotor system        
Cardiovascular system 
       
Respiratory system  
       
Gastro intestinal system  
       
Central nervous system  
       
Genito-urinary system 
       
Endocrine system        
 
 
 
 
 
 
 12. GENERAL EXAMINATION 
 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Height (cms)        
Weight (kg)        
Temperature (F0)           
Pulse rate (per min)        
Heart rate (per min)        
Respiratory rate (per min)        
Pallor        
Jaundice        
Cyanosis        
Lymph adenopathy        
Pedal edema        
Clubbing        
Jugular vein pulsation        
 
 
 
 
 
 
 
13. EXAMINATION OF THE INTERNAL ORGANS  
Organs 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Brain        
Lungs        
Liver        
Pancreas        
Kidney        
Urinary Bladder        
Heart        
Stomach        
Gall Bladder        
Intestines        
Uterus        
Rectum        
 
 
 14. CLINICAL SYMPTOMS 
Complaints 0stDay 05thDay 10th Day 15th Day 20th Day 25th Day 30thDay 
Pain and swelling 
in small joints  
     
  
Symmetrical joint 
involvement 
     
  
Morning stiffness        
Anorexia        
Rheumatoid 
nodules 
     
  
Depression        
 
15. CLINICAL SYMPTOMS:              
CRITERION JOINTS AFFECTED NORMAL SCORE PATIENT’S SCORE 
1 Large joint   0  
2-10 Large joints 1  
1-3 Small joints 2  
4-10 Small joints 5  
SEROLOGY 
Negative RF and Accp 0  
Low Positive RF or Accp 2  
High Positive RF or Accp 3  
DURATION OF SYMPTOMS 
<6 weeks 0  
>6 weeks 1  
ACUTE PHASE REACTANTS 
Normal CRP and ESR 0  
Abnormal CRP or ESR 1  
   
Patient with a score greater than or equal 6 are considered to have definite Rheumatiod Arthritis. 
 
 16. CLINICAL ASSESSMENTOF AFFECTED JOINT 
INSPECTION: 
 
 
 
 
 
 
  
If present, _____________________  
Range of motion:                Affected  /  Not affected 
 
PALPATION: 
 
 
 
 
 
 
 
 
 
 
If present, _____________________  
 
MOVEMENTS: 
 
1. Restriction of movements : Full  Partial     NO 
2. Movements: 
 
Movements 
Pain Muscular 
spasm 
Range of movement 
Yes No Yes No Normal Reduced 
i). Flexion       
ii). Extension       
iii). Abduction       
iv). Adduction       
v). Circumduction       
vi). Rotation        
vii). Lateral rotation (External)       
viii). Medical rotation (Internal)       
ix). Others       
 
Inspection Present Absent 
Symmetry   
Swelling   
Joint deformity   
Muscle wasting   
Inspection Present Absent 
Symmetry   
Warmth    
Tenderness    
Crepitation   
  
DISEASE ACTIVITY SCORE OF 28 JOINTS (DAS 28) 
 
 
 
       VERY WELL         VERY POOR 
 
 
 
 
 
 
VAS (0-100)  28TJC  28SJC     ESR 
 
DAS 28 = 0.56  + 0.28  0.70  In (ESR) + 0.14  VAS 
 
DAS  28   
 
Interpretation: 
 
 Low disease activity  : 2.6<DAS28 3.2 
 Moderate disease activity : 3.2<DAS28 5.1 
 High disease activity  : DAS28>5.1 
 
 Before treatment After treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date :                                                               ___________________________ 
Place  : ___________________                   Signature of the Investigator   
 
 
 
 
 
 
 
 
 
 
 
__________________________                                     ___________________________ 
         Signature of guide            Signature of Supervisor 
Date :                                                 Date    ::   
 
Place  : ___________________                                         Place   : ____________________ 
 GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI 
DEPARTMENT OF POTHU MARUTHUVAM 
 
A PROSPECTIVE, OPEN LABELLED, RANDOMIZED PHASE – II CLINICAL TRIAL 
ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH EVALUATION OF 
THE TRIAL DRUG “AKKINI CHOORANAM” 
FORM – II B 
 
 
BEFORE TREATMENT & FORTIGHTLY DURING TREATMENT 
01. Name of the subject :  
02. S. No. of the Subject :    
03. OP No :        04.  IP No :  
05. Date of Admisión :    
06. Address :  
 
07. Contact Number : 
08. Date of Birth  :                                                                      09. Age (in yrs): 
10. Code No (of clinical trial) :  
11. Gender :  Male    1    Female    2 
12. Date of Assessment :    
13. Chief complaint with duration (if any) in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If Yes specify :  _________________________________________________________ 
14. Physiological Assessment 
 Weight (in kgs) :  
 Blood Pressure (in sitting position)   Systolic (mm Hg) :  
       Diastolic (mm Hg) :  
 
 
 
 
Date :                                                     ___________________________ 
Place  : ___________________                   Signature of the Investigator   
               
 
 
 
                                                                                 ______________________                           ___________________________ 
                    Signature of guide           Signature of Supervisor 
Date :                                                    Date    ::   
 
Place  : ___________________                                       Place   : ____________________ 
Absent 1 Present 2      
No Chief complaint 1or 2 Duration 
01 Severe pain and swelling in small joints    
02 Symmetrical joint involvement   
03 Morning stiffness   
04 Anorexia   
05 Rheumatoid nodules   
06 Depression   
07 Severe pain and swelling in small joints    
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI 
DEPARTMENT OF POTHU MARUTHUVAM 
 
A PROSPECTIVE, OPEN LABELLED, RANDOMIZED PHASE – II CLINICAL
TRIAL ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH 
EVALUATION OF THE TRIAL DRUG “AKKINI CHOORANAM” 
 
FORM - III 
 
LABORATORY PARAMETERS - CHART 
 
01. Name of the subject :  
02. Sr. No. of the Subject :    
03. OP No :       04.  IP No :  
05. Date of Admisión :    
06. Date of Discharge  :    
07. Address :  
 
08. Contact Number : 
09. Date of Birth  :                                                                     10. Age (in yrs): 
11. Code No (of clinical trial) :  
12. Gender :  Male    1    Female    2 
13. Bed No :   
 
 LAB INVESTIGATION CHART 
Blood Investigation Normal Values 
Before TMT 
(With Date) 
In Between 
(With Date) 
After TMT
(With Date)
Hb (gms%) M : 12 - 15 
W : 11.5 - 14 
    
T.RBC(milli/cu.mm) 
M : 4.0 - 5.5 
W : 3.5 - 4.5 
    
ESR  
(mm /hr) 
1/2 hr _________     
1 hr 
M : 6 - 12 
W : 7 - 18 
    
T.WBC (cells  /cu.mm) 4000 - 10000     
D
iff
er
en
tia
l C
o
u
n
t (
%
) Polymorphs 40 - 75     
Lymphocytes 20 - 40     
Monocytes 02 - 10     
Esionophils 01 - 06     
Basophils 00 - 01     
Platelets ;  
(lak/ cubic mm) 
1,50000-500000 
    
Blood 
glucose 
(mg/dl) 
Fasting < 100     
PP < 140 
 
   
Random < 120     
Serum Cholesterol < 200     
Urea       
Creatinine      
Uric Acid      
 
Urine investigation 
Before Treatment 
(with Date) InBetween (WithDate) 
After Treatment 
(With Date) 
Neerkuri 
 
   
Neikuri 
 
   
Niram     
Manam     
Nurai     
Edai     
Enjal     
Albumin     
Sugar (F)     
Sugar (PP)     
Sugar ( R) 
 
   
Deposits     
 
 SPECIFIC INVESTIGATIONS  
 Before treatment After treatment 
CRP   
RA Factor   
ASO Titer   
 
 RADIOLOGICAL INVESTIGATIONS 
 X- ray of affected joints (AP and Lateral  view) 
 
 
Date :                                                      ___________________________
Place  : ___________________                   Signature of the Investigator   
 
 
 
 
 
 
 
 
__________________________                                     ___________________________
         Signature of guide            Signature of Supervisor 
Date :                                                   Date    ::   
 
Place  : ___________________                                         Place   : ____________________ 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI 
DEPARTMENT OF POTHU MARUTHUVAM 
 
A PROSPECTIVE, OPEN LABELLED, RANDOMIZED PHASE – II CLINICAL
TRIAL ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH 
EVALUATION OF THE TRIAL DRUG “AKKINI CHOORANAM” 
 
FORM – IV  A 
 
 
 
CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
         
I certify that I have disclosed all details about the study in the terms easily understood by 
the patient. 
 
Name of Investigator : DR.P.PRIYANGA 
 
Date : __________                  Signature of the Investigator : ______________________
 
CONSENT BY SUBJECT 
  I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory investigations 
to be performed to monitor and safeguard my body functions. 
  I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
 I, exercising my free power of choice, hereby give my consent to be included        
 As a subject in An Open Labeled Randomized Clinical Trial of Poly Herbal Formulation of 
“AKKINI CHOORANAM” for VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS
 
 Name of the Subject : __________________________________________ 
 
Date : _________      Signature or Thumb impression : ________________ 
 
 Name of witness : _____________________________________________ 
 
Date : _________   Signature or Thumb impression : ________________ 
 
Relationship : ________________________________________________ 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI 
DEPARTMENT OF POTHU MARUTHUVAM 
 
A PROSPECTIVE, OPEN LABELLED,RANDOMIZED PHASE – II CLINICAL
TRIAL ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH 
EVALUATION OF THE TRIAL DRUG “AKKINI CHOORANAM” 
 
FORM – IV   B 
 
WITHDRAWAL FORM 
 
01. Name of the subject :  
02. S. No. of the Subject :      
03. OP No :        04.  IP No :  
05. Date of Admisión :        
06. Address :  
 
07. Contact Number : 
08. Date of Birth  :                                                                      09. Age (in yrs): 
10. Code No (of clinical trial) :  
11. Gender :  Male    1    Female    2 
 
12. Date of trial commencement   :  
13. Date of withdrawal from trial :  
Reasons for withdrawal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Date :                                                     ___________________________
Place  : ___________________                   Signature of the Investigator  
 
 
 
__________________________                                     ___________________________
         Signature of guide            Signature of Supervisor 
Date :                                                    Date    ::   
 
Place  : ___________________                                       Place   : ____________________ 
 
Yes 1 No 2 
Long absence at reporting  
Irregular treatment  
Shift of locality  
Increase in severity of symptoms  
Development of severe adverse drug reactions  
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI 
DEPARTMENT OF POTHU MARUTHUVAM 
 
A PROSPECTIVE, OPEN LABELLED,RANDOMIZED PHASE – II CLINICAL
TRIAL ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH 
EVALUATION OF THE TRIAL DRUG “AKKINI CHOORANAM” 
 
FORM – IV  C 
 
 
 
PATENT INFORMATION SHEET 
 
 
 Name of the Principal Investigator :  DR.P.PRIYANGA 
 
 Name of the Institution                    :  Government Siddha Medical College & Hospital
 Palayamkottai, Tirunelveli                                     
                                                                    Tamil Nadu 
 I, Dr.P.Priyanga studying M.D (Siddha) in Government Siddha Medical College
Palayamkottai. The disease called VALI AZHAL KEEL VAYU ( RHEUMATOID
ARTHRITIS ). It is mainly caused due to vitiated Vatha and Pitha humours. 
 
 This condition is being treated in GSMC & H with many siddha formulations. As a part of 
M.D (s) research programme and developing new efficacious medicine, I propose to study 
the AKKINI CHOORNAM formulation for treating the condition. This formulation has 
been mentioned in siddha literature and empirical evidence with contemporary tools is 
required for documentation. You can receive medicines free of cost. The duration of 
treatment period is 30 days. You have to visit GSMC & H every 2 days  and collect drugs 
for 2 days. The diagnosis tests will be carried out free of cost. We will assess the effect of 
treatment after completion of 30 days of treatment using clinical and lab parameters.   
 The trial drug is prepared at the Gunapadam lab of government siddha medical college & 
hospital, palayamkottai, under the   direct supervision of teaching faculties of   Maruthuvam 
and Gunapadam Dept. 
 
 Patients are advised to do exercise, reduce the intake of salt. Patients are advised to avoid 
tamarind, betel chewing, tobacco, alcohol and smoking.    
Details of the trial drug      
 Trial Medicine  : Akkini Chooranam  
 Dosage       : 4.1 gram – twice a day 
 Adjuvant   : Ghee or Sugar 
 Duration   : 30 days   
 In this regard, I need to ask you few questions. We will maintain confidentiality of your 
comments and data obtained from you. There will be no risk of disclosing your identity and 
no physical, psychological or professional risk is involved by taking part in this study. 
 
 Taking part in this study is voluntary. No compensation will be paid to you for taking part in 
this study. You can choose not to answer any specific question. There is no specific benefit 
for you if you take part in the study, but you will be under our clinical monitoring and 
specific attention will be given for your health. Taking part in the study may be of benefit to 
the community, as it may help us to develop medicine for VALI AZHAL KEEL VAYU
(RHEUMATOID ARTHRITIS). In case of any adverse symptoms during the treatment 
few patients during the treatment, shall be reported to PIs and care will be taken in GSMC
H for relief. You can withdraw from the study at the midst of treatment period, if you are 
not interested to continue and you will receive our usual treatment without condition. 
 
 The information we will collect in this study, will remain between you and the principal 
investigator. We will ask you a few questions through questionnaire. We will not write your 
name on different forms which sent to different investigating / analysis sections and we will 
use a code instead given by the principal investigator. Only the principal investigator will 
know the key to this code which will be kept in safe custody. If you agree to be a particip
in this study, you will be screened as per the study protocol.  
 
 If you wish to find out more about this study before taking part, you can ask me all the 
questions you want or contact Dr.P.PRIYANGA, PG scholar cum principal investigator of 
this study, attached to the Government Siddha Medical College & Hospital, Palayamkottai
(Mobile Phone No : 8489023383).    
 GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI 
DEPARTMENT OF POTHU MARUTHUVAM 
 
A PROSPECTIVE, OPEN LABELLED,RANDOMIZED PHASE – II CLINICAL 
TRIAL ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH 
EVALUATION OF THE TRIAL DRUG “AKKINI CHOORANAM” 
 
FORM – IV  D 
 
 
 
ADVERSE DRUG REACTION FORM 
 
 
01. Name of the subject :  
 
02. S. No. of the Subject :      
 
03. OP No :        04.  IP No :  
 
05. Date of Admisión :    
 
06. Address :  
 
 
07. Contact Number : 
 
08. Date of Birth  :                                                                      09. Age (in yrs): 
 
10. Code No (of clinical trial) :  
 
11. Gender :  Male    1    Female    2 
 
12. Date of trial commencement :   
 
13. Date of withdrawal from trial :     
 
14. Description of adverse reaction : _______________________________________________ 
   _______________________________________________ 
 
 
 
 
Date :                                                       ___________________________ 
Place  : ___________________                   Signature of the Investigator   
 
 
 
 
 
 
 
 
__________________________                                     ___________________________ 
         Signature of guide            Signature of Supervisor 
Date :                                                  Date    ::   
Place  : ___________________                                       Place   : ____________________ 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
PALAYAMKOTTAI, TIRUNELVELI 
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A PROSPECTIVE, OPEN LABELLED,RANDOMIZED PHASE – II CLINICAL
TRIAL ON VALI AZHAL KEEL VAYU (RHEUMATOID ARTHRITIS) WITH 
EVALUATION OF THE TRIAL DRUG “AKKINI CHOORANAM” 
 
FORM – IV  E 
 
 
 
DRUG COMPLIANCE FORM 
 
01. Name of the subject :  
02. S. No. of the Subject :    
03. OP No :        04.  IP No :  
05. Date of Admisión :    
06. Date of Discharge 
07. Address :  
 
08. Contact Number : 
09. Date of Birth                    :                                                                   10. Age (in yrs): 
11. Code No (of clinical trial) :  
12. Gender :  Male    1    Female    2 
08. Bed No  :   
10. Name of the Drug :  AKKINI CHOORANAM 
     Drugs issued :                  
     Drugs returned date :       
             
S.No Date 
Drug Taken Time 
Morning / Time Noon / Time Night / Time 
Day 01     
Day 02     
Day 03     
Day 04     
Day 05     
Day 06     
Day 07     
Day 08     
Day 09     
Day 10     
Day 11     
Day 12     
Day 13     
Day 14     
Day 15     
Day 16     
Day 17     
Day 18     
Day 19     
Day 20     
Day 21     
Day 22     
Day 23     
Day 24     
Day 25     
Day 26     
Day 27     
Day 28     
Day 29     
Day 30     
 
 
 
 
 
Date :                                                              ___________________________
Place  : ___________________                        Signature of the Investigator  
 
 
 
 
 
 
 
 
__________________________                                          ___________________________
         Signature of guide                 Signature of Supervisor 
Date :                                                      Date   ::  
 
Place  : ___________________                                           Place  : _____________________
